U.S. patent application number 13/412747 was filed with the patent office on 2012-08-02 for substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors.
This patent application is currently assigned to TransTech Pharma, Inc.. Invention is credited to Robert C. Andrews, Adnan M.M. Mjalli, Dharma R. Polisetti, James C. Quada, Govindan Subramanian, Rongyuan Xie, Ravindra R. Yarragunta.
Application Number | 20120196906 13/412747 |
Document ID | / |
Family ID | 38042619 |
Filed Date | 2012-08-02 |
United States Patent
Application |
20120196906 |
Kind Code |
A1 |
Mjalli; Adnan M.M. ; et
al. |
August 2, 2012 |
Substituted Imidazole Derivatives, Compositions, and Methods of Use
as PTPase Inhibitors
Abstract
The present invention provides imidazole derivatives of Formula
(I-IV), methods of their preparation, pharmaceutical compositions
comprising the compounds of Formula (I-IV), and their use in
treating human or animal disorders. The compounds of the invention
inhibit protein tyrosine phosphatase 1B and thus can be useful for
the management, treatment, control, or the adjunct treatment of
diseases mediated by PTPase activity. Such diseases include Type I
diabetes and Type II diabetes.
Inventors: |
Mjalli; Adnan M.M.; (Oak
Ridge, NC) ; Polisetti; Dharma R.; (High Point,
NC) ; Subramanian; Govindan; (Belle Mead, NJ)
; Quada; James C.; (High Point, NC) ; Yarragunta;
Ravindra R.; (Greensboro, NC) ; Andrews; Robert
C.; (Jamestown, NC) ; Xie; Rongyuan;
(Greensboro, NC) |
Assignee: |
TransTech Pharma, Inc.
High Point
NC
|
Family ID: |
38042619 |
Appl. No.: |
13/412747 |
Filed: |
March 6, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12685178 |
Jan 11, 2010 |
|
|
|
13412747 |
|
|
|
|
11699780 |
Jan 30, 2007 |
7723369 |
|
|
12685178 |
|
|
|
|
60763256 |
Jan 30, 2006 |
|
|
|
Current U.S.
Class: |
514/362 ;
548/135 |
Current CPC
Class: |
A61P 31/00 20180101;
A61P 31/18 20180101; A61P 3/08 20180101; A61P 37/08 20180101; A61P
43/00 20180101; A61P 37/04 20180101; A61P 5/00 20180101; A61P 29/00
20180101; A61P 35/00 20180101; A61P 3/00 20180101; A61P 3/10
20180101; A61P 17/06 20180101; C07D 417/14 20130101; A61P 37/06
20180101; A61P 37/02 20180101; A61P 3/04 20180101; A61P 25/28
20180101; C07D 417/10 20130101; A61P 37/00 20180101 |
Class at
Publication: |
514/362 ;
548/135 |
International
Class: |
A61K 31/433 20060101
A61K031/433; A61P 3/10 20060101 A61P003/10; A61P 31/18 20060101
A61P031/18; A61P 37/08 20060101 A61P037/08; A61P 25/28 20060101
A61P025/28; A61P 17/06 20060101 A61P017/06; A61P 31/00 20060101
A61P031/00; A61P 3/04 20060101 A61P003/04; A61P 35/00 20060101
A61P035/00; C07D 417/10 20060101 C07D417/10; A61P 29/00 20060101
A61P029/00 |
Claims
1.
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(3,3-dimethyl-butoxy)-biphenyl-4-y-
lmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein the pharmaceutically acceptable
salt is a sodium salt or a potassium salt.
3.
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(3,3-dimethyl-butoxy)-biphenyl-4-y-
lmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
4. A pharmaceutical composition comprising the compound of claim 1,
and a pharmaceutically acceptable carrier, diluents, excipient, or
a mixture thereof.
5. A pharmaceutical composition comprising the pharmaceutically
acceptable salt of claim 1, and a pharmaceutically acceptable
carrier, diluents, excipient, or a mixture thereof.
6.
5-{3-[2-(4'-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6, wherein the pharmaceutically acceptable
salt is a sodium salt or a potassium salt.
8.
5-{3-[2-(4'-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
9. A pharmaceutical composition comprising the compound of claim 6,
and a pharmaceutically acceptable carrier, diluents, excipient, or
a mixture thereof.
10. A pharmaceutical composition comprising the pharmaceutically
acceptable salt of claim 6, and a pharmaceutically acceptable
carrier, diluents, excipient, or a mixture thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation application and
claims priority under 35 USC .sctn.120 to U.S. application Ser. No.
12/685,178, filed Jan. 11, 2010, which is a divisional application
of U.S. application Ser. No. 11/699,780, filed Jan. 30, 2007, which
claims the benefit of priority under 35 USC .sctn.119(e) to U.S.
Provisional Application No. 60/763,256, filed Jan. 30, 2006 and
entitled "Substituted Imidazole Derivatives, Compositions, and
Methods of Use." All of these related applications are incorporated
herein by reference.
FIELD OF THE INVENTION
[0002] This invention relates to substituted imidazole derivatives,
compositions, and methods of treatment using the compounds and
compositions which may be useful for the management, treatment,
control, or adjunct treatment of diseases caused by activity of a
protein phosphatase.
BACKGROUND OF THE INVENTION
[0003] Protein phosphorylation is now recognized as central to the
fundamental processes of cellular signal transduction. Alterations
in protein phosphorylation may therefore constitute either a
physiological or pathological change in an in vivo system. Protein
de-phosphorylation, mediated by phosphatases, is also central to
certain signal transduction processes.
[0004] The two major classes of phosphatases are (a) protein
serine/threonine phosphatases (PSTPases), which catalyze the
dephosphorylation of serine and/or threonine residues on proteins
or peptides; and (b) the protein tyrosine phosphatases (PTPases),
which catalyze the dephosphorylation of tyrosine residues on
proteins and/or peptides. A third class of phosphatases is the dual
specificity phosphatases, or DSP's, which possess the ability to
act both as PTPases and as PSTPases.
[0005] Among the PTPases there exist two important families, the
intracellular PTPases, and the transmembrane PTPases. The
intracellular PTPases include PTP1B, STEP, PTPD1, PTPD2, PTPMEG1,
T-cell PTPase, PTPH1, FAP-1/BAS, PTP1D, and PTP1C. The
transmembrane PTPases include LAR, CD45, PTP.alpha., PTP.beta.,
PTP.delta., PTP.epsilon., PTP.xi., PTP.kappa., PTP.mu., PTP.sigma.,
HePTP, SAP-1, and PTP-U2. The dual--specificity phosphatases
include KAP, cdc25, MAPK phosphatase, PAC-1, and rVH6.
[0006] The PTPases, especially PTP1B, are implicated in insulin
insensitivity characteristic of type II diabetes (Kennedy, B. P.;
Ramachandran, C. Biochem. Pharm. 2000, 60, 877-883). The PTPases,
notably CD45 and HePTP, are also implicated in immune system
function, and in particular T-cell function. Certain PTPases,
notably TC-PTP, DEP-1, SAP-1, and CDC25, are also implicated in
certain cancers. Certain PTPases, notably the bone PTPase OST-PTP,
are implicated in osteoporosis. PTPases are implicated in mediating
the actions of somatostatin on target cells, in particular the
secretion of hormone and/or growth factor secretion.
[0007] Thus, there is a need for agents which inhibit the action of
protein tyrosine phosphatases. Such agents may be useful for the
treatment of glucose intolerance including Type I diabetes and Type
II diabetes, immune dysfunction including AIDS, allergic diseases,
inflammatory diseases, and autoimmunity such as psoriasis,
infectious diseases, obesity, cancer, diseases involving the
modulated synthesis of growth hormone or the modulated synthesis of
growth factors or cytokines which affect the production of growth
hormone, or Alzheimer's disease.
SUMMARY OF THE INVENTION
[0008] This invention provides substituted imidazole derivatives
and compositions which inhibit PTP1B. In an embodiment, the present
invention provides compounds of Formula (I-IV) as depicted below.
In another embodiment, the present invention provides methods of
preparation of compounds of Formula (I-IV). In another embodiment,
the present invention provides pharmaceutical compositions
comprising the compounds of Formula (I-IV). In another embodiment,
the present invention provides methods of using the compounds of
Formula (I-IV) in treating human or animal disorders. The compounds
of the invention are useful as inhibitors of protein tyrosine
phosphatases and thus may be useful for the management, treatment,
control and adjunct treatment of a disease mediated by PTPase
activity. Such diseases may comprise glucose intolerance including
Type I diabetes and Type II diabetes, immune dysfunction including
AIDS, allergic diseases, inflammatory diseases, and autoimmunity
such as psoriasis, infectious diseases, obesity, cancer, diseases
involving the modulated synthesis of growth hormone or the
modulated synthesis of growth factors or cytokines which affect the
production of growth hormone, or Alzheimer's disease.
DETAILED DESCRIPTION
[0009] Embodiments of the present invention comprise substituted
imidazole derivatives, compositions, and methods of use. The
present invention may be embodied in a variety of ways.
[0010] In a first aspect, the present invention provides imidazole
inhibitors of protein tyrosine phosphatases (PTPases) which are
useful for the management and treatment of disease caused by
PTPases.
[0011] In another aspect, the present invention provides a compound
of Formula I, II, III, or IV:
##STR00001##
wherein [0012] Ar.sup.1, Ar.sup.2, Ar.sup.4, and Ar.sup.5 are
independently selected from the group consisting of: phenyl,
indanyl, tetrahydronaphthyl, pyridazine, pyrimidine, pyrazine,
pyridine, piperidine, 4,5-diaza-indanyl,
5,6,7,8-tetrahydro-cinnoline, and 1-H-pyridin-2-one, and [0013]
Ar.sup.3 is phenyl, naphthalene, indanyl, tetrahydronaphthyl,
pyridazine, pyrimidine, pyrazine, pyridine, piperidine,
4,5-diaza-indanyl, or 5,6,7,8-tetrahydro-cinnoline, wherein [0014]
Ar.sup.1, Ar.sup.2, Ar.sup.3, and Ar.sup.4 are each optionally
substituted 1 to 4 times with a group independently selected from
R.sup.b, and [0015] Ar.sup.5 is optionally substituted 1 to 4 times
with a group selected from R.sup.a;
V is C, W is C, X is N, Y is C, Z is N,
[0016] when sides b, c, and e are single bonds, and sides a and d
are double bonds; or
V is C, W is N, X is C, Y is N, Z is C,
[0017] when sides a, c, and d are single bonds, and sides b and e
are double bonds; or
V is C, W is N, X is C, Y is C, Z is N,
[0018] when sides a, b, and d are single bonds, and sides c and e
are double bonds; [0019] L' is -T'-L.sup.3-T.sup.2-, [0020] wherein
[0021] L.sup.3 is a direct bond, --C.sub.1-10 alkylene,
--C.sub.2-10 alkenylene, or --C.sub.2-10 alkynylene; [0022] T.sup.1
and T.sup.2 are independently selected from the group consisting of
a direct bond, --CH.sub.2--, --O--, --N(R.sup.16)--, --C(O)--,
--CON(R.sup.16)--, --N(R.sup.16)C(O)--,
--N(R.sup.16)CON(R.sup.17)--, --N(R.sup.16)C(O)O--,
--OC(O)N(R.sup.16)--, --N(R.sup.16)SO.sub.2--,
--SO.sub.2N(R.sup.16)--, --C(O)--O--, --O--C(O)--, --S--, --S(O)--,
--S(O).sub.2--, --N(R.sup.16)SO.sub.2N(R.sup.17)--, --N.dbd.N--,
and --N(R.sup.16)--N(R.sup.17)--; [0023] wherein [0024] R.sup.16
and R.sup.17 are independently selected from the group consisting
of: -hydrogen, --C.sub.1-10 alkyl, -aryl, -arylene-C.sub.1-10
alkyl, and --C.sub.1-10 alkylene-aryl, wherein alkyl and aryl are
optionally substituted with R.sup.c; [0025] L.sup.2 is selected
from the group consisting of: --CH(R.sup.18)--CH(R.sup.19)--,
--N(R.sup.18)C(O)--, --N(R.sup.18)--, --N(R.sup.18)S(O).sub.2--,
--C(O)N(R.sup.18)--, --S(O).sub.2N(R.sup.18),
(trans)-C(R.sup.18).dbd.C(R.sup.19)--,
(cis)-C(R.sup.18).dbd.C(R.sup.19)--, --C.dbd.C--, --C(O)--, --O--,
--C.sub.1-5 alkylene-O--, O--C.sub.1-5 alkylene,
--(CH.sub.2).sub.r--, 1,1 cycloalkylmethylene, or a direct bond,
[0026] wherein [0027] R.sup.18 and R.sup.19 are independently
selected from the group consisting of: -hydrogen,
--C.sub.1-10alkyl, -aryl, -arylene-C.sub.1-10 alkyl, and
--C.sub.1-10 alkylene+ aryl, wherein alkyl and aryl are optionally
substituted with R.sup.c; [0028] L.sup.4 is selected from the group
consisting of: a direct bond and --CH.sub.2--, R.sup.1, R.sup.2,
R.sup.3, R.sup.4, and R.sup.5 are independently selected from the
group consisting of hydrogen and R.sup.b, R.sup.6 is selected from
the group consisting of hydrogen and R.sup.b, R.sup.11 is selected
from the group consisting of R.sup.b,
G is
##STR00002##
[0030] wherein [0031] a) D is C(R.sup.7)(R.sup.8), and [0032] E is
C(R.sup.7) or N, [0033] when side f is a single bond, or [0034] b)
D is C(R.sup.7), and [0035] E is C, [0036] when side f is a double
bond, [0037] wherein [0038] R.sup.7 and R.sup.8 are independently
selected from the group consisting of halo, hydroxy, amino, cyano,
nitro, carboxy, --SO.sub.3H, R.sup.f and R.sup.g; [0039] Or
##STR00003##
[0040] wherein [0041] a) D is C(R.sup.7), and [0042] E is
C(R.sup.7)(R.sup.8) or N(R.sup.9), [0043] when side f is a single
bond, or [0044] b) D is C, and [0045] E is C(R.sup.7) or N, [0046]
when side f is a double bond, [0047] wherein [0048] R.sup.7 and
R.sup.9 are independently selected from the group consisting of:
halo, hydroxy, amino, cyano, nitro, carboxy, --SO.sub.3H, R.sup.f
and R.sup.g; and [0049] R.sup.g is R.sup.d, [0050] M is hydrogen or
a counter ion selected from the group consisting of: Na.sup.+,
K.sup.+, and other pharmaceutically acceptable counter ions; [0051]
R.sup.a is [0052] a) -cycloalkyl, [0053] b) -cyano, [0054] c)
--OR.sup.d, [0055] d) --NO.sub.2, [0056] e) -halogen, [0057] f)
--S(O).sub.m C.sub.2-10alkyl, [0058] g) --SR.sup.d, [0059] h)
--S(O).sub.2OR.sup.d, [0060] i) --S(O).sub.mNR.sup.dR.sup.e, [0061]
j) --NR.sup.dS(O).sub.mR.sup.e, [0062] k) --NR.sup.dR.sup.e, [0063]
l) --O(CR.sup.fR.sup.g).sub.nNR.sup.dR.sup.e, [0064] m)
--C(O)R.sup.d, [0065] n) --CO.sub.2R.sup.d, [0066] o)
--CO.sub.2(CR.sup.fR.sup.g).sub.nCONR.sup.dR.sup.e, [0067] p)
--OC(O)R.sup.d, [0068] q) --C(O)NR.sup.dR.sup.e, [0069] r)
--NR.sup.dC(O)R.sup.e, [0070] s) --OC(O)NR.sup.dR.sup.e, [0071] t)
--NR.sup.dC(O)OR.sup.e, [0072] u) --NR.sup.dC(O)NR.sup.dR.sup.e,
[0073] v) --CF.sub.3, [0074] w) --OCF.sub.3 [0075] x)
--C.sub.1-10alkyl, [0076] y) --C.sub.2-10 alkenyl, [0077] z)
--C.sub.2-10 alkynyl, [0078] aa) --C.sub.1-10 alkylene-aryl, [0079]
bb) --C.sub.1-10 alkylene-heteroaryl, [0080] cc) -heteroaryl,
[0081] dd) --C(R.sup.f).dbd.C(R.sup.g)--R.sup.f, or [0082] ee)
--C.ident.C--R.sup.f, [0083] wherein alkyl, alkenyl, alkynyl, aryl,
heteroaryl, and cycloalkyl groups are optionally substituted 1-4
times with a group independently selected from R.sup.c; [0084]
R.sup.b is [0085] a) -cycloalkyl, [0086] b) -cyano, [0087] c)
--OR.sup.d, [0088] d) --NO.sub.2, [0089] e) -halogen, [0090] f)
--S(O).sub.mR.sup.d, [0091] g) --SR.sup.d, [0092] h)
--S(O).sub.2OR.sup.d, [0093] i) --S(O).sub.mNR.sup.dR.sup.e, [0094]
j) --NR.sup.dS(O).sub.mR.sup.e, [0095] k) ---NR.sup.dR.sup.e,
[0096] l) --O(CR.sup.fR.sup.g).sub.nNR.sup.dR.sup.e, [0097] m)
--C(O)R.sup.d, [0098] n) --CO.sub.2R.sup.d, [0099] o)
--OC.sub.2(CR.sup.fR.sup.g).sub.nCONR.sup.dR.sup.e, [0100] p)
--OC(O)R.sup.d, [0101] q) --C(O)NR.sup.dR.sup.e, [0102] r)
--NR.sup.dC(O)R.sup.e, [0103] s) --OC(O)NR.sup.dR.sup.e, [0104] t)
--NR.sup.dC(O)OR.sup.e, [0105] u) --NR.sup.dC(O)NR.sup.dR.sup.e,
[0106] v) --CF.sub.3, [0107] w) --OCF.sub.3 [0108] x) --C.sub.1-10
alkyl, [0109] y) --C.sub.2-.sub.10 alkenyl, [0110] z) --C.sub.2-10
alkynyl, [0111] aa) --C.sub.1-10 alkylene-aryl, [0112] bb)
--C.sub.1-10 alkylene-heteroaryl, [0113] cc) -heteroaryl, [0114]
dd) --C(R.sup.f).dbd.C(R.sup.g)--R.sup.f, or [0115] ee)
--C.ident.C--R.sup.f, [0116] wherein alkyl, alkenyl, alkynyl, aryl,
heteroaryl, and cycloalkyl groups are optionally substituted 1-4
times with a group independently selected from R.sup.c; [0117]
R.sup.c is [0118] a) -halogen, [0119] b) -amino, [0120] c)
-carboxy, [0121] d) --C.sub.1-4 alkyl, [0122] e) --O--C.sub.1-4
alkyl, [0123] f) -cycloalkyl, [0124] g) --O-cycloalkyl, [0125] h)
-aryl, [0126] i) --C.sub.1-4 alkylene-aryl, [0127] j) -hydroxy,
[0128] k) --CF.sub.3, [0129] l) --O-aryl, [0130] m) -heteroaryl,
[0131] n) -heteroaryl-C.sub.1-10 alkyl, [0132] o) heterocyclyl,
[0133] p) --CO.sub.2--C.sub.1-10 alkyl, or [0134] q)
--CO.sub.2--C.sub.1-10 alkyl-aryl, [0135] R.sup.d and R.sup.e are
independently selected from hydrogen, C.sub.1-10 alkyl, C.sub.2-10
alkenyl, C.sub.2-10 alkynyl, cycloalkyl, --C.sub.1-10
alkylene-cycloalkyl, aryl, heterocyclyl, wherein alkyl, alkenyl,
alkynyl, cycloalkyl, aryl, heterocyclyl groups are optionally
substituted with one to four substituents independently selected
from R.sup.c; or R.sup.d and R.sup.e together with the atoms to
which they are attached form a heterocyclic ring of 5 to 7 members
containing 0-2 additional heteroatoms independently selected from
oxygen, sulfur and nitrogen and optionally substituted with 1-3
times with R.sup.c, and wherein 1 or 2 carbon atoms in the
heterocyclic ring may be oxidized, [0136] R.sup.f and R.sup.g are
independently selected from hydrogen, C.sub.1-10 alkyl, cycloalkyl,
--C.sub.1-10 alkylene-cycloalkyl, and aryl, wherein alkyl,
cycloalkyl, and aryl groups are optionally substituted with one to
four substituents independently selected from R.sup.c; or R.sup.f
and R.sup.g together with the carbon to which they are attached
form a ring of 5 to 7 members containing 0-2 heteroatoms
independently selected from oxygen, sulfur and nitrogen optionally
substituted with 1-3 times with R.sup.c, and wherein 1 or 2 carbon
atoms in the heterocyclic ring may be oxidized; [0137] m is an
integer from 1 to 2, [0138] n is an integer from 1 to 10, [0139] q
is an integer from 1 to 2, [0140] r is an integer from 1 to 5, and
[0141] s is an integer from 0 to 3, or pharmaceutically acceptable
salt, solvate, or prodrug thereof.
[0142] In an embodiment, M is hydrogen or a counter ion selected
from the group consisting of: sodium (Na.sup.+), potassium
(K.sup.+), ammonium, morpholinium, barium, calcium salt. In another
embodiment, M is hydrogen. In another embodiment, M is selected
from the group consisting of: hydrogen, sodium and potassium. In
another embodiment, M is selected from the group consisting of:
sodium and potassium.
[0143] In another embodiment, the present invention provides a
compound of Formula I, II, III, or IV, having the formula:
##STR00004##
wherein
V is C, W is C--R.sup.6, X is N, Y is C, Z is N,
[0144] when sides b, c, and e are single bonds, and sides a and d
are double bonds; or
V is C, W is N, X is C, Y is N, Z is C--R.sup.6,
[0145] when sides a, c, and d are single bonds, and sides b and e
are double bonds; or
V is C, W is N--R.sup.6, X is C, Y is C, Z is N,
[0146] when sides a, b, and d are single bonds, and sides c and e
are double bonds;
R.sup.6 is selected from the group consisting of hydrogen and
R.sup.b.
[0147] In another embodiment, the present invention provides a
compound of Formula I, II, III, or IV, having the formula:
##STR00005##
wherein
V is C, W is N, X is C, Y is N--R.sup.6, Z is C,
[0148] and sides a, c, and d are single bonds, and sides b and e
are double bonds; and
R.sup.6 is selected from the group consisting of hydrogen and
R.sup.b.
[0149] In another embodiment, Ar.sup.1 and Ar.sup.4 are
independently selected from the group consisting of: phenyl-1,4-yl,
pyridazine-3,6-yl, pyrimidine-2,5-yl, and pyrazine-2,5-yl.
[0150] In another embodiment, Ar.sup.1, Ar.sup.2, Ar.sup.4, and
Ar.sup.5 are independently selected from the group consisting of:
phenyl and pyridazine.
[0151] In another embodiment, one of Ar.sup.1 and Ar.sup.2 is
phenyl and the other is pyridazine.
[0152] In another embodiment, both of Ar.sup.1 and Ar.sup.2 are
either phenyl or pyridazine.
[0153] In another embodiment, Ar.sup.2 is phenyl and Ar.sup.1 is
pyridazine-3,6-yl.
[0154] In another embodiment, Ar.sup.1 is phenyl-1,4-yl and
Ar.sup.2 is pyridazine-3-yl.
[0155] In another embodiment, one of Ar.sup.4 and Ar.sup.5 is
phenyl and the other is pyridazine.
[0156] In another embodiment, both of Ar.sup.4 and Ar.sup.5 are
either phenyl or pyridazine.
[0157] In another embodiment, Ar.sup.5 is phenyl and Ar.sup.4 is
pyridazine-3,6-yl.
[0158] In another embodiment, Ar.sup.4 is phenyl-1,4-yl and
Ar.sup.5 is pyridazine-3-yl.
[0159] In another embodiment, Ar.sup.3 is phenyl and substituted
with a halogen.
[0160] In another embodiment, Ar.sup.2, Ar.sup.3, and Ar.sup.5 are
substituted with at least one lipophilic group.
[0161] In an embodiment, said compound has Formula Ia. In another
embodiment, said compound has Formula IIa. In another embodiment,
said compound has Formula IIIa. In another embodiment, said
compound has Formula IVa.
[0162] In an embodiment wherein said compound has Formula Ia, IIa,
IIIa, or IVa, V is C, W is C--R.sup.6, X is N, Y is C, Z is N,
sides b, c, and e are single bonds, and sides a and d are double
bonds.
[0163] In another embodiment where said compound has Formula Ia,
IIa, IIIa, or IVa, V is C, W is N, X is C, Y is N, Z is C--R.sup.6,
and sides a, c, and d are single bonds, and sides b and e are
double bonds.
[0164] In another embodiment where said compound has Formula Ia,
IIa, IIIa, or IVa, V is C, W is N--R.sup.6, X is C, Y is C, Z is N,
and sides a, b, and d are single bonds, and sides c and e are
double bonds.
[0165] In another embodiment, R.sup.6 is selected from the group
consisting of hydrogen and C.sub.1-4 alkyl.
[0166] In another embodiment wherein said compound has Formula Ia,
IIa, IIIa, or IVa, V is C, W is N, X is C, Y is N, Z is C--R.sup.6,
and sides a, c, and d are single bonds, and sides b and e are
double bonds, and R.sup.6 is selected from the group consisting of
hydrogen and C.sub.1-10 alkyl.
[0167] In another embodiment, L.sup.1 is T.sup.1-L.sup.3-T.sup.2-,
wherein L.sup.3, T.sup.1 and T.sup.2 are direct bonds.
[0168] In another embodiment, L.sup.1 is -T.sup.1-L.sup.3-T.sup.2-,
wherein T.sup.1 and T.sup.2 are direct bonds and L.sup.3 is
--CH.sub.2
[0169] In another embodiment, L.sup.1 is -T.sup.1-L.sup.3-T.sup.2-,
wherein L.sup.3 is a direct bond or C.sub.1-10 alkylene, T.sup.1 is
a direct bond, and T.sup.2 is selected from the group consisting of
--O--, --N(R.sup.16)--, --C(O)--, --CON(R.sup.16)--,
--N(R.sup.17)C(O)--, --N(R.sub.6)CON(R.sup.16)--,
--N(R.sup.16)C(O)O--, --OC(O)N(R.sup.16)--,
--N(R.sup.16)SO.sub.2--, --SO.sub.2N(R.sup.16)--, --C(O)--O--,
--O--C(O)--, --S--, --S(O)--, --S(O).sub.2--, and
--N(R.sup.16)SO.sub.2N(R.sup.17)--.
[0170] In another embodiment, L.sup.1 is -T.sup.1-L.sup.3-T.sup.2-,
wherein L.sup.3 is a direct bond or C.sub.1-10 alkylene, T.sup.2 is
a direct bond, and T.sup.1 is selected from the group consisting of
--O--, --N(R.sup.16)--, --C(O)--, --CON(R.sup.16)--,
--N(R.sup.17)C(O)--, --N(R.sub.6)CON(R.sup.16)--,
--N(R.sup.16)C(O)O--, --OC(O)N(R.sup.16)--,
--N(R.sup.16)SO.sub.2--, --SO.sub.2N(R.sup.16)--, --C(O)--O--,
--O--C(O)--, --S--, --S(O)--, --S(O).sub.2--, and
--N(R.sup.16)SO.sub.2N(R.sup.17)--.
[0171] In another embodiment, L.sup.2 is selected from the group
consisting of --CH.sub.2-- or --CH.sub.2--O--. In another
embodiment, L.sup.2 is --CH.sub.2--. In another embodiment, L.sup.4
is --CH.sub.2
[0172] In an embodiment, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and
R.sup.5 are independently selected from the group consisting of:
[0173] a) -hydrogen; [0174] b) -fluoro; [0175] c) -chloro; [0176]
d) trifluoromethyl; [0177] e) trifluoromethoxy; [0178] f)
--SO.sub.2--C.sub.1-6 alkyl; [0179] g) -cyano; [0180] h) -nitro;
and [0181] i) -phenyl. In another embodiment, at least one of
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 is not hydrogen. In
another embodiment, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5
are independently selected from the group consisting of hydrogen,
fluoro, and chloro, wherein at least one of at least one of
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 is not hydrogen. In
another embodiment, R.sup.1 and R.sup.3 are chloro or fluoro, and
R.sup.2, R.sup.4, and R.sup.5 are hydrogen.
[0182] In an embodiment, s is an integer from 1 to 3 and R.sup.11
is independently selected from the group consisting of: methyl,
methoxy, chloro, fluoro, nitro, cyano, hydroxy, trifluoromethyl,
trifluoromethoxy, --SO.sub.2--CH.sub.3, --SO.sub.2--CF.sub.3,
--NHSO.sub.2--CH.sub.3, --NHSO.sub.2--CF.sub.3, and cyclopropyl. In
another embodiment, s is zero.
[0183] In an embodiment, G is
##STR00006##
[0184] wherein [0185] a) q is 2, D is C(R.sup.7)(R.sup.8), E is
C(R.sup.7) or N, when side f is a single bond, or [0186] b) q is 2,
D is C(R.sup.7), E is C, when side f is a double bond. In a further
embodiment, R.sup.7 and R.sup.8 are selected from the group
consisting of: hydrogen and C.sub.1-4 alkyl.
[0187] In another embodiment, G is
##STR00007##
[0188] wherein [0189] q is 2, D is C(R.sup.7)(R.sup.8), E is N, and
side f is a single bond. In a further embodiment, R.sup.7 and
R.sup.8 are selected from the group consisting of: hydrogen and
C.sub.1-4 alkyl.
[0190] In another embodiment, G is
##STR00008##
[0191] wherein [0192] a) q is 2, D is C(R.sup.7), E is
C(R.sup.7)(R.sup.8) or N(R.sup.9), when side f is a single bond, or
[0193] b) q is 2, D is C, E is C(R.sup.7) or N, when side f is a
double bond. In a further embodiment, R.sup.7, R.sup.8, and R.sup.9
are selected from the group consisting of: hydrogen and C.sub.1-4
alkyl.
[0194] In an embodiment wherein the compound has the Formula IV,
Ar.sup.3 is naphthyl-2-yl and is substituted at the 6 position with
a group selected from R.sup.b and may be further optionally
substituted with 1 to 2 groups independently selected from
R.sup.b.
[0195] In another embodiment wherein the compound has the Formula
IV, Ar.sup.3 is phenyl and is substituted at the 4 position with a
group selected from --C(R.sup.f).dbd.C(R.sup.g)--R.sup.f, and
--C.ident.C--R.sup.f, and the phenyl group may be further
optionally substituted with 1 to 2 groups independently selected
from R.sup.b.
[0196] In an embodiment wherein the compound has the Formula II or
III, Ar.sup.2 is substituted with 1 to 3 groups independently
selected from R.sup.b.
[0197] In an embodiment wherein the compound has the Formula I,
Ar.sup.5 is substituted with 1 to 3 groups independently selected
from R.sup.a.
[0198] In another embodiment, Ar.sup.1 and Ar.sup.4 are
unsubstituted, and Ar.sup.2, Ar.sup.3, and Ar.sup.5 are each
substituted with 1 to 3 groups independently selected from the
group consisting of: [0199] --C.sub.1-10 alkyl, [0200] -cycloalkyl,
[0201] -heterocyclyl, [0202] -trifluoroalkyl, [0203] -halogen,
[0204] -nitro, [0205] -carboxy, [0206] --CO.sub.2--C.sub.1-10
alkyl, [0207] --C.sub.1-10 alkylene-CO.sub.2--C.sub.1-10 alkyl,
[0208] --C.sub.2-10 alkenylene-CO.sub.2--C.sub.1-10 alkyl, [0209]
--C.sub.1-10 alkylene-CO.sub.2H, [0210] --C.sub.2-10
alkenylene-CO.sub.2H, [0211] --O--C.sub.1-10
alkylene-C(O)NH--C.sub.1-10 alkyl, [0212] --C(O)--C.sub.1-10 alkyl,
[0213] --C(O)NH--C.sub.1-10 alkyl, [0214] --O-heterocyclyl, [0215]
--O--C.sub.1-10 alkyl, [0216] --O--C.sub.1-10 haloalkyl, [0217]
--O--C.sub.1-10 perhaloalkyl, [0218] --O-cycloalkyl, [0219]
--O-phenyl, [0220] -hydroxy, [0221] --O--C.sub.1-10
alkylene-cycloalkyl, [0222] --O--C.sub.1-10 alkylene-phenyl, [0223]
--S-heterocyclyl, [0224] --S--C.sub.1-10 alkyl, [0225]
--S--C.sub.1-10 haloalkyl, [0226] --S--C.sub.1-10 perhaloalkyl,
[0227] --S-cycloalkyl, [0228] --S-phenyl, [0229] --S--C.sub.1-10
alkylene-cycloalkyl, [0230] --S--C.sub.1-10 alkylene-phenyl, [0231]
--C.sub.1-10 alkylene-cycloalkyl, [0232] --C.sub.1-10
alkylene-phenyl, [0233] -amino, [0234] --NH(C.sub.1-10 alkyl),
[0235] --N(C.sub.1-10 alkyl).sub.2, [0236] --N(C.sub.1-10
alkyl)(C.sub.1-10 alkylene-cycloalkyl), [0237]
--NHCO.sub.2--C.sub.1-10 alkyl, [0238] --NH(C.sub.1-10
alkylene-cycloalkyl), [0239] --S(O).sub.2--O.sub.2-10 alkyl, [0240]
--SO.sub.2-cycloalkyl, [0241] --SO.sub.2--C.sub.1-10
alkylene-cycloalkyl, [0242] --S(O)--C.sub.1-10 alkyl, [0243]
--S(O)-cycloalkyl, and [0244] --S(O)--C.sub.1-10
alkylene-cycloalkyl,
[0245] wherein alkyl, alkenyl, aryl, heteroaryl, and cycloalkyl
groups are optionally substituted 1-4 times with a group
independently selected from R.sup.c.
[0246] In another embodiment, Ar.sup.1 and Ar.sup.4 are
unsubstituted, and Ar.sup.2, Ar.sup.3, and Ar.sup.5 are each
substituted with 1 to 3 groups independently selected from the
group consisting of: [0247] --C.sub.1-10 alkyl, [0248] -cycloalkyl,
[0249] -heterocyclyl, [0250] -trifluoroalkyl, [0251] -halogen,
[0252] -nitro, [0253] --COO.sub.2--C.sub.1-10 alkyl, --C.sub.1-10
alkylene-CO.sub.2--C.sub.1-10 alkyl, [0254] --C.sub.2-10
alkenylene-CO.sub.2--C.sub.1-10 alkyl, [0255] --O--C.sub.1-10
alkylene-C(O)NH--C.sub.1-10 alkyl, [0256] --C(O)--C.sub.1-10 alkyl,
[0257] --C(O)NH--C.sub.1-10 alkyl, [0258] --O-heterocyclyl, [0259]
--O--C.sub.1-10 alkyl, [0260] --O--C.sub.1-10 haloalkyl, [0261]
--O--C.sub.1-10 perhaloalkyl, [0262] --O-cycloalkyl, [0263]
--O-phenyl, [0264] --O--C.sub.1-10 alkylene-cycloalkyl, [0265]
--O--C.sub.1-10 alkylene-phenyl, [0266] --S-heterocyclyl, [0267]
--S--C.sub.1-10 alkyl, [0268] --S--C.sub.1-10 haloalkyl, [0269]
--S--C.sub.1-10 perhaloalkyl, [0270] --S-cycloalkyl, [0271]
--S-phenyl, [0272] --S--C.sub.1-10 alkylene-cycloalkyl, [0273]
--S--C.sub.1-10 alkylene-phenyl, [0274] --C.sub.1-10
alkylene-cycloalkyl, [0275] --C.sub.1-10 alkylene-phenyl, [0276]
--NH(C.sub.1-10 alkyl), [0277] --N(C.sub.1-10 alkyl).sub.2, [0278]
--N(C.sub.1-10 alkyl)(C.sub.1-10 alkylene-cycloalkyl), [0279]
--NHCO.sub.2--C.sub.1-10 alkyl, [0280] --NH(C.sub.1-10
alkylene-cycloalkyl), [0281] --S(O).sub.2--C.sub.2-10 alkyl, [0282]
--SO.sub.2-cycloalkyl, [0283] --SO.sub.2--C.sub.1-10
alkylene-cycloalkyl, [0284] --S(O)--C.sub.1-10 alkyl, [0285]
--S(O)-cycloalkyl, and [0286] --S(O)--C.sub.1-10
alkylene-cycloalkyl.
[0287] In another embodiment, Ar.sup.1 and Ar.sup.4 are
unsubstituted, and Ar.sup.2, Ar.sup.3, and Ar.sup.5 are each
substituted with 1 to 3 groups independently selected from the
group consisting of: [0288] --C.sub.1-10 alkyl, [0289] -cycloalkyl,
[0290] -trifluoroalkyl, [0291] -halogen, [0292]
--CO.sub.2--C.sub.1-10 alkyl, [0293] --C.sub.1-10
alkylene-CO.sub.2--C.sub.1-10 alkyl, [0294] --C.sub.2-10
alkenylene-CO.sub.2--C.sub.1-10 alkyl, [0295] --O--C.sub.1-10
alkylene-C(O)NH--C.sub.1-10 alkyl, [0296] --C(O)--C.sub.1-10 alkyl,
[0297] --O--C.sub.1-10 alkyl, [0298] --O--C.sub.1-10 haloalkyl,
[0299] --O--C.sub.1-10 perhaloalkyl, [0300] --O-cycloalkyl, [0301]
--O-phenyl, [0302] --O--C.sub.1-10 alkylene-cycloalkyl, [0303]
--O--C.sub.1-10 alkylene-phenyl, [0304] --S--C.sub.1-10 alkyl,
[0305] --S--C.sub.1-10 haloalkyl, [0306] --S--C.sub.1-10
perhaloalkyl, [0307] --S-cycloalkyl, [0308] --S-phenyl, [0309]
--S--C.sub.1-10 alkylene-cycloalkyl, [0310] --S--C.sub.1-10
alkylene-phenyl, [0311] --C.sub.1-10 alkylene-cycloalkyl, [0312]
--C.sub.1-10 alkylene-phenyl, [0313] --S(O).sub.2--O.sub.2-10
alkyl, [0314] --SO.sub.2-cycloalkyl, [0315] --SO.sub.2--C.sub.1-10
alkylene-cycloalkyl, [0316] --S(O)--C.sub.1-10 alkyl, [0317]
--S(O)-cycloalkyl, and [0318] --S(O)--C.sub.1-10
alkylene-cycloalkyl.
[0319] In another embodiment, Ar.sup.1 and Ar.sup.4 are
unsubstituted, and Ar.sup.2, Ar.sup.3, and Ar.sup.5 are each
substituted with 1 to 3 groups independently selected from the
group consisting of: [0320] morpholine-4-yl, [0321]
piperidine-4-yl, [0322] piperidine-1-yl, [0323] 4-piperidinyl-oxy,
[0324] 3-piperidinyl-oxy, [0325] 2-oxo-piperidine-1-yl, [0326]
3-oxo-piperidine-1-yl, [0327] [1-(C.sub.1-10
alkylsulfonyl)-piperidine-4-yl]-oxy, [0328] [1-(C.sub.1-10
alkyloxycarbonyl)-piperidine-4-yl]-oxy, [0329] [1-(C.sub.1-10
alkyloxycarbonyl)-piperidine-3-yl]-oxy, [0330] piperazine-1-yl,
[0331] 4-(C.sub.1-10 alkyl)-piperazine-1-yl, [0332]
2-oxo-piperazine-4-yl, [0333] 1-C.sub.1-10
alkyl-2-oxo-piperazine-4-yl, [0334]
1-cycloalkyl-2-oxo-piperazine-4-yl, [0335] 4-tetrahydropyranyloxy,
[0336] 3-tetrahydrofuranyloxy, [0337] 4-(C.sub.1-10
alkyloxycarbonyl)piperazine-1-yl, [0338] pyrrolidine-1-yl, [0339]
3-phenyl-pyrrolidine-1-yl, [0340] 3-cycloalkyl-pyrrolidine-1-yl,
[0341] [1-(C.sub.1-10 alkoxycarbonyl)-pyrrolidine-3-yl]-oxy, [0342]
2-thiophenyloxy, [0343] 2-thiazolyloxy, [0344]
(1,2,4-oxadiazole-3-yl)-oxy, [0345] (1-methyl-imidazole-2-yl)-oxy,
and [0346] (imidazole-2-yl)-C.sub.1-10 alkyoxy, [0347] wherein the
alkyl, phenyl, cycloalkyl, morpholine, piperidine, piperazine,
cycloalkyl, tetrahydropyran, tetrahydrofuran, pyrrolidine,
thiazole, imidazole groups are optionally substituted 1-4 times
with a group independently selected from IR'. [0348] In another
embodiment where the compound has the Formula Ia, IIa, IIIa, or
IVa, Ar.sup.1, Ar.sup.2, Ar.sup.4, and Ar.sup.5 are independently
selected from the group consisting of: [0349] phenyl and
pyridazine, [0350] L.sup.1 is a direct bond or --CH.sub.2--, [0351]
L.sup.2 is --CH.sub.2--, [0352] L.sup.4 is --CH.sub.2--, [0353] V
is C, W is N, X is C, Y is N, Z is C--R.sup.6, and sides a, c, and
d are single bonds, and sides b and e are double bonds, and [0354]
G is
[0354] ##STR00009## [0355] wherein [0356] q is 2, D is
C(R.sup.7)(R.sup.8), E is N, and side f is a single bond.
[0357] In another embodiment, Ar.sup.1 and Ar.sup.4 are
unsubstituted, and Ar.sup.2, Ar.sup.3, and Ar.sup.5 are substituted
with at least one group selected from the group consisting of:
methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-ethyl-propyl,
1-propyl-butyl, 3,3-dimethyl-butyl, 4-methyl-pentyl,
4,4-dimethyl-pentyl, 1-(3,3-dimethyl-butyl)-4,4-dimethyl-pentyl,
isobutyl, isopropyl, sec-butyl, tert-butyl, trifluoromethyl,
4,4,4-trifluorobutoxy, methoxy, ethoxy, propoxy, butoxy, pentoxy,
hexyloxy, isobutoxy, isopropoxy, tert-butoxy, 2-phenethoxy,
2,2-dimethylpropoxy, 3-methyl-butoxy, 3,3-dimethyl-butoxy,
3'-phenethyloxy, 2-cyclohexyl-ethanesulfonyl,
3,3-dimethyl-butane-1-sulfonyl, cyclohexanesulfonyl,
cyclohexylmethanesulfonyl, cyclohexylmethylsulfonyl,
2-cyclohexyl-ethanesulfinyl, 3,3-dimethyl-butane-1-sulfinyl,
cyclohexylmethylsulfinyl, 2-cyclohexyl-ethylsulfanyl,
3,3-dimethyl-butylsulfanyl, phenethylsulfanyl,
cyclohexylmethylsulfanyl, cyclopentyl, cyclohexyl, cyclopentyloxy,
cyclohexyloxy, cyclopentylmethyl, cyclohexylmethyl,
2-cyclopentylethyl, 2-cyclohexylethyl, cyclopentylmethoxy,
cyclohexylmethoxy, 2-cyclopentylethoxy, 2-cyclohexylethoxy,
2-cyclohexyl-vinyl, 3-ethyl-cyclobutyl, amino, butylamino,
diethylamino, Bis-(3,3-dimethyl-butyl)-amino,
cyclohexylmethyl-amino, cyclohexylmethyl-ethyl-amino,
3-phenyl-pyrrolidin-1-yl, cyclohexyl-pyrrolidin-1-yl,
piperidin-1-yl, piperidin-2-one-1-yl, piperazin-1-yl,
piperazin-2-one-1-yl, piperazin-2-one-4-yl, piperazine-1-carboxylic
acid 2,2-dimethyl-propyl ester, 1-cyclohexyl-piperazin-2-one-4-yl,
1-ethyl-piperazin-2-one-4-yl, 1-isopropyl-piperazin-2-one-4-yl,
1-methyl-piperazin-2-one-4-yl, 4-methyl-piperazin-1-yl, chloro,
fluoro, nitro, phenyl, propionyl, carboxy, carboxymethyl, and
morpholin-4-yl.
[0358] In another embodiment, Ar.sup.1 and Ar.sup.4 are
unsubstituted, and Ar.sup.2, Ar.sup.3, and Ar.sup.y are substituted
with at least one group selected from the group consisting of:
methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-ethyl-propyl,
1-propyl-butyl, 3,3-dimethyl-butyl, 4-methyl-pentyl,
4,4-dimethyl-pentyl, 1-(3,3-dimethyl-butyl)-4,4-dimethyl-pentyl,
isobutyl, isopropyl, sec-butyl, tert-butyl, trifluoromethyl,
4,4,4-trifluorobutoxy, methoxy, ethoxy, propoxy, butoxy, pentoxy,
hexyloxy, isobutoxy, isopropoxy, tert-butoxy, 2-phenethoxy,
2,2-dimethylpropoxy, 3-methyl-butoxy, 3,3-dimethyl-butoxy,
3'-phenethyloxy, 2-cyclohexyl-ethanesulfonyl,
3,3-dimethyl-butane-1-sulfonyl, cyclohexanesulfonyl,
cyclohexylmethanesulfonyl, cyclohexylmethylsulfonyl,
2-cyclohexyl-ethanesulfinyl, 3,3-dimethyl-butane-1-sulfinyl,
cyclohexylmethylsulfinyl, 2-cyclohexyl-ethylsulfanyl,
3,3-dimethyl-butylsulfanyl, phenethylsulfanyl,
cyclohexylmethylsulfanyl, cyclopentyl, cyclohexyl, cyclopentyloxy,
cyclohexyloxy, cyclopentylmethyl, cyclohexylmethyl,
2-cyclopentylethyl, 2-cyclohexylethyl, cyclopentylmethoxy,
cyclohexylmethoxy, 2-cyclopentylethoxy, 2-cyclohexylethoxy,
2-cyclohexyl-vinyl, 3-ethyl-cyclobutyl, chloro, fluoro, and
phenyl.
[0359] In another embodiment, the present invention provides a
compound of Formula IIa having the formula:
##STR00010##
wherein [0360] V is C, W is C--R.sup.6, X is N, Y is C, Z is N,
[0361] when sides b, c, and e are single bonds, and sides a and d
are double bonds; or [0362] V is C, W is N, X is C, Y is N, Z is
C--R.sup.6, [0363] when sides a, c, and d are single bonds, and
sides b and e are double bonds; or [0364] V is C, W is N--R.sup.6,
X is C, Y is C, Z is N, [0365] when sides a, b, and d are single
bonds, and sides c and e are double bonds; [0366] wherein R.sup.6
is hydrogen or R.sup.b, [0367] D.sup.1 is C--R.sup.21 and D.sup.2
is C--R.sup.22, or D.sup.1 and D.sup.2 are N; [0368] D.sup.3 is
C--R.sup.23 and D.sup.4 is C--R.sup.24, or D.sup.3 and D.sup.4 are
N; [0369] L.sup.1 is -T.sup.1-L.sup.3-T.sup.2-, [0370] wherein
[0371] L.sup.3 is a direct bond, --C.sub.1-10 alkylene,
--C.sub.2-10 alkenylene, or --C.sub.2-10 alkynylene; [0372] T.sup.1
and T.sup.2 are independently selected from the group consisting of
a direct bond, --CH.sub.2--, --O--, --N(R.sup.16)--, --C(O)--,
--CON(R.sup.16)--, --N(R.sup.16)C(O)--,
--N(R.sup.16)CON(R.sup.17)--, --N(R.sup.16)C(O)O--,
--OC(O)N(R.sup.16)--, --N(R.sup.16)SO.sub.2--,
--SO.sub.2N(R.sup.16)--, --C(O)--O--, --O--C(O)--, --S--, --S(O)--,
--S(O).sub.2--, --N(R.sup.16)SO.sub.2N(R.sup.17)--, --N.dbd.N--, or
--N(R.sup.16)--N(R.sup.17)--; [0373] wherein [0374] R.sup.16 and
R.sup.17 are independently selected from the group consisting of:
-hydrogen, --C.sub.1-10alkyl, -aryl, -arylene-C.sub.1-10 alkyl, or
--C.sub.1-10 alkylene-aryl, wherein alkyl and aryl are optionally
substituted with R.sup.c; [0375] L.sup.2 is selected from the group
consisting of: --CH(R.sup.18)--CH(R.sup.19)--, --N(R.sup.18)C(O)--,
--N(R.sup.18)--, --N(R.sup.18)S(O).sub.2--, --C(O)N(R.sup.18)--,
--S(O).sub.2N(R.sup.18), (trans)-C(R.sup.18).dbd.C(R.sup.19)--,
(cis)-C(R.sup.18).dbd.C(R.sup.19)--, --C.dbd.C--, --C(O)--, --O--,
-alkylene-O--, -alkylene-O--, --(CH.sub.2).sub.r--, 1,1
cycloalkylmethylene, or a direct bond, [0376] wherein [0377]
R.sup.18 and R.sup.19 are independently selected from the group
consisting of: -hydrogen, --C.sub.1-10 alkyl, -aryl,
-arylene-C.sub.1-10 alkyl, or --C.sub.1-10 alkylene-aryl, wherein
alkyl and aryl are optionally substituted with R.sup.c; [0378]
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently
selected from the group consisting of hydrogen and R.sup.b; [0379]
R.sup.11 is selected from the group consisting of R.sup.b; [0380]
R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24, R.sup.25,
R.sup.26, and R.sup.27 are independently selected from the group
consisting of hydrogen and R.sup.b; [0381] G is
[0381] ##STR00011## [0382] wherein [0383] a) D is
C(R.sup.7)(R.sup.8), E is C(R.sup.7) or N, when side f is a single
bond, or [0384] b) D is C(R.sup.7), E is C, when side f is a double
bond, [0385] wherein [0386] R.sup.7 and R.sup.9 are independently
selected from the group consisting of halo, hydroxy, amino, cyano,
nitro, carboxy, --SO.sub.3H, --R.sup.f and R.sup.g; [0387] Or
[0387] ##STR00012## [0388] wherein [0389] a) D is C(R.sup.7), E is
C(R.sup.7)(R.sup.9) or N(R.sup.9), when side f is a single bond, or
[0390] b) D is C, E is C(R.sup.7) or N, when side f is a double
bond, wherein [0391] R.sup.7 and R.sup.9 are independently selected
from the group consisting of: halo, hydroxy, amino, cyano, nitro,
carboxy, --SO.sub.3H, R.sup.f and R.sup.g; and [0392] R.sup.9 is
R.sup.d; [0393] M is hydrogen or a counter ion selected from the
group consisting of: Na.sup.+, K.sup.+, and other pharmaceutically
acceptable counter ions; [0394] R.sup.b is [0395] a) -cycloalkyl,
[0396] b) -cyano, [0397] c) --OR.sup.d, [0398] d) --NO.sub.2,
[0399] e) -halogen, [0400] f) --S(O).sub.mR.sup.d, [0401] g)
--SR.sup.d, [0402] h) --S(O).sub.2OR.sup.d, [0403] i)
--S(O).sub.mNR.sup.dR.sup.e, [0404] j) --NR.sup.dS(O).sub.mR.sup.e,
[0405] k) --NR.sup.dR.sup.e, [0406] l)
--O(CR.sup.fR.sup.g).sub.nNR.sup.dR.sup.e, [0407] m) --C(O)R.sup.d,
[0408] n) --CO.sub.2R.sup.d, [0409] o)
--OO.sub.2(CR.sup.fR.sup.g).sub.nCONR.sup.dR.sup.e, [0410] p)
--OC(O)R.sup.d, [0411] q) --C(O)NR.sup.dR.sup.e, [0412] r)
--NR.sup.dC(O)R.sup.e, [0413] s) --OC(O)NR.sup.dR.sup.e, [0414] t)
--NR.sup.dC(O)OR.sup.e, [0415] u) --NR.sup.dC(O)NR.sup.dR.sup.e,
[0416] v) --CF.sub.3, [0417] w) --OCF.sub.3 [0418] x) --C.sub.1-10
alkyl, [0419] y) --C.sub.2-10 alkenyl, [0420] z) --C.sub.2-10
alkynyl, [0421] aa)-C.sub.1-10 alkylene-aryl, [0422] bb)
--C.sub.1-10, alkylene-heteroaryl, [0423] cc)-heteroaryl, [0424]
dd) --C(R.sup.f).dbd.C(R.sup.g)--R.sup.f, or [0425] ee)
--C.ident.C--R.sup.f, [0426] wherein alkyl, alkenyl, alkynyl, aryl,
heteroaryl, and cycloalkyl groups are optionally substituted 1-4
times with a group independently selected from R.sup.c; [0427]
R.sup.c is [0428] a) -halogen, [0429] b) -amino, [0430] c)
-carboxy, [0431] d) --C.sub.1-4 alkyl, [0432] e) --O--C.sub.1-4
alkyl, [0433] f) -cycloalkyl, [0434] g) --O-cycloalkyl, [0435] h)
-aryl, [0436] i) --C.sub.1-4 alkylene-aryl, [0437] j) -hydroxy,
[0438] k) --CF.sub.3, [0439] l) --O-aryl, [0440] m) -heteroaryl,
[0441] n) -heteroaryl-C.sub.1-10 alkyl, [0442] o) heterocyclyl,
[0443] p) --CO.sub.2--C.sub.1-10 alkyl, or [0444] q)
--CO.sub.2--C.sub.1-10 alkyl-aryl, [0445] R.sup.d and R.sup.e are
independently selected from hydrogen, C.sub.1-10 alkyl,
C.sub.2-.sub.10 alkenyl, C.sub.2-10 alkynyl, cycloalkyl,
--C.sub.1-10 alkylene-cycloalkyl, aryl, heterocyclyl, wherein
alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl groups are
optionally substituted with one to four substituents independently
selected from R.sup.c; or R.sup.d and R.sup.e together with the
atoms to which they are attached form a heterocyclic ring of 5 to 7
members containing 0-2 additional heteroatoms independently
selected from oxygen, sulfur and nitrogen and optionally
substituted with 1-3 times with R.sup.c, and wherein 1 or 2 carbon
atoms in the heterocyclic ring may be oxidized, [0446] R.sup.f and
R.sup.g are independently selected from hydrogen, C.sub.1-10 alkyl,
cycloalkyl, --C.sub.1-10 alkylene-cycloalkyl, and aryl, wherein
alkyl, cycloalkyl, and aryl groups are optionally substituted with
one to four substituents independently selected from R.sup.c; or
R.sup.f and R.sup.g together with the carbon to which they are
attached form a ring of 5 to 7 members containing 0-2 heteroatoms
independently selected from oxygen, sulfur and nitrogen optionally
substituted with 1-3 times with R.sup.c, and wherein 1 or 2 carbon
atoms in the heterocyclic ring may be oxidized; [0447] m is an
integer from 1 to 2, [0448] n is an integer from 1 to 10, [0449] q
is an integer from 1 to 2, [0450] r is an integer from 1 to 5,
[0451] s is an integer from 0 to 3.
[0452] In an embodiment of the compound of Formula (IIc), L.sup.1
is -T.sup.1-L.sup.3-T.sup.2-, wherein L.sup.3, T.sup.1 and T.sup.2
are direct bonds. In another embodiment, L.sup.1 is
-T.sup.1-L.sup.3-T2-, wherein T.sup.1 and T.sup.2 are direct bonds
and L.sup.3 is --CH.sub.2--. In another embodiment, L.sup.1 is
-T.sup.1-L.sup.3-T.sup.2-, wherein L.sup.3 is a direct bond or
alkylene, T.sup.1 is a direct bond, and T.sup.2 is selected from
the group consisting of --O--, --N(R.sup.16)--, --C(O)--,
--CON(R.sup.16)--, --N(R.sup.17)C(O)--,
--N(R.sub.6)CON(R.sup.16)--, --N(R.sup.16)C(O)O--,
--OC(O)N(R.sup.16)--, --N(R.sup.16)SO.sub.2--,
--SO.sub.2N(R.sup.16)--, --C(O)--O--, --O--C(O)--, --S--, --S(O)--,
--S(O).sub.2--, and --N(R.sup.16)SO.sub.2N(R.sup.17)--. In another
embodiment, L.sup.1 is -T.sup.1-L.sup.3-T.sup.2-, wherein L.sup.3
is a direct bond or alkylene, T.sup.2 is a direct bond, and T.sup.1
is selected from the group consisting of --O--, --N(R.sup.16)--,
--C(O)--, --CON(R.sup.16)--, --N(R.sup.17)C(O)--,
--N(R.sub.6)CON(R.sup.16)--, --N(R.sup.16)C(O)O--,
--OC(O)N(R.sup.16)--, --N(R.sup.16)SO.sub.2--,
--SO.sub.2N(R.sup.16)--, --C(O)--O--, --O--C(O)--, --S--, --S(O)--,
--S(O).sub.2--, and --N(R.sup.16)SO.sub.2N(R.sup.17)--.
[0453] In another embodiment of the compound of Formula (IIc),
L.sup.2 is selected from the group consisting of --CH.sub.2-- or
--CH.sub.2--O--. In another embodiment, L.sup.2 is
--CH.sub.2--.
[0454] In another embodiment of the compound of Formula (IIc),
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently
selected from the group consisting of:
[0455] a) -hydrogen;
[0456] b) -fluoro;
[0457] c) -chloro;
[0458] d) trifluoromethyl;
[0459] e) trifluoromethoxy;
[0460] f) --SO.sub.2--C.sub.1-6alkyl;
[0461] g) -cyano;
[0462] h) -nitro; and
[0463] i) -phenyl.
[0464] In another embodiment, at least one of R.sup.1, R.sup.2,
R.sup.3, R.sup.4, and R.sup.5 is not hydrogen. In another
embodiment, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are
independently selected from the group consisting of hydrogen,
fluoro, and chloro, wherein at least one of at least one of
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 is not hydrogen. In
another embodiment, R.sup.1 and R.sup.3 are chloro or fluoro, and
R.sup.2, R.sup.4, and R.sup.5 are hydrogen.
[0465] In another embodiment of the compound of Formula (IIc), s is
an integer from 1 to 3 and R.sup.11 is independently selected from
the group consisting of: methyl, methoxy, chloro, fluoro, nitro,
cyano, hydroxy, trifluoromethyl, trifluoromethoxy,
--SO.sub.2--CH.sub.3, --SO.sub.2--CF.sub.3, --NHSO.sub.2--CH.sub.3,
--NHSO.sub.2--CF.sub.3, and cyclopropyl. In another embodiment, s
is zero.
[0466] In another embodiment of the compound of Formula (IIc),
R.sup.20, R.sup.21, and R.sup.22 are hydrogen, and one or more of
R.sup.23--R.sup.27 is independently selected from the group
consisting of: [0467] --C.sub.1-10 alkyl, [0468] -cycloalkyl,
[0469] -heterocyclyl, [0470] -trifluoroalkyl, [0471] -halogen,
[0472] -nitro, [0473] -carboxy, [0474] --CO.sub.2--C.sub.1-10
alkyl, [0475] --C.sub.1-10 alkylene-CO.sub.2--C.sub.1-10 alkyl,
[0476] --C.sub.2-10 alkenylene-CO.sub.2--C.sub.1-10 alkyl, [0477]
--C.sub.1-10 alkylene-CO.sub.2H, [0478] C.sub.2-10
alkenylene-CO.sub.2H, [0479] --O--C.sub.1-10
alkylene-C(O)NH--C.sub.1-10 alkyl, [0480] --C(O)--C.sub.1-10 alkyl,
[0481] --C(O)NH--C.sub.1-10 alkyl, [0482] --O-heterocyclyl, [0483]
--O--C.sub.1-10 alkyl, [0484] --O--C.sub.1-10 haloalkyl, [0485]
--O--C.sub.1-10 perhaloalkyl, [0486] --O-cycloalkyl, [0487]
--O-phenyl, [0488] -hydroxy, [0489] --O--C.sub.1-10
alkylene-cycloalkyl, --O--C.sub.1-10 alkylene-phenyl,
--S-heterocyclyl, [0490] --S--C.sub.1-10 alkyl, [0491]
--S--C.sub.1-10 haloalkyl, [0492] --S--C.sub.1-10 perhaloalkyl,
[0493] --S-cycloalkyl, --S-phenyl, [0494] --S--C.sub.1-10
alkylene-cycloalkyl, [0495] --S--C.sub.1-10 alkylene-phenyl, [0496]
--C.sub.1-10 alkylene-cycloalkyl, [0497] --C.sub.1-10
alkylene-phenyl, [0498] -amino, [0499] --NH(C.sub.1-10 alkyl),
[0500] --N(C.sub.1-10 alkyl).sub.2, [0501] --N(C.sub.1-10
alkyl)(C.sub.1-10 alkylene-cycloalkyl), [0502]
--NHCO.sub.2--C.sub.1-10 alkyl, [0503]
--NH(C.sub.1-10alkylene-cycloalkyl), [0504]
--S(O).sub.2--O.sub.2-10 alkyl, [0505] --SO.sub.2-cycloalkyl,
[0506] --SC.sub.2-C.sub.1-10 alkylene-cycloalkyl, [0507]
--S(O)--C.sub.1-10 alkyl, [0508] --S(O)-cycloalkyl, and [0509]
--S(O)--C.sub.1-10 alkylene-cycloalkyl, [0510] wherein alkyl,
alkenyl, aryl, heteroaryl, and cycloalkyl groups are optionally
substituted 1-4 times with a group independently selected from
R.sup.c.
[0511] In another embodiment of the compound of Formula (IIc),
R.sup.20, R.sup.21, and R.sup.22 are hydrogen, and one or more of
R.sup.23-R.sup.27 is independently selected from the group
consisting of: [0512] --C.sub.1-10 alkyl, [0513] -cycloalkyl,
[0514] -heterocyclyl, [0515] -trifluoroalkyl, [0516] -halogen,
[0517] -nitro, [0518] --CO.sub.2--C.sub.1-10 alkyl, [0519]
--C.sub.1-10 alkylene-CO.sub.2--C.sub.1-10 alkyl, [0520]
--C.sub.2-10 alkenylene-CO.sub.2--C.sub.1-10 alkyl, [0521]
--O--C.sub.1-10 alkylene-C(O)NH--C.sub.1-10 alkyl, [0522]
--C(O)--C.sub.1-10 alkyl, [0523] --C(O)NH--C.sub.1-10 alkyl, [0524]
--O-heterocyclyl, [0525] --O--C.sub.1-10 alkyl, [0526]
--O--C.sub.1-10 haloalkyl, [0527] --O--C.sub.1-10 perhaloalkyl,
[0528] --O-cycloalkyl, [0529] --O-phenyl, [0530] --O--C.sub.1-10
alkylene-cycloalkyl, [0531] --O--C.sub.1-10 alkylene-phenyl, [0532]
--S-heterocyclyl, [0533] --S--C.sub.1-10 alkyl, [0534]
--S--C.sub.1-10 haloalkyl, [0535] --S--C.sub.1-10 perhaloalkyl,
[0536] --S-cycloalkyl, [0537] --S-phenyl, [0538] --S--C.sub.1-10
alkylene-cycloalkyl, [0539] --S--C.sub.1-10 alkylene-phenyl, [0540]
--C.sub.1-10 alkylene-cycloalkyl, [0541] --C.sub.1-10
alkylene-phenyl, [0542] --NH(C.sub.1-10 alkyl), [0543]
--N(C.sub.1-10 alkyl).sub.2, [0544] --N(C.sub.1-10
alkyl)(C.sub.1-10 alkylene-cycloalkyl), [0545]
--NHCO.sub.2--C.sub.1-10 alkyl, [0546] --NH(C.sub.1-10
alkylene-cycloalkyl), [0547] --S(O).sub.2--C.sub.2-10 alkyl, [0548]
--SO.sub.2-cycloalkyl, [0549] --SO.sub.2--C.sub.1-10
alkylene-cycloalkyl, [0550] --S(O)--C.sub.1-10 alkyl, [0551]
--S(O)-cycloalkyl, and [0552] --S(O)--C.sub.1-10
alkylene-cycloalkyl.
[0553] In another embodiment of the compound of Formula (IIc),
R.sup.20, R.sup.21, and R.sup.22 are hydrogen, and one or more of
R.sup.23--R.sup.27 is independently selected from the group
consisting of: [0554] --C.sub.1-10 alkyl, [0555] -cycloalkyl,
[0556] -trifluoroalkyl, [0557] -halogen, [0558]
--CO.sub.2--C.sub.1-10 alkyl, [0559] --C.sub.1-10
alkylene-CO.sub.2--C.sub.1-10 alkyl, [0560] --C.sub.2-10
alkenylene-CO.sub.2--C.sub.1-10 alkyl, [0561] --O--C.sub.1-10
alkylene-C(O)NH--C.sub.1-10 alkyl, [0562] --C(O)--C.sub.1-10 alkyl,
[0563] --O--C.sub.1-10 alkyl, [0564] --O--C.sub.1-10 haloalkyl,
[0565] --O--C.sub.1-10 perhaloalkyl, [0566] --O-cycloalkyl, [0567]
--O-phenyl, [0568] --O--C.sub.1-10 alkylene-cycloalkyl, [0569]
--O--C.sub.1-10 alkylene-phenyl, [0570] --S--C.sub.1-10 alkyl,
[0571] --S--C.sub.1-10 haloalkyl, [0572] --S--C.sub.1-10
perhaloalkyl, [0573] --S-cycloalkyl, [0574] --S-phenyl, [0575]
--S--C.sub.1-10 alkylene-cycloalkyl, [0576] --S--C.sub.1-10
alkylene-phenyl, [0577] --C.sub.1-10 alkylene-cycloalkyl, [0578]
--C.sub.1-10 alkylene-phenyl, [0579] --S(O).sub.2--C.sub.2-10
alkyl, [0580] --SO.sub.2-cycloalkyl, [0581] --SO.sub.2--C.sub.1-10
alkylene-cycloalkyl, [0582] --S(O)--C.sub.1-10 alkyl, [0583]
--S(O)-cycloalkyl, and [0584] --S(O)--C.sub.1-10
alkylene-cycloalkyl.
[0585] In another embodiment of the compound of Formula (IIc),
R.sup.20, R.sup.21, and R.sup.22 are hydrogen, and one or more of
R.sup.23-R.sup.27 is independently selected from the group
consisting of: [0586] morpholine-4-yl, [0587] piperidine-4-yl,
[0588] piperidine-1-yl, [0589] 4-piperidinyl-oxy, [0590]
3-piperidinyl-oxy, [0591] 2-oxo-piperidine-1-yl, [0592]
3-oxo-piperidine-1-yl, [0593] [1-(C.sub.1-10
alkylsulfonyl)-piperidine-4-yl]-oxy, [0594] [1-(C.sub.1-10
alkyloxycarbonyl)-piperidine-4-yl]-oxy, [0595] [1-(C.sub.1-10
alkyloxycarbonyl)-piperidine-3-yl]-oxy, piperazine-1-yl, [0596]
4-(C.sub.1-10 alkyl)-piperazine-1-yl, [0597] 2-oxo-piperazine-4-yl,
[0598] 1-C.sub.1-10 alkyl-2-oxo-piperazine-4-yl, [0599]
1-cycloalkyl-2-oxo-piperazine-4-yl, [0600] 4-tetrahydropyranyloxy,
[0601] 3-tetrahydrofuranyloxy, [0602] 4-(C.sub.1-10
alkyloxycarbonyl)piperazine-1-yl, [0603] pyrrolidine-1-yl, [0604]
3-phenyl-pyrrolidine-1-yl, [0605] 3-cycloalkyl-pyrrolidine-1-yl,
[0606] [1-(C.sub.1-10 alkoxycarbonyl)-pyrrolidine-3-yl]-oxy, [0607]
2-thiophenyloxy, [0608] 2-thiazolyloxy, [0609]
(1,2,4-oxadiazole-3-yl)-oxy, [0610] (1-methyl-imidazole-2-yl)-oxy,
and [0611] (imidazole-2-yl)-C.sub.1-10 alkyoxy, [0612] wherein the
alkyl, phenyl, cycloalkyl, morpholine, piperidine, piperazine,
cycloalkyl, tetrahydropyran, tetrahydrofuran, pyrrolidine,
thiazole, imidazole groups are optionally substituted with a group
independently selected from IR'.
[0613] In another embodiment of the compound of Formula (IIc),
R.sup.20, R.sup.21, and R.sup.22 are hydrogen, and one or more of
R.sup.23-R.sup.27 is independently selected from the group
consisting of: methyl, ethyl, propyl, butyl, pentyl, hexyl,
1-ethyl-propyl, 1-propyl-butyl, 3,3-dimethyl-butyl,
4-methyl-pentyl, 4,4-dimethyl-pentyl,
1-(3,3-dimethyl-butyl)-4,4-dimethyl-pentyl, isobutyl, isopropyl,
sec-butyl, tert-butyl, trifluoromethyl, 4,4,4-trifluorobutoxy,
methoxy, ethoxy, propoxy, butoxy, pentoxy, hexyloxy, isobutoxy,
isopropoxy, tert-butoxy, 2-phenethoxy, 2,2-dimethylpropoxy,
3-methyl-butoxy, 3,3-dimethyl-butoxy, 3'-phenethyloxy,
2-cyclohexyl-ethanesulfonyl, 3,3-dimethyl-butane-1-sulfonyl,
cyclohexanesulfonyl, cyclohexylmethanesulfonyl,
cyclohexylmethylsulfonyl, 2-cyclohexyl-ethanesulfinyl,
3,3-dimethyl-butane-1-sulfinyl, cyclohexylmethylsulfinyl,
2-cyclohexyl-ethylsulfanyl, 3,3-dimethyl-butylsulfanyl,
phenethylsulfanyl, cyclohexylmethylsulfanyl, cyclopentyl,
cyclohexyl, cyclopentyloxy, cyclohexyloxy, cyclopentylmethyl,
cyclohexylmethyl, 2-cyclopentylethyl, 2-cyclohexylethyl,
cyclopentylmethoxy, cyclohexylmethoxy, 2-cyclopentylethoxy,
2-cyclohexylethoxy, 2-cyclohexyl-vinyl, 3-ethyl-cyclobutyl, chloro,
fluoro, and phenyl.
[0614] In another embodiment of the compound of Formula (IIc), V is
C, W is N, X is C, Y is N, Z is C--R.sup.6, and sides a, c, and d
are single bonds, and sides b and e are double bonds, and R.sup.6
is selected from the group consisting of hydrogen and --C.sub.1-10
alkyl.
[0615] In another embodiment of the compound of Formula (IIc),
D.sup.1 is C--R.sup.21, D.sup.2 is C--R.sup.22, R.sup.21 and
R.sup.22 are hydrogen, D.sup.3 is C--R.sup.23 and D.sup.4 is
C--R.sup.24. In another embodiment, D.sup.1 is C--R.sup.21, D.sup.2
is C--R.sup.22, R.sup.21 and R.sup.22 are hydrogen, and D.sup.3 and
D.sup.4 are N.
[0616] In an embodiment of the compound of Formula (IIc), G is
##STR00013##
[0617] wherein [0618] a) q is 2, D is C(R.sup.7)(R.sup.8), E is
C(R.sup.7) or N, when side f is a single bond, or [0619] b) q is 2,
D is C(R.sup.7), E is C, when side f is a double bond. In a further
embodiment, R.sup.7 and R.sup.8 are selected from the group
consisting of: hydrogen and C.sub.1-4 alkyl.
[0620] In another embodiment of the compound of Formula (IIc), G
is
##STR00014##
[0621] wherein [0622] q is 2, D is C(R.sup.7)(R.sup.8), E is N, and
side f is a single bond. In a further embodiment, R.sup.7 and
R.sup.8 are selected from the group consisting of: hydrogen and
C.sub.1-4 alkyl.
[0623] In another embodiment, G is
##STR00015##
[0624] wherein [0625] a) q is 2, D is C(R.sup.7), E is
C(R.sup.7)(R.sup.8) or N(R.sup.9), when side f is a single bond, or
[0626] b) q is 2, D is C, E is C(R.sup.7) or N, when side f is a
double bond. In a further embodiment, R.sup.7, R.sup.8, and R.sup.9
are selected from the group consisting of: hydrogen and C.sub.1-4
alkyl.
[0627] In another embodiment of the compound of Formula (IIc), the
compound has the formula:
##STR00016##
[0628] In another embodiment of the compound of Formula (IIc), the
compound has the formula:
##STR00017##
[0629] In the compounds of Formula (I-IV), the various functional
groups represented should be understood to have a point of
attachment at the functional group having the hyphen. In other
words, in the case of -alkylene-aryl, it should be understood that
the point of attachment is the alkylene group; an example would be
benzyl. In the case of a group such as --C(O)--NH-- alkylene-aryl,
the point of attachment is the carbonyl carbon.
[0630] Also included within the scope of the invention are the
individual enantiomers of the compounds represented by Formula
(I-IV) above as well as any wholly or partially racemic mixtures
thereof. The present invention also covers the individual
enantiomers of the compounds represented by formula above as
mixtures with diastereoisomers thereof in which one or more
stereocenters are inverted. Unless otherwise stated, structures
depicted herein are also meant to include compounds that differ
only in the presence of one or more isotopically enriched atoms.
For example, compounds having the present structure except for the
replacement of a hydrogen atom by a deuterium or tritium, or the
replacement of a carbon atom by a .sup.13C or .sup.14C-enriched
carbon are within the scope of the invention.
[0631] In another aspect, the present invention provides a
pharmaceutically acceptable salt, solvate, or prodrug of compounds
of Formula (I-IV). In an embodiment, the prodrug comprises a
biohydrolyzable ester or biohydrolyzable amide of a compound of
Formula (I-IV).
[0632] Examples of compounds of Formula (I-IV) of the present
invention having potentially useful biological activity are listed
by name below in Table 1. The ability of compounds Formula (I-IV)
to inhibit PTP-1B was established with representative compounds of
Formula (I-IV) listed in Table I using a standard primary/secondary
assay test procedure that measures the inhibition of PTP-1B
activity. The compounds of Formula I in Table I may inhibit PTP-IB
with an IC50 of less than 10 microMolar (.mu.M; 10.sup.-6 M).
[0633] Compounds that inhibit PTP-1B activity are potentially
useful in treating metabolic disorders related to insulin
resistance or hyperglycemia, typically associated with obesity or
glucose intolerance. The compounds of Formula (I-IV) of the present
invention may therefore be particularly useful in the treatment or
inhibition of Type II diabetes. The compounds of this invention may
also potentially be useful in modulating glucose levels in
disorders such as Type I diabetes.
TABLE-US-00001 TABLE 1 Ex Structure Name 1 ##STR00018##
5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 2 ##STR00019##
5-{4-[2-(4'-Cyclopentyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 3 ##STR00020##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(3'-propoxy-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 4 ##STR00021## 5-{4-[4-(2,4-Dichloro-phenyl)-
2-(4'-propoxy-biphenyl-4- ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 5 ##STR00022##
5-{4-[2-(3'- cyclopentylmethoxy- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 6 ##STR00023##
5-(4-{4-(2,4-Dichloro- phenyl)-2-[3'-(3,3-dimethyl-
butoxy)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 7 ##STR00024##
5-(4-{4-(2,4-Dichloro- phenyl)-2-[4-(4-phenyl-
piperidin-1-yl)-benzyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 8 ##STR00025##
4'-{4-(2,4-Dichloro-phenyl)-1- [4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-3- carboxylic acid methyl ester 9 ##STR00026##
4'-{4-(2,4-Dichloro-phenyl)-1- [4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-3- carboxylic acid 10 ##STR00027##
5-{4-[2-[4-(6-Chloro-pyridin- 3-yl)-benzyl]-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 11 ##STR00028## 5-{4-[2-(6-Cyclohexyloxy-
pyridin-3-yl)-benzyl]-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 12
##STR00029## 5-(4-{4-(2,4-Dichloro- phenyl)-2-[4-(3,4,5,6-
tetrahydro-2H- [1,2']bipyridinyl-5'-yl)-benzyl]-
imidazol-1-yl}-phenyl)-1,2,5- thiadiazolidine-3-one-1,1- dioxide 13
##STR00030## 5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-2-methyl-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 14 ##STR00031##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
difluoro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 15 ##STR00032##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
difluoro-phenyl)-imidazol-1- yl]-2-methyl-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 16 ##STR00033##
5-{4-[4-(4-Chloro-phenyl)-2- (4'-cyclohexyl-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 17 ##STR00034## 5-{4-[4-(2-Chloro-phenyl)-2-
(4'-cyclohexyl-biphenyl-4- ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 18 ##STR00035##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,6-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 19 ##STR00036##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-
(2,4,6-trichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 20 ##STR00037##
5-{4-[4-(2-Chloro-4-fluoro- phenyl)-2-(4'-cyclohexyl-
biphenyl-4-ylmethyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 21 ##STR00038##
(4'-{4-(2,4-Dichloro-phenyl)- 1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)-(5- methyl-isoxazol-3-ylmethyl)- carbamic
acid isopropyl ester 22 ##STR00039## (4'-{4-(2,4-Dichloro-phenyl)-
1-[4-(1,1,4-trioxo- [1,2,5]thiadiazolidin-2-yl)-
phenyl]-1H-imidazol-2- ylmethyl}-biphenyl-4-yl)- isobutyl-carbamic
acid isopropyl ester 23 ##STR00040## 5-{3-[2-(4'-Cyclohexyl-
biphenyl-4-ylmethyl)-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 24
##STR00041## 5-{3-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 25 ##STR00042##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(3,3-dimethyl-
butoxy)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 26 ##STR00043##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(3'-methanesulfonyl-
biphenyl-4-ylmethyl)- imidazol-1-yl]phenyl}-1,2,5-
thiadiazolidine-3-one-1,1 dioxide 27 ##STR00044## 5-{3-[2-(3'-
Cyclohexanesulfonyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 28 ##STR00045## 5-{3-[2-(4'-
Cyclohexanesulfonyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 29 ##STR00046##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(3'-propoxy-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiazolidine-
3-one-1,1-dioxide 30 ##STR00047## 5-{3-[2-(3'-Butoxy-biphenyl-
4-ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 31 ##STR00048##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(4,4,4-trifluoro-
butoxy)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 32 ##STR00049##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(3'-ethoxy-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dione 33 ##STR00050## 5-{3-[2-(3'- Cyclohexylmethoxy-
biphenyl-4-ylmethyl)-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 34
##STR00051## 5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(3-methyl-
butoxy)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 35 ##STR00052## 5-{3-[2-(3'-
Cyclopentylmethoxy- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 36 ##STR00053##
5-{3-[2-(3'-Cyclohexyloxy- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 37 ##STR00054##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(2,2-dimethyl-
propoxy)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 38 ##STR00055##
5-{3-[2-(3'-Tert-butoxy- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxid 39 ##STR00056##
5-{3-[2-[3'-(2-Cyclohexyl- ethoxy)-biphenyl-4-ylmethyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 40 ##STR00057##
5-{3-[2-[3'-(2-Cyclopentyl- ethoxy)-biphenyl-4-ylmethyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 41 ##STR00058##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(3'-phenethyloxy-biphenyl-
4-ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 42 ##STR00059## 5-(3-{4-(2,4-Dichloro-
phenyl)-2-[3'-(4,4-dimethyl- pentyl)-biphenyl-4-ylmethyl]-
imidazol-1-yl}-phenyl)-1,2,5- thiadiazolidine-3-one-1,1- dioxide 43
##STR00060## 5-{3-[2-[3'-(2-Cyclohexyl-
ethyl)-biphenyl-4-ylmethyl]-4- (2,4-dichloro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 44
##STR00061## 5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(3,3-dimethyl-
butylsulfanyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 45 ##STR00062##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(3,3-dimethyl-
butane-1-sulfonyl)-biphenyl- 4-ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 46 ##STR00063##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[3'-(3,3-dimethyl-
butane-1-sulfinyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 47 ##STR00064##
5-{3-[2-(3'- Cyclohexylmethylsulfanyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 48 ##STR00065## 5-{3-[2-(3'-
Cyclohexylmethylsulfonyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 49 ##STR00066## 5-{3-[2-(3'-
Cyclohexylmethylsulfinyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 50 ##STR00067##
5-{3-[2-(3'-(2-Cyclohexyl- ethylsulfanyl)-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 51 ##STR00068##
5-{3-[2-(3'-(2-Cyclohexyl- ethanesulfonyl)-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadazolidine- 3-one-1,1-dioxide 52 ##STR00069##
5-{3-[2-(3'-(2-Cyclohexyl- ethanesulfinyl)-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 53 ##STR00070##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(3'-phenethylsulfanyl-
biphenyl-4-ylmethyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 54 ##STR00071##
5-(3-{4-(2,4-Difluoro-phenyl)- 2-[3'-(3,3-dimethyl-
butylsulfanyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 55 ##STR00072##
5-(3-{4-(2,4-Difluoro-phenyl)- 2-[3'-(3,3-dimethyl-butane-1-
sulfonyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 56 ##STR00073##
5-(3-{4-(2,4-Difluoro-phenyl)- 2-[3'-(3,3-dimethyl-butane-1-
sulfinyl)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 57 ##STR00074##
5-{3-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
difluoro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 58 ##STR00075##
5-{5-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
difluoro-phenyl)-imidazol-1- yl]-2-methyl-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 59 ##STR00076##
5-{5-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-2-methyl-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 60 ##STR00077##
5-{5-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-2-methoxy-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 61 ##STR00078##
5-{5-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,6-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 62 ##STR00079##
5-{3-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-
(2,4,6-trichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 63 ##STR00080##
5-(3-{4-(2,6-Dichloro- phenyl)-2-[3'-(3,3-dimethyl-
butoxy)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 64 ##STR00081## 5-{3-[2-(3'-
Cyclohexylmethoxy- biphenyl-4-ylmethyl)-4-(2,6-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 65 ##STR00082##
5-(3-{4-(2,4-Difluoro-phenyl)- 2-[3'-(3,3-dimethyl-butoxy)-
biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 66 ##STR00083##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(4'-piperazin-1-yl-biphenyl-
4-ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 67 ##STR00084## 5-(4-{4-(2,4-Dichloro-
phenyl)-2-[4'-(4-methyl- piperazin-1-yl)-biphenyl-4-
ylmethyl]-imidazol-1-yl}- phenyl)-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 68 ##STR00085## 4-(4'-{4-(2,4-Dichloro-
phenyl)-1-[4-(1,1,4-trioxo- [1,2,5]thiadiazolidin-2-yl)-
phenyl]-1H-imidazol-2- ylmethyl}-biphenyl-4-yl)- piperazin-2-one 69
##STR00086## 4-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- piperazine-1-carboxylic acid
2,2-dimethyl-propyl ester 70 ##STR00087## 4-(4'-{4-(2,4-Dichloro-
phenyl)-1-[4-(1,1,4-trioxo- [1,2,5]thiadiazolidin-2-yl)-
phenyl]-1H-imidazol-2- ylmethyl}-biphenyl-4-yl)-1-
methyl-piperazin-2-one 71 ##STR00088## 4-(4'-{4-(2,4-Dichloro-
phenyl)-1-[4-(1,1,4-trioxo- [1,2,5]thiadiazolidin-2-yl)-
phenyl]-1H-imidazol-2- ylmethyl}-biphenyl-4-yl)-1-
ethyl-piperazin-2-one 72 ##STR00089## 4-(4'-{4-(2,4-Dichloro-
phenyl)-1-[4-(1,1,4-trioxo- [1,2,5]thiadiazolidin-2-yl)-
phenyl]-1H-imidazol-2- ylmethyl}-biphenyl-4-yl)-1-
isopropyl-piperazin-2-one 73 ##STR00090##
1-Cyclohexyl-4-(4'-{4-(2,4- dichloro-phenyl)-1-[4-(1,1,4-
trioxo-[1,2,5]thiadiazolidin-2- yl)-phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- piperazin-2-one 74 ##STR00091##
1-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- piperidin-2-one 75 ##STR00092##
1-Cyclohexyl-4-(4-{4-(2,4- dichloro-phenyl)-1-[4-(1,1,4-
trioxo-[1,2,5]thiadiazolidin-2- yl)-phenyl]-1H-imidazol-2-
ylmethyl}-phenyl)-1H-pyridin- 2-one 76 ##STR00093##
5-(4-{4-(2,4-Dichloro- phenyl)-2-[4'-(3-ethyl-
cyclobutyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 77 ##STR00094##
5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-4-methyl-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 78 ##STR00095##
5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-4-ethyl-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 79 ##STR00096##
5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-4,4-dimethyl-
1,2,5-thiadiazolidine-3-one 1,1-dioxide 80 ##STR00097##
1-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-2,2-dioxo-thia-
1,3-diaza-spiro[4.5]decan-4- one 81 ##STR00098##
5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
difluoro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 82 ##STR00099##
(4R)-5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-4-ethyl-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 83 ##STR00100##
(4S)-5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-4-ethyl-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 84 ##STR00101##
(4S)-5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-4-propyl-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 85 ##STR00102##
5-(3-{4-(2,4-Dichloro- phenyl)-2-{4'-[(3S)-3-phenyl-
pyrrolidin-1-yl]-biphenyl-4- ylmethyl}-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 86 ##STR00103##
5-(3-{4-(2,4-Dichloro- phenyl)-2-{4'-[(3R)-3-phenyl-
pyrrolidin-1-yl]-biphenyl-4- ylmethyl}-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 87 ##STR00104##
5-{3-[2-{4'-[(3S)-3- Cyclohexyl-pyrrolidin-1-yl]-
biphenyl-4-ylmethyl}-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 88
##STR00105## 5-{3-[2-{4'-[(3R)-3- Cyclohexyl-pyrrolidin-1-yl]-
biphenyl-4-ylmethyl}-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 89
##STR00106## 5-{3-[2-{3'-[(3S)-3- Cyclohexyl-pyrrolidin-1-yl]-
biphenyl-4-ylmethyl}-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 90
##STR00107## 5-{4-[2-(4'-Tert-butyl- biphenyl-4-yl)-5-(2,4-
dichloro-phenyl)-3H- imidazol-4-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 91 ##STR00108##
5-{4-[2-(4'-Tert-butyl- biphenyl-4-ylmethyl)-5-(2,4-
dichloro-phenyl)-3H- imidazol-4-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 92 ##STR00109##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- ylmethyl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 93 ##STR00110##
5-{4-[1-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-1H- imidazol-2-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 94 ##STR00111##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(3'-hydroxy-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 95 ##STR00112## 5-{4-[2-[4-(5-Cyclohexyl-
pyridin-2-yl)-benzyl]-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 96
##STR00113## 5-{3-[2-{4-[6-(2-Cyclohexyl- ethoxy)-pyridazin-3-yl]-
benzyl}-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 97 ##STR00114##
5-{3-[2-{4-[6-(2-Cyclohexyl- ethylsulfanyl)-pyridazin-3-yl]-
benzyl}-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 98 ##STR00115##
5-{4-[2-(4'-sec-Butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- ylmethyl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 99 ##STR00116##
5-{4-[2-(4'-sec-Butyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 100 ##STR00117##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 101 ##STR00118##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(4'-isobutyl-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 102 ##STR00119## 5-{4-[4-(2,4-Dichloro-phenyl)-
2-(4'-morpholin-4-yl- biphenyl-4-ylmethyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
103 ##STR00120## 5-{4-[2-(4'-Butyl-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 104 ##STR00121##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(4'-piperidin-1-yl-biphenyl-
4-ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 105 ##STR00122## 5-{4-[4-(2,4-Dichloro-phenyl)-
2-(4'-isopropyl-biphenyl-4- ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 106 ##STR00123##
5-{4-[2-(3'-Nitro-4'-isobutyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 107 ##STR00124##
5-{4-[2-(3'-Amino-4'-isobutyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 108 ##STR00125##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(3'-diethylamino-4'-
isobutyl-biphenyl-4- ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 109 ##STR00126##
4-{2-(4'-Cyclohexyl-biphenyl- 4-ylmethyl)-1-[4-(1,1,1-trioxo-
1-[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-4-yl}- benzoic
acid methyl ester 110 ##STR00127## 4-{2-(4'-Cyclohexyl-biphenyl-
4-ylmethyl)-1-[4-(1,1,4-trioxo- 1-[1,2,5]thiadiazolidin-2-yl)-
phenyl]-1H-imidazol-4-yl}- benzoic acid 111 ##STR00128##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(4'-propionyl-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 112 ##STR00129## 5-{4-[4-(2,4-Dichloro-phenyl)-
2-(4'-pentyl-biphenyl-4- ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 113 ##STR00130##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(4-
trifluoromethyl-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 114 ##STR00131##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(4'-propyl-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 115 ##STR00132## 5-{4-[2-(4'-Cyclohexyl-
biphenyl-4-ylmethyl)-4-(4- methanesulfonyl-phenyl)-
imidazol-1-yl]-phenyl]-1,2,5- thiadiazolidine-3-one-1,1- dioxide
116 ##STR00133## 5-(4-{4-(2,4-Dichloro-
phenyl)-2-[4'-(1-ethyl-propyl)- biphenyl-4-ylmethyl]-
imidazol-1-yl}-phenyl)-1,2,5- thiadiazolidine-3-one-1,1- dioxide
117 ##STR00134## (4'-{4-(2,4-Dichloro-phenyl)-
1-[4-(1,1,4-trioxo-1-[1,2,5] thiadiazolidin-2-yl)-phenyl]-
1H-imidazol-2-ylmethyl}-4- isobutyl-biphenyl-3-yl)- carbamic acid
isopropyl ester 118 ##STR00135## 5-{4-[2-(3'-Butylamino-4'-
isobutyl-biphenyl-4- ylmethyl)-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 119 ##STR00136## 5-{3-[2-(4'-Butyl-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 120 ##STR00137##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(4'-isobutyl-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 121 ##STR00138## 5-{3-[4-(2,4-Dichloro-phenyl)-
2-(4'-piperidin-1-yl-biphenyl- 4-ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 122 ##STR00139##
5-{3-[2-(3'-Nitro-4'-isobutyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 123 ##STR00140##
5-{3-[2-(3'-Amino-4'-isobutyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 124 ##STR00141##
(4'-{4-(2,4-Dichloro-phenyl)- 1-[3-(1,1,4-trioxo-1-[1,2,5]
thiadiazolidin-2-yl)-phenyl]-
1H-imidazol-2-ylmethyl}-4- isobutyl-biphenyl-3-yl)- carbamic acid
methyl ester 125 ##STR00142## 5-{3-[4-(2,4-Dichloro-phenyl)-
2-(2'-fluoro-5-propoxy- biphenyl-4-ylmethyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
126 ##STR00143## 5-{3-[2-(2'-Butoxy-biphenyl-
4-ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 127 ##STR00144##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[4'-(3,3-dimethyl-
butoxy)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 128 ##STR00145##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(4'-isobutoxy-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 129 ##STR00146## 5-{3-[2-(4'- Cyclohexylmethoxy-
biphenyl-4-ylmethyl)-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 130
##STR00147## 5-(3-{4-(2,4-Dichloro- phenyl)-2-[4'-(3,3-dimethyl-
butylsulfanyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 131 ##STR00148##
5-{3-[2-(4'- Cyclohexylmethylsulfanyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 132 ##STR00149## 5-{3-[2-(4'-
Cyclohexylmethanesulfonyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 133 ##STR00150##
5-{3-[2-[4'-(2-Cyclohexyl- ethoxy)-biphenyl-4-ylmethyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 134 ##STR00151## 5-{3-[2-[4'-
(Cyclohexylmethyl-amino)- biphenyl-4-ylmethyl]-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 135 ##STR00152##
5-{3-[2-(4'-Amino-biphenyl-4- ylmethyl)-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 136 ##STR00153## 5-{3-[2-{4'-[Bis-(3,3-dimethyl-
butyl)-amino]-biphenyl-4- ylmethyl}-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 137 ##STR00154## 5-{3-[4-(2,4-Dichloro-phenyl)-
2-(4'-morpholin-4-yl- biphenyl-4-ylmethyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
138 ##STR00155## 5-{3-[2-[4'-(2-Cyclohexyl-
ethylsulfanyl)-biphenyl-4- ylmethyl]-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 139 ##STR00156## 5-{3-[2-[4'-
(Cyclohexylmethyl-ethyl- amino)-biphenyl-4-ylmethyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 140 ##STR00157##
2-tert-Butyl-5-{3-[2-(4'- cyclohexylmethoxy-biphenyl-
4-ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-isothiazol-3-one-1,1- dioxide 141 ##STR00158##
4-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yloxy)- piperidine-1-carboxylic acid
2,2-dimethyl-propyl ester 142 ##STR00159##
5-{4-[4-(2,4-Dichloro-phenyl)- 2-(3'-isopropyl-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 143 ##STR00160## 5-{4-[4-(2,4-Dichloro-phenyl)-
2-(4'-trifluoromethyl-biphenyl- 4-ylmethyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 144 ##STR00161##
5-{2-Chloro-4-[2-(4'- cyclohexyl-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 145 ##STR00162##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-3-methyl-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 146 ##STR00163##
5-{3-Chloro-4-[2-(4'- cyclohexyl-biphenyl-4-
ylmethyl)-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 147 ##STR00164##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-3-trifluoromethyl-phenyl}-
1,2,5-thiadiazolidine-3-one 1,1-dioxide 148 ##STR00165##
5-{4-[2-(4'-Cyclohexyl- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-3-fluoro-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 149 ##STR00166##
3-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- acrylic acid ethyl ester 150 ##STR00167##
3-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- propionic acid ethyl ester 151
##STR00168## 3-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- acrylic acid 152 ##STR00169##
3-(4'-{4-(2,4-Dichloro- phenyl)-1-[4-(1,1,4-trioxo-
[1,2,5]thiadiazolidin-2-yl)- phenyl]-1H-imidazol-2-
ylmethyl}-biphenyl-4-yl)- propionic acid 153 ##STR00170##
5-(4-{4-(2,4-Dichloro- phenyl)-2-[4'-(1-propyl-butyl)-
biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 154 ##STR00171##
5-[3-(4-(2,4-Dichloro-phenyl)- 2-{4'-[1-(3,3-dimethyl-butyl)-
4,4-dimethyl-pentyl]- biphenyl-4-ylmethyl}-
imidazol-1-yl)-phenyl]-1,2,5- thiadiazolidine-3-one-1,1- dioxide
155 ##STR00172## 5-(3-{4-(2,4-Dichloro-
phenyl)-2-[4'-(4,4-dimethyl- pentyl)-biphenyl-4-ylmethyl]-
imidazol-1-yl}-phenyl)-1,2,5- thiadiazolidine-3-one-1,1- dioxide
156 ##STR00173## 5-{3-[2-[4'-(2-Cyclohexyl-
ethyl)-biphenyl-4-ylmethyl]-4- (2,4-dichloro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
157 ##STR00174## 5-(3-{4-(2,4-Dichloro-
phenyl)-2-[4'-(3,3-dimethyl- butyl)-biphenyl-4-ylmethyl]-
imidazol-1-yl}-phenyl)-1,2,5- thiadiazolidine-3-one-1,1- dioxide
158 ##STR00175## 5-{3-[2-(4'-Cyclohexylmethyl-
biphenyl-4-ylmethyl)-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide 159
##STR00176## 5-(3-{4-(2,4-Dichloro- phenyl)-2-[4'-(4-methyl-
pentyl)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 160 ##STR00177##
5-{3-[2-[4'-(2-Cyclohexyl- vinyl)-biphenyl-4-ylmethyl]-4-
(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 161 ##STR00178##
5-{4-[2-(4-Bromo-benzyl)-4- (2,4-dichloro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
162 ##STR00179## 5-{4-[2-(4-Bromo-benzyl)-4- (2,6-dichloro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
163 ##STR00180## 5-{3-[2-(4-Bromo-benzyl)-4- (2,4-dichloro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
164 ##STR00181## 5-{4-[2-(4-Bromo-benzyl)-4- (2,4-difluoro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
165 ##STR00182## 5-{5-[2-(4-Bromo-benzyl)-4- (2,4-dichloro-phenyl)-
imidazol-1-yl]-2-methyl- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 166 ##STR00183## 5-{5-[2-(4-Bromo-benzyl)-4-
(2,4-difluoro-phenyl)- imidazol-1-yl]-2-methyl-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 167 ##STR00184##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(4'-phenoxy-biphenyl-4-
ylmethyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 168 ##STR00185## 5-{3-[4-(2,4-Dichloro-phenyl)-
2-(4-hex-1-enyl-benzyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 169 ##STR00186##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[4-(3,3-dimethyl-
but-1-enyl)-benzyl]-imidazol- 1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 170 ##STR00187##
5-{3-[2-[4-(2-Cyclohexyl- vinyl)-benzyl]-4-(2,4-dichloro-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 171 ##STR00188##
5-{4-[2-[3'-(2-Cyclohexyl- ethoxy)-biphenyl-4-ylmethyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 172 ##STR00189##
5-{4-[2-{4-[6-(2-Cyclohexyl- ethoxy)-pyridazin-3-yl]-
benzyl}-4-(2,4-dichloro- phenyl)-imidazol-1-yl]-
phenyl}-1,2,5-thiadiazolidine- 3-one-1,1-dioxide 173 ##STR00190##
5-{3-[2-[4-(6-Cyclohex-1- enyl-pyridazin-3-yl)-benzyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 174 ##STR00191##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(4-oct-1-enyl-benzyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
175 ##STR00192## 5-{4-[4-(2,4-Dichloro-phenyl)-
2-(4-hex-1-ynyl-benzyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 176 ##STR00193## 5-{3-[2-(4'-
Cyclohexylmethoxy- biphenyl-4-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-isothiazol-3-one
1,1-dioxide 177 ##STR00194## 5-{4-[2-(4'- Cyclohexylmethoxy-
biphenyl-4-ylmethyl)-4-(2,4- dichloro-phenyl)-imidazol-1-
yl]-phenyl}1,2,5]- thiadiazolidin-3-one-1,1- dioxide 178
##STR00195## 5-(4-{4-(2,4-Dichloro- phenyl)-2-[4'-(3,3-dimethyl-
butoxy)-biphenyl-4-yl methyl]-imidazol-1-yl}-
phenyl)-1,2,5]-thiadiazolidin- 3-one-1,1-dioxide 179 ##STR00196##
5-{4-[2-[4'-(2-Cyclohexyl- ethoxy)-biphenyl-4-ylmethyl]-
4-(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-
1,2,5]-thiadiazolidin-3-one- 1,1-dioxide 180 ##STR00197##
5-{4-[2-(6- Cyclohexylmethoxy- naphthalen-2-ylmethyl)-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}1,2,5]-
thiadiazolidin-3-one-1,1- dioxide 181 ##STR00198##
5-{4-[2-[4-(2-Cyclohexyl- vinyl)-benzyl]-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl} 1,2,5]thiadiazolidin-3-one-
1,1-dioxide 182 ##STR00199## 5-{3-[2-[4'-(2-Cyclopentyl-1-
hydroxy-ethyl)-biphenyl-4- ylmethyl]-4-(2,4-dichloro-
phenyl)-imidazol-1-yl]- phenyl}-1,2,5-thiadiazolidin-
3-one-1,1-dioxide 183 ##STR00200## 5-{3-[2-[4'-(2-Cyclopentyl-
ethyl)-biphenyl-4-ylmethyl]-4- (2,4-dichloro-phenyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidin-3-one-1,1- dioxide 184
##STR00201## 5-(3-{4-(2,4-Dichloro- phenyl)-2-[4'-(4,4-dimethyl-
pent-1-enyl)-biphenyl-4- ylmethyl]-imidazol-1-yl}-
phenyl)-1,2,5-thiadiazolidin- 3-one-1,1-dioxide 185 ##STR00202##
5-(4-{4-(2,4-Dichloro- phenyl)-2-[4'-(4-methyl-
pentyl)-biphenyl-4-ylmethyl]- imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidin-3-one-1,1- dioxide 186 ##STR00203##
5-{4-[2-[4'-(2-Cyclopentyl- ethyl)-biphenyl-4-ylmethyl]-4-
(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidin-3-one-1,1- dioxide 187 ##STR00204##
5-{3-[4-(2,4-Dichloro-phenyl)- 2-(4-hept-1-enyl-benzyl)-
imidazol-1-yl]-phenyl}-1,2,5- thiadiazolidine-3-one-1,1- dioxide
188 ##STR00205## 5-{3-[4-(2,4-Dichloro-phenyl)-
2-(4-pent-1-enyl-benzyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 189 ##STR00206##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[4-(3-phenyl-
propenyl)-benzyl]-imidazol-1- yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 190 ##STR00207## 5-{3-[2-[4-(6-
Cyclohexylmethoxy- pyridazin-3-yl)-benzyl]-4-
(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 191 ##STR00208##
5-{3-[2-[4-(6-Cyclohexyl- pyridazin-3-yl)-benzyl]-4-
(2,4-dichloro-phenyl)- imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 192 ##STR00209##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[4-(4-methyl-pent-
1-enyl)-benzyl]-imidazol-1- yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 193 ##STR00210##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[4-(1-methyl-hex-
1-enyl)-benzyl]-imidazol-1- yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 194 ##STR00211##
5-(3-{4-(2,4-Dichloro- phenyl)-2-[4-(5-methyl-hex-
1-enyl)-benzyl]-imidazol-1- yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1- dioxide 195 ##STR00212##
5-{3-[2-[4-(3-Cyclohexyl- propenyl)-benzyl]-4-(2,4-
dichloro-phenyl)-imidazol-1- yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1- dioxide
[0634] Incomplete valences for heteroatoms such as oxygen and
nitrogen in the chemical structures listed in Table 1 are assumed
to be completed by hydrogen.
[0635] In another aspect, the present invention comprises a
pharmaceutical composition comprising the compound of Formula
(I-IV) and a pharmaceutically acceptable carrier, excipient,
diluent, or a mixture thereof.
[0636] As used herein, the term "lower" refers to a group having
between one and six carbons.
[0637] As used herein, the term "alkyl" refers to a straight or
branched chain hydrocarbon having from one to ten carbon atoms,
optionally substituted and multiple degrees of substitution being
allowed. Examples of "alkyl" as used herein include, but are not
limited to, methyl, n-butyl, t-butyl, n-pentyl, isobutyl, and
isopropyl, and the like.
[0638] As used herein, the term "alkylene" refers to a straight or
branched chain divalent hydrocarbon radical having from one to ten
carbon atoms, optionally substituted and multiple degrees of
substitution being allowed. Examples of "alkylene" as used herein
include, but are not limited to, methylene, ethylene, and the
like.
[0639] As used herein, the term "alkenyl" refers to a hydrocarbon
radical having from two to ten carbons and at least one
carbon-carbon double bond, optionally substituted and multiple
degrees of substitution being allowed. Examples of "alkenyl" as
used herein include, but are not limited to,
3,3-dimethyl-but-1-enyl, 4-hex-1-enyl, and the like.
[0640] As used herein, the term "alkenylene" refers to a straight
or branched chain divalent hydrocarbon radical having from two to
ten carbon atoms and one or more carbon--carbon double bonds,
optionally substituted and multiple degrees of substitution being
allowed. Examples of "alkenylene" as used herein include, but are
not limited to, ethene-1,2-diyl, propene-1,3-diyl,
methylene-1,1-diyl, and the like.
[0641] As used herein, the term "alkynyl" refers to a hydrocarbon
radical having from two to ten carbons and at least one
carbon-carbon triple bond, optionally substituted and multiple
degrees of substitution being allowed. Examples of "alkynyl" as
used herein include, but are not limited to, 4-hex-lynyl,
3,3-dimethyl-but-lynyl, and the like.
[0642] As used herein, the term "alkynylene" refers to a straight
or branched chain divalent hydrocarbon radical having from two to
ten carbon atoms and one or more carbon-carbon triple bonds,
optionally substituted and multiple degrees of substitution being
allowed. Examples of "alkynylene" as used herein include, but are
not limited to, ethyne-1,2-diyl, propyne-1,3-diyl, and the
like.
[0643] As used herein, "cycloalkyl" refers to an alicyclic
hydrocarbon group and optionally possessing one or more degrees of
unsaturation, having from three to twelve carbon atoms, optionally
substituted and multiple degrees of substitution being allowed.
Examples of "cycloalkyl" as used herein include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclooctyl, and the like.
[0644] As used herein, the term "cycloalkylene" refers to an
non-aromatic alicyclic divalent hydrocarbon radical having from
three to twelve carbon atoms and optionally possessing one or more
degrees of unsaturation, optionally substituted with substituents
and multiple degrees of substitution being allowed. Examples of
"cycloalkylene" as used herein include, but are not limited to,
cyclopropyl-1,1-diyl, cyclopropyl-1,2-diyl, cyclobutyl-1,2-diyl,
cyclopentyl-1,3-diyl, cyclohexyl-1,4-diyl, cycloheptyl-1,4-diyl,
cyclooctyl-1,5-diyl, and the like.
[0645] As used herein, the term "heterocyclic" or the term
"heterocyclyl" refers to a non-aromatic three to twelve-membered
heterocyclic ring optionally possessing one or more degrees of
unsaturation, containing one or more heteroatomic substitutions
selected from S, SO, SO.sub.2, O, or N, optionally substituted and
multiple degrees of substitution being allowed. Such a ring may be
optionally fused to one or more of another "heterocyclic" ring(s)
or cycloalkyl ring(s). Examples of "heterocyclyl" include, but are
not limited to, tetrahydrofuran, tetrahydropyran, 1,4-dioxane,
1,3-dioxane, piperidine, pyrrolidine, morpholine, piperazine, and
the like.
[0646] As used herein, the term "heterocyclylene" refers to a
non-aromatic three to twelve-membered heterocyclic ring diradical
optionally having one or more degrees of unsaturation containing
one or more heteroatoms selected from S, SO, SO.sub.2, O, or N,
optionally substituted and multiple degrees of substitution being
allowed. Such a ring may be optionally fused to one or more benzene
rings or to one or more of another "heterocyclic" rings or
cycloalkyl rings. Examples of "heterocyclylene" include, but are
not limited to, tetrahydrofuran-2,5-diyl, morpholine-2,3-diyl,
pyran-2,4-diyl, 1,4-dioxane-2,3-diyl, 1,3-dioxane-2,4-diyl,
piperidine-2,4-diyl, piperidine-1,4-diyl, pyrrolidine-1,3-diyl,
morpholine-2,4-diyl, piperazine-1,4-diyl, and the like.
[0647] As used herein, the term "aryl" refers to a benzene ring or
to benzene ring fused to one to three benzene rings, optionally
substituted and multiple degrees of substitution being allowed.
Examples of aryl include, but are not limited to, phenyl,
2-naphthyl, 1-naphthyl, 1-anthracenyl, and the like.
[0648] As used herein, the term "arylene" refers to a benzene ring
diradical or to a benzene ring system diradical fused to one to
three optionally substituted benzene rings, optionally substituted
and multiple degrees of substitution being allowed. Examples of
"arylene" include, but are not limited to, benzene-1,4-diyl,
naphthalene-1,8-diyl, and the like.
[0649] As used herein, the term "heteroaryl" refers to a five- to
seven-membered aromatic ring, or to a polycyclic heterocyclic
aromatic ring, containing one or more nitrogen, oxygen, or sulfur
heteroatoms, where N-oxides and sulfur monoxides and sulfur
dioxides are permissible heteroaromatic substitutions, optionally
substituted and multiple degrees of substitution being allowed. For
polycyclic aromatic ring systems, one or more of the rings may
contain one or more heteroatoms. Examples of "heteroaryl" used
herein include, but are not limited to, furan, thiophene, pyrrole,
imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole,
isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine,
pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline,
quinazoline, benzofuran, benzothiophene, indole, and indazole, and
the like.
[0650] As used herein, the term "heteroarylene" refers to a five-
to seven-membered aromatic ring diradical, or to a polycyclic
heterocyclic aromatic ring diradical, containing one or more
nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur
monoxides and sulfur dioxides are permissible heteroaromatic
substitutions, optionally substituted and multiple degrees of
substitution being allowed. For polycyclic aromatic ring system
diradicals, one or more of the rings may contain one or more
heteroatoms. Examples of "heteroarylene" used herein include, but
are not limited to, furan-2,5-diyl, thiophene-2,4-diyl,
1,3,4-oxadiazole-2,5-diyl, 1,3,4-thiadiazole-2,5-diyl,
1,3-thiazole-2,4-diyl, 1,3-thiazole-2,5-diyl, pyridine-2,4-diyl,
pyridine-2,3-diyl, pyridine-2,5-diyl, pyrimidine-2,4-diyl,
quinoline-2,3-diyl, and the like.
[0651] As used herein, the term "direct bond", where part of a
structural variable specification, refers to the direct joining of
the substituents flanking (preceding and succeeding) the variable
taken as a "direct bond". Where two or more consecutive variables
are specified each as a "direct bond", those substituents flanking
(preceding and succeeding) those two or more consecutive specified
"direct bonds" are directly joined.
[0652] As used herein, the term "alkoxy" refers to the group
R.sub.aO--, where R.sub.a is alkyl.
[0653] As used herein, the term "alkenyloxy" refers to the group
R.sub.aO--, where R.sub.a is alkenyl.
[0654] As used herein, the term "alkynyloxy" refers to the group
R.sub.aO--, where R.sub.a is alkynyl.
[0655] As used herein, the term "alkylsulfanyl" refers to the group
R.sub.aS--, where R.sub.a is alkyl.
[0656] As used herein, the term "alkenylsulfanyl" refers to the
group R.sub.aS--, where R.sub.a is alkenyl.
[0657] As used herein, the term "alkynylsulfanyl" refers to the
group R.sub.aS--, where R.sub.a is alkynyl.
[0658] As used herein, the term "alkylsulfinyl" refers to the group
R.sub.aS(O)--, where R.sub.a is alkyl.
[0659] As used herein, the term "alkenylsulfinyl" refers to the
group R.sub.aS(O)--, where R.sub.a is alkenyl.
[0660] As used herein, the term "alkynylsulfinyl" refers to the
group R.sub.aS(O)--, where R.sub.a is alkynyl.
[0661] As used herein, the term "alkylsulfonyl" refers to the group
R.sub.aSO.sub.2--, where R.sub.a is alkyl.
[0662] As used herein, the term "alkenylsulfonyl" refers to the
group R.sub.aSO.sub.2--, where R.sub.a is alkenyl.
[0663] As used herein, the term "alkynylsulfonyl" refers to the
group R.sub.aSO.sub.2--, where R.sub.a is alkynyl.
[0664] As used herein, the term "acyl" refers to the group
R.sub.aC(O)--, where R.sub.a is alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, or heterocyclyl.
[0665] As used herein, the term "aroyl" refers to the group
R.sub.aC(O)--, where R.sub.a is aryl.
[0666] As used herein, the term "heteroaroyl" refers to the group
R.sub.aC(O)--, where R.sub.a is heteroaryl.
[0667] As used herein, the term "alkoxycarbonyl" refers to the
group R.sub.aOC(O)--, where R.sub.a is alkyl.
[0668] As used herein, the term "acyloxy" refers to the group
R.sub.aC(O)O--, where R.sub.a is alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, or heterocyclyl.
[0669] As used herein, the term "aroyloxy" refers to the group
R.sub.aC(O)O--, where R.sub.a is aryl.
[0670] As used herein, the term "heteroaroyloxy" refers to the
group R.sub.aC(O)O--, where R.sub.a is heteroaryl.
[0671] As used herein, the term "optionally" means that the
subsequently described event(s) may or may not occur, and includes
both event(s) which occur and events that do not occur.
[0672] As used herein, the term "substituted" refers to
substitution of one or more hydrogens of the designated moiety with
the named substituent or substituents, multiple degrees of
substitution being allowed unless otherwise stated, provided that
the substitution results in a stable or chemically feasible
compound. A stable or chemically feasible compound is one in which
the chemical structure is not substantially altered when kept at a
temperature from about -80.degree. C. to about +40.degree. C., in
the absence of moisture or other chemically reactive conditions,
for at least a week, or a compound which maintains its integrity
long enough to be useful for therapeutic or prophylatic
administration to a patient. The phrase "one or more substituents",
as used herein, refers to a number of substituents that equals from
on to the maximum number of substituents possible based on the
number of available bonding sites, provided that the above
conditions of stability and chemical feasibility are met.
[0673] As used herein, the terms "contain" or "containing" can
refer to in-line substitutions at any position along the above
defined alkyl, alkenyl, alkynyl or cycloalkyl substituents with one
or more of any of O, S, SO, SO.sub.2, N, or N-alkyl, including, for
example, --CH.sub.2--O--CH.sub.2--,
--CH.sub.2--SO.sub.2--CH.sub.2--, --CH.sub.2--NH--CH.sub.3 and so
forth.
[0674] Whenever the terms "alkyl" or "aryl" or either of their
prefix roots appear in a name of a substituent (e.g.
arylalkoxyaryloxy) they shall be interpreted as including those
limitations given above for "alkyl" and "aryl". Designated numbers
of carbon atoms (e.g. C.sub.1-10) shall refer independently to the
number of carbon atoms in an alkyl, alkenyl or alkynyl or cyclic
alkyl moiety or to the alkyl portion of a larger substituent in
which the term "alkyl" appears as its prefix root.
[0675] As used herein, the term "oxo" shall refer to the
substituent .dbd.O.
[0676] As used herein, the term "halogen" or "halo" shall include
iodine, bromine, chlorine and fluorine.
[0677] As used herein, the term "mercapto" shall refer to the
substituent --SH.
[0678] As used herein, the term "carboxy" shall refer to the
substituent --COOH.
[0679] As used herein, the term "cyano" shall refer to the
substituent --CN.
[0680] As used herein, the term "aminosulfonyl" shall refer to the
substituent --SO.sub.2NH.sub.2.
[0681] As used herein, the term "carbamoyl" shall refer to the
substituent --C(O)NH.sub.2.
[0682] As used herein, the term "sulfanyl" shall refer to the
substituent --S--.
[0683] As used herein, the term "sulfinyl" shall refer to the
substituent --S(O)--.
[0684] As used herein, the term "sulfonyl" shall refer to the
substituent --S(O).sub.2--.
[0685] As used herein, the term "haloalkyl" refers to a straight or
branched chain hydrocarbon having from one to ten carbon atoms,
substituted with at least one halogen atom and optionally
substituted at the remaining positions with a halogen atom. A
haloalkyl group may be substituted with one or more types of
halogen atoms. Examples of "haloalkyl" as used herein include, but
are not limited to, a trifluoromethyl group, a 2,2,2-trifluoroethyl
group, and the like.
[0686] As used herein, the term "perhaloalkyl" refers to a straight
or branched chain hydrocarbon having from one to ten carbon atoms,
where each position for substitution is substituted with a halogen
atom. A perhaloalkyl group may be substituted with one or more
types of halogen atoms. Examples of "perhaloalkyl" as used herein
include, but are not limited to, a trifluoromethyl group and a
1,1-dichloro-2,2,2-trifluoroethyl group, and the like.
[0687] The compounds can be prepared according to the following
reaction Schemes (in which variables are as defined before or are
defined) using readily available starting materials, and reagents.
In these reactions, it is also possible to make use of variants
which are themselves known to those of ordinary skill in this art,
but are not mentioned in greater detail.
[0688] The present invention also provides a method for the
synthesis of compounds useful as intermediates in the preparation
of compounds of Formula (I-IV) along with methods for the
preparation of compounds of Formula (I-IV). Unless otherwise
specified, structural variables in the schemes below are as defined
for Formula (I-IV). In Schemes 1-7, Ar.sup.a and Ar.sup.d may be a
ring selected from the group consisting of: phenyl, indanyl,
tetrahydronaphthyl, pyridazine, pyrimidine, pyrazine, pyridine,
piperidine, 4,5-diaza-indanyl, 5,6,7,8-tetrahydro-cinnoline, and
1-H-pyridin-2-one, 5,6,7,8-tetrahydro-cinnoline, wherein Ara and
Ar.sup.d are optionally substituted with R.sup.b. In an embodiment,
Ar.sup.a and Ar.sup.d form a biphenyl group where Ar.sup.d is
unsubstituted and Ara is substituted 1-3 times with R.sup.b. In
Schemes 1-7, L.sup.a is a linker group including, but not limited
to, C.sub.1-10 alkylene and a direct bond. In an embodiment,
L.sup.a may be --CH.sub.2--. For simplicity of the figures, in
schemes other than Scheme 1, a phenyl group substituted with the
group --R.sup.1-5 is used to refer the a phenyl group having groups
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5.
[0689] Compounds of formula (1) may be prepared according to Scheme
1. In one embodiment, a bromo or iodo aryl compound (2) can be
subjected to palladium catalyzed coupling (Syn. Commu. 1981, 11,
513-574) with an optionally substituted boronic acid
Ar.sup.d--B(OH).sub.2. Typical conditions used to carry out the
coupling reaction include the use of a boronic acid or ester as the
coupling partner, a palladium catalyst (2 to 20 mole %) such as
Pd(PPh.sub.3).sub.4 or [1,1-bis(diphenylphosphino)-ferrocene]
dichloro-palladium (II) and base such as potassium carbonate,
sodium carbonate, barium hydroxide, potassium phosphate or triethyl
amine in a suitable solvent such as aqueous dimethoxyethane, THF,
acetone, DMF or toluene at temperatures ranging from 25.degree. C.
to 125.degree. C.
##STR00213##
[0690] In the place of boronic acids of the formula
Ar.sup.d-B(OH).sub.2, one may use 1-alkenyl boronic acids of the
formula R.sup.f--CH.dbd.CH--B(OH).sub.2 to prepare compounds of
formula (3) in Scheme 2. Alternately, a 9-BBN derived alkenyl
borane may be employed to synthesize similar compounds.
##STR00214##
[0691] In another embodiment, under Sonogashihara reaction
conditions, aryl bromides of formula (2) may be coupled with
acetylenes to prepare compounds of formula (4) shown in Scheme
3.
##STR00215##
[0692] Construction of isothiazolidinonedioxide ring in the
compound of formula (2) is outlined in Scheme 4. The nitro group of
an aryl nitro compound (5) may be reduced to an aniline using
iron-acetic acid or under a variety of other well-known reagent
systems. Resulting anilines are converted to .alpha.-substituted
glycine ester derivatives (6) by alkylating the amines with an
.alpha.-bromoacetate derivative. The glycine ester derivatives (6)
are then treated with chlorosulfonyl isocyanate followed by
t-butanol to form a sulfamoyl chloride. Treatment of sulfamoyl
carbamate with trifluoroacetic acid followed by sodium hydroxide
provides bromo aryl compound (2).
##STR00216##
[0693] In another scenario to circumvent chemoselectivity issues,
glycine ester derivatives (6) may be converted into a compound of
formula (1) via Suzuki coupling using boronic acid
Ar.sup.d-B(OH).sub.2 followed by isothiazolidinonedioxide ring
construction as described above (Scheme 5).
##STR00217##
[0694] Aryl nitro compounds (5) may be accessed via aromatic
nucleophilic substitution of appropriate halo-nitrobenzene or via
Ullman type reaction on imidazoles of formula (7).
##STR00218##
[0695] Imidazoles of formula (7) may be prepared according to
Scheme 7. A carboxylic acid (8) may be reacted with an aryl acyl
bromide (9) in the presence of base such as DIEA, triethylamine, or
DBU, in a polar solvent such as THF or DMF to afford intermediate
keto-ester (10), which can be treated with ammonium acetate in
acetic acid at temperatures ranging from 60-120.degree. C., which
leads to a mixture of oxazole and imidazole (7) (Strzybny, P. P.
E., van Es, T.; Backeberg, O. G., J. Org. Chem. 1963, 25, 1151).
The ratio of oxazole and imidazole (7) may vary depending on the
substitution and reaction conditions. The oxazole and imidazole (7)
may be separated through silica gel column. Alternatively other
conditions may also be employed for cyclization of keto-ester (10),
such as BF.sub.3/Et.sub.2O, methanolic ammonia, at temperatures
ranging from room temperature to 120.degree. C.
##STR00219##
[0696] Imidazoles of formula (1) may also be prepared according to
Scheme 8. A tertiary amide (11) may be cyclized in a polar solvent
such as THF or DMF and ammonium acetate in acetic acid at
temperatures ranging from 60-120.degree. C., which leads to an
imidazole (1).
##STR00220##
[0697] Embodiments of the present invention demonstrate utility in
inhibiting protein tyrosine phosphatase PTP 1B. The compounds of
the present invention set forth in the present examples were found
to inhibit protein tyrosine phosphatase PTP1B with inhibitory
potencies (IC50's) of less than about 10 .mu.M.
[0698] In general, embodiments of the present invention useful for
pharmaceutical applications may have inhibitory potencies (IC50's)
for a protein of interest of below about 100 .mu.M. In an
embodiment, embodiments of the present invention useful for
pharmaceutical applications may have inhibitory potencies (IC50's)
for a protein of interest of below about 50 .mu.M. For particular
applications, lower inhibitory potencies are useful. Thus, in
another embodiment, compounds of the present invention may inhibit
protein tyrosine phosphatase PTP1B with inhibitory potencies
(IC50's) in a range of about 0.001 .mu.M to about 10 .mu.M. In
another embodiment, compounds of the present invention may inhibit
protein tyrosine phosphatase PTP1B with inhibitory potencies
(IC50's) of about 0.001 .mu.M to about 3 .mu.M.
[0699] Embodiments of the compounds of the present invention
demonstrate utility as inhibitors of protein tyrosine phosphatases
(PTPases). Embodiments of the invention described herein are
additionally directed to pharmaceutical compositions and methods of
inhibiting PTPase activity in a mammal, which methods comprise
administering, to a mammal in need of inhibition of PTPase
activity, a therapeutically defined amount of a compound of Formula
(I-IV), defined above, as a single or polymorphic crystalline form
or forms, an amorphous form, a single enantiomer, a racemic
mixture, a single stereoisomer, a mixture of stereoisomers, a
single diastereoisomer, a mixture of diastereoisomers, an
isotopically enriched form, a solvate, a pharmaceutically
acceptable salt, a solvate, a prodrug, a biohydrolyzable ester, or
a biohydrolyzable amide thereof.
[0700] As used herein the terms "pharmaceutically acceptable
carrier", "pharmaceutically acceptable diluent", and
pharmaceutically acceptable excipient" means the carrier, diluent
or excipient must be compatible with the other ingredients of the
formulation and not deleterious to the recipient thereof.
[0701] As used herein the term "therapeutically effective amount"
as used herein means that amount of active compound or
pharmaceutical agent that elicits the biological or medicinal
response in a tissue, system, animal or human that is being sought
by a researcher, veterinarian, medical doctor or other clinician,
which includes alleviation of the symptoms of the disease being
treated. When the active compound (i.e., active ingredient) is
administered as the salt, references to the amount of active
ingredient are to the free acid or free base form of the
compound.
[0702] Thus, the present invention provides a method of inhibiting
a PTPase, comprising the step of administering to a subject in need
thereof a therapeutically effective amount of a compound of the
present invention. The invention further provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of the present
invention sufficient to inhibit a PTPase. A PTPase--inhibiting
amount can be an amount that reduces or inhibits a PTPase activity
in the subject.
[0703] The compound of Formula (I-IV) may comprise a single or
polymorphic crystalline form or forms, an amorphous form, a single
enantiomer, a racemic mixture, a single stereoisomer, a mixture of
stereoisomers, a single diastereoisomer, a mixture of
diastereoisomers, an isotopically enriched form, a solvate, a
pharmaceutically acceptable salt, a solvate, a prodrug, a
biohydrolyzable ester, or a biohydrolyzable amide thereof.
[0704] Additionally provided is a pharmaceutical composition
comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat glucose intolerance.
[0705] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat Type I diabetes.
[0706] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat Type II diabetes.
[0707] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat immune dysfunction. In an
embodiment, the immune dysfunction is AIDS. In another embodiment,
the immune dysfunction is an allergic disease. In another
embodiment, the immune dysfunction is an inflammatory disease. In
another embodiment, the immune dysfunction is an autoimmune
disease. In another embodiment, the immune dysfunction is an
autoimmune disease selected from the group consisting of
psoriasis.
[0708] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat obesity.
[0709] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat cancer.
[0710] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat an infectious
disease.
[0711] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat a disease involving the
modulated synthesis of growth hormone.
[0712] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat a disease that involves
at least in part the modulated synthesis of growth factors or
cytokines that affect the production of growth hormone.
[0713] Further, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of a compound of Formula (I-IV) of
the present invention sufficient to treat Alzheimer's disease.
[0714] The compounds of the present invention can be administered
to subjects in need of inhibition of PTPase activity. Such subjects
can include, for example, horses, cows, sheep, pigs, mice, dogs,
cats, primates such as chimpanzees, gorillas, rhesus monkeys, and,
humans. In an embodiment, a subject is a human in need of
inhibition of PTPase activity.
[0715] The pharmaceutical compositions containing a compound of the
invention may be in a form suitable for oral use, for example, as
tablets, troches, lozenges, aqueous, or oily suspensions,
dispersible powders or granules, emulsions, hard or soft capsules,
or syrups or elixirs. Compositions intended for oral use may be
prepared according to any known method, and such compositions may
contain one or more agents selected from the group consisting of
sweetening agents, flavoring agents, coloring agents, and
preserving agents in order to provide pharmaceutically elegant and
palatable preparations. Tablets may contain the active ingredient
in admixture with non-toxic pharmaceutically-acceptable excipients
which are suitable for the manufacture of tablets. These excipients
may be for example, inert diluents, such as calcium carbonate,
sodium carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example corn starch or
alginic acid; binding agents, for example, starch, gelatin or
acacia; and lubricating agents, for example magnesium stearate,
stearic acid or talc. The tablets may be uncoated or they may be
coated by known techniques to delay disintegration and absorption
in the gastrointestinal tract and thereby provide a sustained
action over a longer period. For example, a time delay material
such as glyceryl monostearate or glyceryl distearate may be
employed. They may also be coated by the techniques to form osmotic
therapeutic tablets for controlled release.
[0716] Formulations for oral use may also be presented as hard
gelatin capsules where the active ingredient is mixed with an inert
solid diluent, for example, calcium carbonate, calcium phosphate or
kaolin, or a soft gelatin capsules wherein the active ingredient is
mixed with water or an oil medium, for example peanut oil, liquid
paraffin, or olive oil.
[0717] Aqueous suspensions may contain the active compounds in an
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents may be a naturally-occurring phosphatide such as
lecithin, or condensation products of an alkylene oxide with fatty
acids, for example polyoxyethylene stearate, or condensation
products of ethylene oxide with long chain aliphatic alcohols, for
example, heptadecaethyl-eneoxycetanol, or condensation products of
ethylene oxide with partial esters derived from fatty acids and a
hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of ethylene oxide with partial esters derived
from fatty acids and hexitol anhydrides, for example polyethylene
sorbitan monooleate. The aqueous suspensions may also contain one
or more coloring agents, one or more flavoring agents, and one or
more sweetening agents, such as sucrose or saccharin.
[0718] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as a liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0719] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
compound in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients, for example,
sweetening, flavoring, and coloring agents may also be present.
[0720] The pharmaceutical compositions of the invention may also be
in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, for example, olive oil or arachis oil, or a mineral
oil, for example a liquid paraffin, or a mixture thereof. Suitable
emulsifying agents may be naturally-occurring gums, for example gum
acacia or gum tragacanth, naturally-occurring phosphatides, for
example soy bean, lecithin, and esters or partial esters derived
from fatty acids and hexitol anhydrides, for example sorbitan
monooleate, and condensation products of said partial esters with
ethylene oxide, for example polyoxyethylene sorbitan monooleate.
The emulsions may also contain sweetening and flavoring agents.
[0721] Syrups and elixirs may be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol or sucrose. Such
formulations may also contain a demulcent, a preservative and
flavoring and coloring agents. The pharmaceutical compositions may
be in the form of a sterile injectable aqueous or oleaginous
suspension. This suspension may be formulated according to the
known methods using suitable dispersing or wetting agents and
suspending agents described above. The sterile injectable
preparation may also be a sterile injectable solution or suspension
in a non-toxic parenterally-acceptable diluent or solvent, for
example as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that may be employed are water, Ringer's
solution, and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conveniently employed as solvent or
suspending medium. For this purpose, any bland fixed oil may be
employed using synthetic mono- or diglycerides. In addition, fatty
acids such as oleic acid find use in the preparation of
injectables.
[0722] The compositions may also be in the form of suppositories
for rectal administration of the compounds of the invention. These
compositions can be prepared by mixing the drug with a suitable
non-irritating excipient which is solid at ordinary temperatures
but liquid at the rectal temperature and will thus melt in the
rectum to release the drug. Such materials include cocoa butter and
polyethylene glycols, for example.
[0723] For topical use, creams, ointments, jellies, solutions of
suspensions, etc., containing the compounds of the invention are
contemplated. For the purpose of this application, topical
applications shall include mouth washes and gargles.
[0724] The compounds of the present invention may also be
administered in the form of liposome delivery systems, such as
small unilamellar vesicles, large unilamellar vesicles, and
multilamellar vesicles. Liposomes may be formed from a variety of
phospholipids, such as cholesterol, stearylamine, or
phosphatidylcholines.
[0725] Also provided by the present invention are prodrugs of the
invention. Pharmaceutically-acceptable salts of the compounds of
the present invention, where a basic or acidic group is present in
the structure, are also included within the scope of the invention.
The term "pharmaceutically acceptable salts" refers to non-toxic
salts of the compounds of this invention which are generally
prepared by reacting the free base with a suitable organic or
inorganic acid or by reacting the acid with a suitable organic or
inorganic base. Representative salts include the following salts:
Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate,
Bitartrate, Borate, Bromide, Calcium Edetate, Camsylate, Carbonate,
Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate,
Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate,
Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine,
Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide,
Isethionate, Lactate, Lactobionate, Laurate, Malate, Maleate,
Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate,
Monopotassium Maleate, Mucate, Napsylate, Nitrate,
N-methylglucamine, Oxalate, Pamoate (Embonate), Palmitate,
Pantothenate, Phosphate/diphosphate, Polygalacturonate, Potassium,
Salicylate, Sodium, Stearate, Subacetate, Succinate, Tannate,
Tartrate, Teoclate, Tosylate, Triethiodide, Trimethylammonium and
Valerate. When an acidic substituent is present, such as --COOH,
there can be formed the ammonium, morpholinium, sodium, potassium,
barium, calcium salt, and the like, for use as the dosage form.
When a basic group is present, such as amino or a basic heteroaryl
radical, such as pyridyl, an acidic salt, such as hydrochloride,
hydrobromide, phosphate, sulfate, trifluoroacetate,
trichloroacetate, acetate, oxalate, maleate, pyruvate, malonate,
succinate, citrate, tartarate, fumarate, mandelate, benzoate,
cinnamate, methanesulfonate, ethanesulfonate, picrate and the like,
and include acids related to the pharmaceutically-acceptable salts
listed in the Journal of Pharmaceutical Science, 66, 2 (1977) p.
1-19.
[0726] As used herein, the term "other pharmaceutically acceptable
counter ions" refers to a non-toxic counter ions such as, but not
limited to, ammonium, morpholinium, sodium, potassium, barium,
calcium, and the like, and which may be installed by reacting the
acidic hydrogen of a thiadiazolidine derivative with the
appropriate organic or inorganic base.
[0727] Other salts which are not pharmaceutically acceptable may be
useful in the preparation of compounds of the invention and these
form a further aspect of the invention.
[0728] In addition, some of the compounds of the present invention
may form solvates with water or common organic solvents. Such
solvates are also encompassed within the scope of the
invention.
[0729] Thus, in a further embodiment, there is provided a
pharmaceutical composition comprising a compound of the present
invention, or a pharmaceutically acceptable salt, solvate, or
prodrug thereof, and one or more pharmaceutically acceptable
carriers, excipients, or diluents.
[0730] The compounds of the present invention may selectively act
as inhibitors of one PTPase in preference to one or more other
PTPases, and therefore may possess advantage in the treatment of
one or more PTPase-mediated disease in preference to others.
[0731] In a further aspect, the present invention may provide a
method comprising administering to a human a compound of Formula
(I-IV). In one embodiment, the present invention comprises method
for the inhibition of PTPases. Thus, an embodiment of the present
invention provides a method for treating a disease state mediated
at least in part by a PTPase enzyme, comprising administering to a
subject in need thereof a compound of the present invention. In
alternate embodiments, the disease treated using a method of the
present invention comprises glucose intolerance including Type I
diabetes and Type II diabetes, immune dysfunction including AIDS,
allergic diseases, inflammatory diseases, and autoimmunity such as
psoriasis, infectious diseases, obesity, cancer, diseases involving
the modulated synthesis of growth hormone or the modulated
synthesis of growth factors or cytokines which affect the
production of growth hormone, or Alzheimer's disease. In an
embodiment, a therapeutically effective amount may be administered.
In another embodiment a therapeutically effective amount may be
administered. In another embodiment, at least one compound of
Formula (I-IV) is utilized, either alone or in combination with one
or more known therapeutic agents. In a further embodiment, the
present invention provides method of prevention and/or treatment of
PTPase-mediated human diseases, treatment comprising alleviation of
one or more symptoms resulting from that disorder, to an outright
cure for that particular disorder or prevention of the onset of the
disorder, the method comprising administration to a human in need
thereof a therapeutically effective amount of a compound of Formula
(I-IV).
[0732] In this method, factors which may influence what constitutes
an effective amount include, but are not limited to, the size and
weight of the subject, the biodegradability of the therapeutic
agent, the activity of the therapeutic agent, as well as its
bioavailability. As used herein, the phrase "a subject in need
thereof" includes mammalian subjects, such as humans, who either
suffer from one or more of the aforesaid diseases or disease states
or are at risk for such. Accordingly, in the context of the
therapeutic method of the invention, this method also is comprised
of a method for treating a mammalian subject prophylactically, or
prior to the onset of diagnosis such disease(s) or disease
state(s).
[0733] The following is a non-exhaustive listing of adjuvants and
additional therapeutic agents which may be utilized in combination
with the PTPase inhibitors of the present invention: [0734]
Pharmacologic classifications of anticancer agents:
[0735] 1. Alkylating agents: Cyclophosphamide, nitrosoureas,
carboplatin, cisplatin, procarbazine [0736] 2. Antibiotics:
Bleomycin, Daunorubicin, Doxorubicin [0737] 3. Antimetabolites:
Methotrexate, Cytarabine, Fluorouracil [0738] 4. Plant alkaloids:
Vinblastine, Vincristine, Etoposide, Paclitaxel, [0739] 5.
Hormones: Tamoxifen, Octreotide acetate, Finasteride, Flutamide
[0740] 6. Biologic response modifiers: Interferons,
Interleukins
[0741] Pharmacologic classifications of treatment for Rheumatoid
Arthritis (Inflammation) [0742] 1. Analgesics: Aspirin [0743] 2.
NSAIDs (Nonsteroidal anti-inflammatory drugs): Ibuprofen, Naproxen,
Diclofenac [0744] 3. DMARDs (Disease-Modifying Antirheumatic
drugs): Methotrexate, gold preparations, hydroxychloroquine,
sulfasalazine [0745] 4. Biologic Response Modifiers, DMARDs:
Etanercept, Infliximab Glucocorticoids
[0746] Pharmacologic classifications of treatment for Diabetes
Mellitus [0747] 1. Sulfonylureas: Tolbutamide, Tolazamide,
Glyburide, Glipizide [0748] 2. Biguanides: Metformin [0749] 3.
Miscellaneous oral agents: Agents designed to reduce the absorption
of glucose from the intestine (for example Acarbose), PPAR agonists
such as Troglitazone, pioglitazone, and rosiglitazone), DPP-IV
inhibitors, Glucokinase activators [0750] 4. Insulin, insulin
mimetics, insulin secretagogues (for example glibenclamide,
glipizide), insulin sensitizers [0751] 5. GLP-1, GLP-1 mimetics
[0752] Pharmacologic classifications of treatment for Alzheimer's
Disease
[0753] 1. Cholinesterase Inhibitor: Tacrine, Donepezil
[0754] 2. Antipsychotics: Haloperidol, Thioridazine
[0755] 3. Antidepressants: Desipramine, Fluoxetine, Trazodone,
Paroxetine
[0756] 4. Anticonvulsants: Carbamazepine, Valproic acid
[0757] Pharmacologic classifications of treatment for
Hyperlipidemia
[0758] 1. HMG CoA reductase inhibitors Inhibitor: Mevinolin
[0759] 2. Bile acid sequestrants such as cholestyramine
[0760] 3. fibrates
[0761] Additional therapeutic agents which may be utilized in
combination with the PTPase inhibitors of the present invention
include: [0762] 1) Agents designed to treat the complications of
prolonged hyperglycaemia; [0763] 2) Anti-dyslipidaemia agents such
as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PPARa
agonists (fibrates, eg gemfibrozil); cholesterol absorption
inhibitors (plant stanols, synthetic inhibitors); bile acid
absorption inhibitors(IBATi) and nicotinic acid and analogues
(niacin and slow release formulations); [0764] 3) Antihypertensive
agents such as, (3 blockers (eg atenolol, inderal); ACE inhibitors
(eg lisinopril); Calcium antagonists (eg. nifedipine); Angiotensin
receptor antagonists (eg candesartan), a antagonists and diuretic
agents (eg. furosemide, benzthiazide); [0765] 4) Haemostasis
modulators such as, antithrombotics, activators of fibrinolysis and
antiplatelet agents; thrombin antagonists; factor Xa inhibitors;
factor VIIa inhibitors); antiplatelet agents (eg. aspirin,
clopidogrel); anticoagulants (heparin and Low molecular weight
analogues, hirudin) and warfarin; and [0766] 5) Anti-inflammatory
agents, such as non-steroidal anti-inflammatory drugs (eg. aspirin)
and steroidal anti-inflammatory agents (eg. cortisone).
[0767] Antiobesity agents or appetite regulating agents may also be
used in combination with the compounds of the present invention.
Examples of anti-obesity agents or appetite regulating agents that
may be used in combination with the compounds of the present
invention include but are not limited to: [0768] 1. a NPY receptor
antagonist, [0769] 2. a Melanocyte-Concentrating Hormone (MCH)
antagonist, [0770] 3. a GHSR antagonist, [0771] 4. a CRH
antagonist, [0772] 5. a beta 3 adrenergic agonist, [0773] 6. a
lipase inhibitor (orlistat), [0774] 7. a serotonin (and dopamine)
reuptake inhibitor (sibutramine, topiramate or axokine), [0775] 8.
a thyroid receptor beta drug and/or [0776] 9. an anorectic agent
(dexamphetamine, amphetamine, phentermine, phenylpropanolamine or
mazindol), [0777] 10. a CB.sub.1 antagonist (rimonabant).
[0778] The beta 3 adrenergic agonists which may be employed in
combination with a compound of the present invention include known
beta 3 agonists, such as those disclosed in U.S. Pat. Nos.
5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064.
[0779] Examples of lipase inhibitors which may be employed in
combination with compounds of the present invention include
orlistat or ATL-962 (Alizyme).
[0780] The serotonin (and dopamine) reuptake inhibitor which may be
employed in combination with a compound of the present invention
include sibutramine, topiramate (Johnson & Johnson) or axokine
(Regeneron).
[0781] Examples of thyroid receptor beta compounds which may be
employed in combination with a compound of the present invention
include thyroid receptor ligands, such as those disclosed in
WO97/21993 (U. Cal SF), WO99/00353 (KaroBio) and GB98/284425
(KaroBio).
[0782] The anorectic agent which may be employed in combination
with a compound of the present invention include dexamphetamine,
phentermine, phenylpropanolamine or mazindol.
[0783] An example of a CB.sub.1 antagonist which may be employed in
combination with a compound of the present invention include
rimonabant.
[0784] In a further embodiment, the present invention provides a
method of treating diseases mediated at least in part by a PTPase
enzyme (i.e., PTPase mediated diseases), the method comprising
administering to a subject in need thereof, a therapeutically
effective amount of a compound of Formula (I-IV) in combination
with a therapeutic agent. Examples of combination therapeutic
agents may include, but are not limited to, alkylating agents,
antimetabolites, plant alkaloids, antibiotics, hormones, biologic
response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids,
sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV
inhibitors, GK activators, insulin, insulin mimetics, insulin
secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics,
cholinesterase inhibitors, antipsychotics, antidepressants,
anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, or
fibrates.
[0785] Generally speaking, a compound of Formula (I-IV) may be
administered at a dosage level of from about 0.003 to 500 mg/kg of
the body weight of the subject being treated. In an embodiment, a
compound of Formula (I-IV) may be administered at a dosage range
between about 0.003 and 200 mg/kg of body weight per day. In an
embodiment, a compound of Formula (I-IV) may be administered at a
dosage range between about 0.1 to 100 mg/kg of body weight per day.
The amount of active ingredient that may be combined with the
carrier materials to produce a single dosage may vary depending
upon the host treated and the particular mode of administration.
For example, a formulation intended for oral administration to
humans may contain 1 mg to 2 grams of a compound of Formula (I-IV)
with an appropriate and convenient amount of carrier material which
may vary from about 5 to 95 percent of the total composition.
Dosage unit forms may generally contain between from about 5 mg to
about 500 mg of active ingredient. This dosage may be
individualized by the clinician based on the specific clinical
condition of the subject being treated. Thus, it will be understood
that the specific dosage level for any particular patient will
depend upon a variety of factors including the activity of the
specific compound employed, the age, body weight, general health,
sex, diet, time of administration, route of administration, rate of
excretion, drug combination and the severity of the particular
disease undergoing therapy.
EXAMPLES
[0786] The general procedures used in the methods of the present
invention are described below.
General Experimental
[0787] LC-MS data was obtained using gradient elution on a Waters
600 controller equipped with a 2487 dual wavelength detector and a
Leap Technologies HTS PAL Autosampler using an YMC Combiscreen
ODS-A 50.times.4.6 mm column. A three minute gradient was run from
25% B (97.5% acetonitrile, 2.5% water, 0.05% TFA) and 75% A (97.5%
water, 2.5% acetonitrile, 0.05% TFA) to 100% B. The mass
spectrometer used was a Micromass ZMD instrument. All data was
obtained in the positive mode unless otherwise noted. .sup.1H NMR
data was obtained on a Varian 400 MHz spectrometer.
General Procedure A: Imidazole Formation
[0788] To a mixture of a carboxylic acid (1 eq) and an aromatic
acyl bromide (2 eq) in anhydrous DMF (0.1-0.5 M) was added DIEA (3
eq). The reaction mixture was stirred at room temperature under
nitrogen for 6 to 8 hours. After that, it was poured into water,
acidified with 10% citric acid and extracted with ethyl acetate.
The organic extract was washed with water and brine, and dried over
Na.sub.2SO.sub.4. After evaporation of the solvent, the pale-brown
residue was recrystallized from EtOAc-Hexanes, dried and used
directly in the next step.
[0789] The intermediate obtained above was dissolved in glacial
acetic acid (0.1-0.5 M), and ammonium acetate (20 eq) was added.
The mixture was then heated at 120.degree. C. under nitrogen for 8
to 10 hours. At completion, it was poured into water, neutralized
with saturated sodium bicarbonate and extracted with ethyl acetate.
The organic extract was washed with water and brine, and dried over
Na.sub.2SO.sub.4. After removal of the solvent in vacuo, the
residue was purified by flash column chromatography to afford the
desired product.
General Procedure B: Arylation of Imidazole Nitrogen Atom Using
Aryl Fluoride/Aryl Bromide
[0790] To a solution of imidazole compound (1 eq) in anhydrous DMF
(0.1-0.5 M), the appropriate activated aryl fluoride or aryl
bromide (1.5 eq) was added followed by Cs.sub.2CO.sub.3 (3 eq). The
reaction mixture was then heated at 120.degree. C. under nitrogen
for 2 hours. At completion, the reaction mixture was diluted with
water/EtOAc and the layers separated. The aqueous layer was
re-extracted with EtOAc and the organic layers combined, washed
with water and brine. The organic phase was then dried over
Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated and
purified by silica gel chromatography to afford the aryl imidazole
derivative.
General Procedure C: Preparation of
1,2,5-thiadiazolidine-3-one-1,1-dioxide derivatives
[0791] To a suspension of aryl nitro compound (1 eq) in HOAc
(0.1-0.5 M), iron powder (-325 mesh, 8 eq) was added and the
mixture was then heated at 80.degree. C. under nitrogen for 5-10
minutes. The reaction mixture was then diluted with water/EtOAc and
the leftover iron powder was filtered and washed with EtOAc. The
combined organic layer was washed with water, saturated NaHCO.sub.3
and brine. The organic layer was then dried over Na.sub.2SO.sub.4,
filtered, and the filtrate was concentrated and purified by silica
gel chromatography to afford the aniline derivative.
[0792] Alkylation of aniline: Method I) To a suspension of aniline
compound (1 eq) in anhydrous DMF (0.1-0.5 M) at room temperature
was added 1.2 eq of .alpha.-bromo ester followed by 2.5 eq of DIEA.
The reaction mixture was then stirred at room temperature under
nitrogen for 18 hours. The reaction mixture was then diluted with
water/EtOAc and the layers separated. The aqueous layer was
re-extracted with EtOAc and the organic layers were combined and
washed with water and brine. The organic phase was then dried over
Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated and
purified by silica gel chromatography to afford the
.alpha.-anilino-ester derivative. Method II) To a suspension of
aniline compound (1 eq) in anhydrous DMF (0.1-0.5 M) at room
temperature was added 2 eq of .alpha.-bromo ester followed by 5 eq
of anhydrous potassium tert-butoxide. The reaction mixture was then
stirred at 100.degree. C. under nitrogen for 18 hours. The reaction
mixture was then diluted with water/EtOAc and the layers separated.
The aqueous layer was re-extracted with EtOAc and the organic
layers were combined and washed with water and brine. The organic
phase was then dried over Na.sub.2SO.sub.4, filtered, and the
filtrate was concentrated and purified by silica gel chromatography
to afford the .alpha.-anilino-ester derivative.
[0793] Formation of 1,2,5-thiadiazolidine-3-one-1,1-dioxide: To a
solution of chlorosulfonyl isocyanate (1.5 eq) in anhydrous
1,2-dichloroethane (0.1-0.5 M) at 0.degree. C. was added 1.5 eq of
tert-butanol as a solution in anhydrous 1,2-dichloroethane (0.5 M).
The mixture was allowed to warm to room temperature while stirring
and was then cooled to 0.degree. C. again. A suspension of
aniline-ester from the above (1.0 eq) in 1,2-dichloroethane
(0.3-0.5 M) and 2.5 eq DIEA was cooled to 0.degree. C. and the
chlorosulfonyl isocyanate-tert-butanol mixture was added dropwise
while stirring. The mixture was stirred at room temperature for 1
hour, then diluted with water/CH.sub.2Cl.sub.2 and the layers
separated. The organic layers were combined and washed with water
and brine. The organic phase was then dried over Na.sub.2SO.sub.4,
filtered, and the filtrate was concentrated and purified by silica
gel chromatography to afford the aniline N-Boc-sulfamide derivative
(Boc refers to tert-butyloxycarbonyl group).
[0794] The Boc-protected sulfamide was stirred in
dichloromethane/trifluoroacetic acid for 30 minutes. The solvent
was removed and the residue was triturated several times with ether
to afford the deprotected sulfamide.
[0795] To a suspension of the deprotected sulfamide compound in
ethanol (0.1-0.5 M) was added 5.0 eq of NaOH as a 2 M solution in
water. The mixture was stirred at room temperature for 5-7 minutes,
then diluted with 2% citric acid/EtOAc and the layers separated.
The organic layer was washed with water and brine. The organic
layer was then dried over Na.sub.2SO.sub.4, filtered, and the
filtrate was concentrated and purified by silica gel chromatography
to afford the 1,2,5-thiadiazolidine-3-one-1,1-dioxide
derivative.
General Procedure D: Reduction of Aryl Nitro Group
[0796] To a suspension of aryl nitro compound (1 eq) in HOAc
(0.1-0.5 M), iron powder (-325 mesh, 8 eq) was added and the
mixture was then heated at 80.degree. C. under nitrogen for 5-10
minutes. The reaction mixture was then diluted with water/EtOAc and
the leftover iron powder was filtered and washed with EtOAc. The
combined organic layer was washed with water, saturated NaHCO.sub.3
and brine. The organic layer was then dried over Na.sub.2SO.sub.4,
filtered, and the filtrate was concentrated and purified by silica
gel chromatography to afford the aniline derivative.
General Procedure E: Alkylation of Aniline
[0797] Method I) To a suspension of aniline derivative (1 eq) in
anhydrous DMF (0.1-0.5 M) at room temperature was added 1.2 eq of
.alpha.-bromo ester followed by 2.5 eq of DIEA. The reaction
mixture was then stirred at room temperature under nitrogen for 18
hours. The reaction mixture was then diluted with water/EtOAc and
the layers separated. The aqueous layer was re-extracted with EtOAc
and the organic layers were combined and washed with water and
brine. The organic phase was then dried over Na.sub.2SO.sub.4,
filtered, and the filtrate was concentrated and purified by silica
gel chromatography to afford the .alpha.-anilino-ester
derivative.
[0798] Method II) To a suspension of aniline derivative (1 eq) in
anhydrous DMF (0.1-0.5 M) at room temperature was added 2 eq of
.alpha.-bromo ester followed by 5 eq of anhydrous potassium
tert-butoxide. The reaction mixture was then stirred at 100.degree.
C. under nitrogen for 18 hours. The reaction mixture was then
diluted with water/EtOAc and the layers separated. The aqueous
layer was re-extracted with EtOAc and the organic layers were
combined and washed with water and brine. The organic phase was
then dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and purified by silica gel chromatography to afford
the .alpha.-anilino-ester derivative.
General Procedure F: Formation of
1,2,5-thiadiazolidine-3-one-1,1-dioxide
[0799] To a solution of chlorosulfonyl isocyanate (1.5 eq) in
anhydrous 1,2-dichloroethane (0.1-0.5 M) at 0.degree. C. was added
1.5 eq of tert-butanol as a solution in anhydrous
1,2-dichloroethane (0.5 M). The mixture was allowed to warm to room
temperature while stirring and was then cooled to 0.degree. C.
again. A suspension of aniline-ester from general procedure E (1.0
eq) in 1,2-dichloroethane (0.3-0.5 M) and 2.5 eq DIEA was cooled to
0.degree. C. and the chlorosulfonyl isocyanate-tert-butanol mixture
was added drop-wise while stirring. The mixture was stirred at room
temperature for 1 hour, then diluted with water/CH.sub.2Cl.sub.2
and the layers separated. The organic layers were combined and
washed with water and brine. The organic phase was then dried over
Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated and
purified by silica gel chromatography to afford the aniline N-Boc
sulfamide derivative.
[0800] The Boc protected sulfamide was stirred in
dichloromethane/trifluoroacetic acid for 30 minutes. The solvent
was removed and the residue was triturated several times with ether
to afford the deprotected sulfamide.
[0801] To a suspension of the deprotected sulfamide derivative in
ethanol (0.1-0.5 M) was added 5.0 eq of NaOH as a 2 M solution in
water. The mixture was stirred at room temperature for 5-7 minutes,
then diluted with 2% citric acid/EtOAc and the layers separated.
The organic layer was washed with water and brine. The organic
layer was then dried over Na.sub.2SO.sub.4, filtered, and the
filtrate was concentrated and purified by silica gel chromatography
to afford the 1,2,5-thiadiazolidine-3-one-1,1-dioxide.
General Procedure G: Suzuki Coupling
[0802] To a solution of the bromo-compound (1 eq) in a 2:1 mixture
of toluene and ethanol (0.1-0.5 M) was added the appropriate
boronic acid (2 eq) and a catalytic amount of
tetrakis(triphenylphosphine)palladium(0) (0.1 eq), followed by 2 M
sodium carbonate solution in water (30 eq). The reaction mixture
was stirred at 90.degree. C. under nitrogen for 6 hours. After
cooling, the reaction mixture was diluted with water and extracted
with ethyl acetate. The organic extract was washed with water and
brine, and dried over Na.sub.2SO.sub.4. After removal of the
solvent in vacuo, the residue was purified by flash column
chromatography to afford the desired compound.
General Procedure H: Alkylation of Phenolic Oxygen Atom of
Hydroxyphenylboronic Acid
[0803] To a solution of hydroxyphenylboronic acid (1 eq) in
anhydrous DMF (0.1-0.5 M) was added an alkyl bromide or mesylate (2
eq) followed by freshly ground K.sub.2CO.sub.3 (4 eq) and the
reaction mixture was heated at 100.degree. C. under nitrogen for 6
hours. The mixture was then diluted with water/EtOAc and the layers
separated. The aqueous layer was further extracted with EtOAc, and
the organic layers combined and dried over Na.sub.2SO.sub.4. The
solvent was removed in vacuo and the residue was purified by silica
gel chromatography to yield the desired product.
General Procedure I: Alkylation of Sulfur Atom of
Mercaptophenylboronic Acid
[0804] To a solution of mercaptophenylboronic acid (1 eq) in
anhydrous DMF (0.1-0.5 M) was added an alkyl bromide (2 eq)
followed by DIEA (4 eq) and the reaction mixture was stirred at
room temperature under nitrogen overnight. The mixture was then
diluted with water/EtOAc and the layers separated. The aqueous
layer was further extracted with EtOAc, and the organic layers
combined and dried over Na.sub.2SO.sub.4. The solvent was removed
in vacuo and the residue was purified by silica gel chromatography
to yield the desired product.
General Procedure J: Alkylation of Amino-phenylboronic Acid
[0805] To a solution of amino-phenylboronic acid (1 eq) in
anhydrous DMF (0.1-0.5 M) was added an alkyl/aryl bromide followed
by freshly ground K.sub.2CO.sub.3 (4 eq) and the reaction mixture
was stirred under nitrogen at room temperature for 16 hours. The
mixture was then diluted with water/EtOAc and the layers separated.
The aqueous layer was further extracted with EtOAc, and the organic
layers combined and dried over Na.sub.2SO.sub.4. The solvent was
removed in vacuo and the residue was purified by silica gel
chromatography to yield the desired product.
General Procedure K: Alkylation of Aniline, Phenol or Thiol
[0806] To solution of a phenol, aniline or thiol (1 eq) in
anhydrous DMF (0.1-0.5 M) was added an alkyl halide (2 eq) followed
by freshly ground Cs.sub.2CO.sub.3 (4 eq). The reaction mixture was
heated at 100.degree. C. under nitrogen for 2 hours. The mixture
was then diluted with water/EtOAc and the layers separated. The
aqueous layer was further extracted with EtOAc, and the organic
layers combined and dried over Na.sub.2SO.sub.4. The solvent was
removed in vacuo and the residue was purified by silica gel
chromatography to yield the desired product.
General Procedure L: Alkylation of Aniline, Phenol or Imidazole and
Heteroarylation of Alcohol, Thiol or Amine
[0807] To a solution of a phenol, alcohol, aniline or imidazole (1
eq) in anhydrous DMF (0.1-0.5M) was added sodium hydride (2 eq).
The mixture was stirred at room temperature for 20 min and a
solution of alkyl halide or heteroaryl halide in DMF (1-3 eq) was
added. Stirring continued for 3 hour, then the mixture was diluted
with water/EtOAc and neutralized with 10% aqueous citric acid. The
organic layer was washed with brine, dried over Na.sub.2SO.sub.4,
and evaporated in vacuo. The residue was purified by silica gel
chromatography to provide the desired product.
General Procedure M: Preparation of 1-(3-aminophenyl)imidazole
[0808] To a mixture of 3-aminoacetanilide (1 eq) and an aromatic
acyl bromide (2 eq) in anhydrous DMF (0.1-0.5 M) was added
NaHCO.sub.3 (5 eq). The reaction mixture was stirred at room
temperature under nitrogen for 3 hours. At completion, the reaction
mixture was diluted with water/EtOAc and the layers separated. The
aqueous layer was extracted with EtOAc and the organic layers
combined and washed with water and brine. The organic solution was
then dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and the residue was dried and used directly in the
next step.
[0809] The aniline derivative obtained above was dissolved in dry
DMF (0.1-0.5 M) and 5 eq of NaHCO.sub.3 was added. While stirring
under nitrogen on ice, a solution of p-bromophenylacetyl chloride
(1.1 eq) in benzene was added dropwise. The mixture was then
stirred for 1 hour and allowed to warm to room temperature. The
reaction mixture was diluted with water/EtOAc and the layers
separated. The aqueous layer was extracted with EtOAc and the
organic layers combined and washed with water and brine. The
organic solution was then dried over Na.sub.2SO.sub.4, filtered,
and the filtrate was concentrated and the residue was dried and
used directly in the next step.
[0810] The tertiary anilide obtained above was dissolved in glacial
acetic acid (0.1-0.5 M) and ammonium acetate (10 eq) was added. The
mixture was then heated at 110.degree. C. under nitrogen for 8
hours. At completion, the mixture was poured into water,
neutralized with saturated sodium bicarbonate and extracted with
ethyl acetate. The organic extract was washed with water and brine
and dried over Na.sub.2SO.sub.4. After removal of the solvent in
vacuo, the residue was purified by silica gel column chromatography
to afford the desired imidazole N-(3-acetamido)phenyl
derivative.
[0811] The intermediate obtained above was dissolved in a 6:1 v/v
mixture of 4M HCl/dioxane and water (0.1-0.5 M) and heated at
70.degree. C. for 3 hours. The mixture was then poured into water,
neutralized with saturated sodium bicarbonate and extracted with
ethyl acetate. The organic extract was washed with water and brine
and dried over Na.sub.2SO.sub.4. After removal of the solvent in
vacuo, the residue was dried and used without further
purification.
General Procedure N: Preparation of Tertiary Anilide
[0812] The aniline derivative obtained above was dissolved in dry
DMF (0.1-0.5 M) and 5 eq of NaHCO.sub.3 was added. While stirring
under nitrogen on ice, a solution of p-bromophenyl acetyl chloride
(1.1 eq) in benzene was added dropwise. The mixture was then
stirred for 1 hour and allowed to warm to room temperature. The
reaction mixture was diluted with water/EtOAc and the layers
separated. The aqueous layer was extracted with EtOAc and the
organic layers combined and washed with water and brine. The
organic solution was then dried over Na.sub.2SO.sub.4, filtered,
and the filtrate was concentrated and the residue was dried and
used directly in the next step.
General Procedure O: Preparation of Imidazole
[0813] The tertiary anilide obtained above was dissolved in glacial
acetic acid (0.1-0.5 M) and ammonium acetate (10 eq) was added. The
mixture was then heated at 110.degree. C. under nitrogen for 8
hours. At completion, the mixture was poured into water,
neutralized with saturated sodium bicarbonate and extracted with
ethyl acetate. The organic extract was washed with water and brine
and dried over Na.sub.2SO.sub.4. After removal of the solvent in
vacuo, the residue was purified by silica gel column chromatography
to afford the desired 1-(3-acetamido)phenyl]midazole
derivative.
General Procedure P: Hydrolysis of Ester
[0814] The ester (1 eq) was suspended in a mixture of
MeOH:THF:H.sub.2O (1:1:1; 0.1-0.2
[0815] M). LiOH (20 eq) was added and the mixture stirred at
100.degree. C. for 0.5 hours. The solution was acidified with 10%
citric acid solution, and extracted with ethyl acetate. The organic
extracts were combined, washed with brine, dried over
Na.sub.2SO.sub.4, and the solvent removed in vacuo. The residue was
purified by silica gel chromatography to yield the desired
acid.
General Procedure Q: Hydrogenation of Phenyl Group
[0816] To 1 equivalent of the desired substituted phenyl compound
suspension in methanol (0.1-0.5 M) was added a catalytic amount of
platinum(IV) oxide (wet). After degassing and introducing of
nitrogen and degassing again, hydrogen was introduced (.about.50
psi). The reaction mixture was stirred at room temperature for 3 to
4 days (hydrogen was recharged to maintain 40.about.50 psi
pressure). The reaction mixture was then filtered through celite,
the celite cake was washed three times with ethyl acetate, and the
filtrates combined. The solvent was then removed in vacuo, and the
residue was purified by silica gel chromatography to afford the
desired compound.
General Procedure R: Ullmann Coupling
[0817] To a solution of oxygen- or nitrogen-containing nucleophile
(1 eq) in anhydrous NMP (0.1-0.5 M), the appropriate aryl bromide
or iodide (1.5 eq) was added followed by CuCl (0.2 eq),
2,2,6,6-tetramethyl-3,5-heptanedione (0.2 eq) and Cs.sub.2CO.sub.3
(3 eq). The reaction mixture was then heated at 120.degree. C.
under nitrogen for 6 to 8 hours. At completion, the reaction
mixture was diluted with water/EtOAc and the layers separated. The
aqueous layer was re-extracted with EtOAc and the organic layers
combined, washed with water and brine. The organic phase was then
dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and purified by silica gel chromatography to afford
the desired product (diary) ether or substituted aniline
derivative).
General Procedure S: Oxidation of Sulfide using Peracetic Acid
[0818] To a solution of thioether compound (1 eq) in 1:1 DCM/HOAc
(0.1-0.5 M) was added peracetic acid (32 wt. % solution in acetic
acid, 10 eq) at 0.degree. C. and the solution was stirred at the
same temperature for half an hour. At completion, the reaction
mixture was diluted with water/EtOAc. The combined organic layer
was washed with water, saturated NaHCO.sub.3 and brine. The organic
phase was then dried over Na.sub.2SO.sub.4, filtered, and
concentrated. The residue was triturated several times with hexanes
to afford the desired sulfone derivative.
General Procedure T: Oxidation of Sulfide Using Hydrogen
Peroxide
[0819] To a solution or suspension of thioether compound (1 eq) in
methanol (0.1-0.5 M) was added hydrogen peroxide (50% solution in
water, 10 eq) at 0.degree. C. and the reaction mixture was stirred
at room temperature for an hour. At completion, the reaction
mixture was diluted with water/EtOAc. The combined organic layer
was washed with water and brine. The organic phase was then dried
over Na.sub.2SO.sub.4, filtered, and concentrated. The residue was
triturated several times with hexanes to afford the desired
sulfoxide derivative.
General Procedure U: Coupling of Aniline or Amine with Sulfonyl
Chloride, Sulfonic Anhydride or Chloroformate
[0820] To a suspension of amine compound (1 eq) in anhydrous DCM
(0.1-0.5 M) at 0.degree. C. was added DIEA (1.2 eq) followed by the
appropriate sulfonyl chloride, sulfonic anhydride, or chloroformate
(1.2 eq, diluted in anhydrous DCM). The reaction mixture was then
warmed up and stirred at room temperature under nitrogen for 3 to 4
hours. At completion, the reaction mixture was diluted with
water/EtOAc and the layers separated. The aqueous layer was
re-extracted with EtOAc and the organic layers combined, washed
with 10% citric acid, water and brine. The organic phase was then
dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and purified by silica gel chromatography to afford
the sulfonamide or the carbamate derivative.
General Procedure V: Removal of the t-butyl Carbamate Group
[0821] The boc-protected compound was stirred in 4N HCl/dioxane for
1 hour. The solvent removed, and the product triturated several
times with ether to afford the desired compound.
General Procedure W: Silyl group Deprotection
[0822] To a solution of O- or N-silyl compound (1 eq) in THF
(0.1-0.5 M) was added 5 eq of tetrabutylammonium fluoride as a
solution in THF. The mixture was stirred at 65.degree. C. for 1-3
hours, then was evaporated to a small volume and taken up in
water/EtOAc. Layers were separated and the aqueous layer was
further extracted with EtOAc. The combined organic extracts were
washed with brine, dried over Na.sub.2SO.sub.4, and evaporated in
vacuo. The residue was purified by silica gel column chromatography
to give the desired product.
General Procedure X: Reductive Amination
[0823] To a solution of amine (1 eq) in 1,2-dichloroethane (0.1-0.5
M) was added an aldehyde (1.2 eq) and a catalytic amount of acetic
acid. The mixture was stirred at room temperature for 30 minutes
under nitrogen, then sodium triacetoxyborohydride (3 eq) was added
and the mixture was allowed to stir for 12-16 hours at room
temperature. The mixture was then diluted with water/EtOAc and
layers were separated. The aqueous layer was extracted additionally
with EtOAc and the combined organic extracts were washed with
water, brine, dried over Na.sub.2SO.sub.4 and evaporated in vacuo.
The residue was purified by silica gel column chromatography to
provide the desired product.
General Procedure Y: Preparation of Boronic Acid
[0824] To a suspension of m- or p-bromobenzaldehyde in THF (0.1-0.5
M) was added drop-wise alkylmagnesium bromide or chloride in ether
or THF (1.1 eq) while stirring on ice. The mixture was allowed to
warm to room temperature and stirred for 30 minutes, then poured
into saturated NH.sub.4Cl/EtOAc and the layers separated. The
aqueous layer was extracted with EtOAc and the organic layers
combined and washed with water and brine. The organic solution was
then dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and the residue was dried and used directly in the
next step.
[0825] The Grignard product obtained above was dissolved in
trifluoroacetic acid (0.1-0.5 M) under nitrogen and cooled in an
ice-salt bath maintained at -10.degree. C. Triethylsilane (4 eq)
was added to the solution slowly in order to maintain the bath at
-10.degree. C. The solution was then allowed to warm to room
temperature and stirred for 3 hours. At completion, the mixture was
poured into water and extracted with dichloromethane. The organic
extract was washed with saturated aqueous NaHCO.sub.3 and brine and
dried over Na.sub.2SO.sub.4. After removal of the solvent in vacuo,
the residue was purified by silica gel column chromatography to
afford the desired m- or p-bromophenylalkane product.
[0826] A solution of m- or p-bromophenylalkane in dry THF (0.1-0.5
M) was stirred under nitrogen in a dry ice-acetone bath, and
sec-butyllithium in cyclohexane (2 eq) was added drop-wise, all on
dry ice-acetone bath. The mixture was stirred 10 minutes, then
triisopropyl borate (3 eq) was added drop-wise. The mixture was
stirred an additional 30 minutes, then poured into excess 2M HCl
and stirred 20 minutes at room temperature. Then EtOAc was added
and layers were separated. The aqueous layer was extracted with
EtOAc and the organic layers combined and washed with water and
brine. The organic solution was then dried over Na.sub.2SO.sub.4,
filtered, and the filtrate was concentrated. The residue was
re-crystallized from EtOAc/hexanes, dried, and used in boronic acid
coupling reactions.
General Procedure Z: Grignard Reaction
[0827] To a suspension of m- or p-bromobenzaldehyde in THF (0.1-0.5
M) was added drop-wise alkylmagnesium bromide or chloride in ether
or THF (1.1 eq) while stirring on ice. The mixture was allowed to
warm to room temperature and stirred for 30 minutes, then poured
into saturated NH.sub.4Cl/EtOAc and the layers separated. The
aqueous layer was extracted with EtOAc and the organic layers
combined and washed with water and brine. The organic solution was
then dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and the residue was dried and used directly in the
next step.
General Procedure AA: Reduction of Benzyl Alcohol
[0828] The alcohol obtained from general procedure Z was dissolved
in trifluoroacetic acid (0.1-0.5 M) under nitrogen and cooled in an
ice-salt bath maintained at -10.degree. C. Triethylsilane (4 eq)
was added to the solution slowly in order to maintain the bath at
-10.degree. C. The solution was then allowed to warm to room
temperature and stirred for 3 hours. At completion, the mixture was
poured into water and extracted with dichloromethane. The organic
extract was washed with saturated aqueous NaHCO.sub.3 and brine and
dried over Na.sub.2SO.sub.4. After removal of the solvent in vacuo,
the residue was purified by silica gel column chromatography to
afford the desired m- or p-bromophenylalkane product.
General Procedure AB: Preparation of N-alkyl
5-chloro-isothiazole-sulfones:
[0829] Dithio-acid (1.0 eq) was dissolved in thionyl chloride
(0.1-0.5 M) and the mixture was heated at 80-100.degree. C. for 3
to 6 hours. At completion, the excess thionyl chloride was removed
under pressure and compound was dried under vacuum and resulted
white solid was used directly in the next step.
[0830] Tert-butylamine (1.0 eq) was dissolved in dry DMF (0.1-0.5
M) and 5 eq of NaHCO.sub.3 was added. While stirring under nitrogen
on ice, a solution of aryl/alky acetyl chloride (1.1 eq) in benzene
was added drop wise. The mixture was then stirred for one hour and
allowed to warm to room temperature. The reaction mixture was
diluted with water/EtOAc and the layers separated. The aqueous
layer was extracted with EtOAc and the organic layers combined and
washed with water and brine. The organic solution was then dried
over Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated
and the residue was dried and used directly in the next step.
[0831] A solution of di-amide (1.0 eq) was dissolved in anhydrous
dichloromethane (0.1-0.5M) and was treated with sulfuryl chloride
(1.1 eq) drop-wise at 0.degree. C. and stirred at 25.degree. C. for
3 to 6 hours. At completion, the reaction mixture was cooled to
0.degree. C., quenched with water and stirred for 10 to 30 min. The
organic layer was separated and aqueous layer was re-extracted with
dichloromethane. The combined organic layers were dried with
MgSO.sub.4, filtered and concentrated to a light brown oil. The
crude oil was purified by flash column chromatography (100% hexane
to 40% ethyl acetate/hexane to 100% ethyl acetate) to yield off
white solid.
[0832] To a solution of isothiazole compound (1 eq) in 1:1 DCM/HOAc
(0.1-0.5 M) was added peracetic acid (32 wt. % solution in acetic
acid, 10 eq) at 0.degree. C. and the solution was stirred at the
same temperature for 2 to 6 hours. At completion, the reaction
mixture was diluted with water/EtOAc. The combined organic layer
was washed with water, saturated NaHCO.sub.3 and brine. The organic
phase was then dried over Na.sub.2SO.sub.4, filtered, and
concentrated. The residue was triturated several times with hexanes
to afford the desired isothiazole-sulfone derivative.
General Procedure AC: Pd(II)-catalyzed Coupling Reactions
[0833] A solution of aryl boronic acid (1.0 eq) in anhydrous
dioxane (0.1-0.5 M) was added potassium carbonate (5-10 eq), aryl
halide (1.1 eq) and Pd Cl.sub.2 (dppf) (2.5 eq) under nitrogen
atmosphere. The reaction mixture was degassed by the freeze-thaw
method thrice and was heated at 80.degree. C. for 24 to 48 hours.
At completion the reaction mixture was cooled to 25.degree. C.,
poured into water and extracted with dichloromethane. The combined
organic layers were washed with brine, dried with MgSO.sub.4 and
concentrated in vacuo. The crude residue was purified by flash
chromatography to yield light red solid.
General Procedure Ad: Preparation of Boronic Acid Pinacol Cyclic
Ester
[0834] To a solution of substituted aryl bromide (1 eq) in
anhydrous DMF (0.1-0.5 M) was added bis(pinacolato)diboron (3 eq),
[1,1'-bis(diphenylphosphino)ferrocene]-dichloro-palladium(II) (0.1
eq), and cesium carbonate (5 eq). The colored heterogeneous
reaction mixture was stirred at 100.degree. C. for 4-6 hours under
nitrogen. At completion, the resulting slurry was filtered through
celite, washed with ethyl acetate. The combined organic layers was
washed with water and brine, dried over Na.sub.2SO.sub.4 and
evaporated in vacuo. The residue was purified by silica gel column
chromatography to provide the desired arylboronic acid-pinacol
ester.
General Procedure AE: Preparation of 3- or 4-(alkenyl)phenylboronic
acid
[0835] To a suspension of m- or p-bromobenzaldehyde in THF (0.1-0.5
M) was added drop-wise alkylmagnesium bromide or chloride in ether
or THF (1.1 eq) while stirring on ice. The mixture was allowed to
warm to room temperature and stirred for 30 minutes, then poured
into saturated NH.sub.4Cl/EtOAc and the layers separated. The
aqueous layer was extracted with EtOAc and the organic layers
combined and washed with water and brine. The organic solution was
then dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and the residue was dried and used directly in the
next step.
[0836] The Grignard product from step above was dissolved in dry
dichloromethane (0.1-0.5 M) and N,N-diisopropylethylamine (5 eq)
was added. The mixture was cooled on an ice bath and
methanesulfonyl chloride (2 eq) was added drop-wise. The mixture
was allowed to warm to room temperature and stirred for 18 hours.
At completion, the mixture was poured into water and extracted with
dichloromethane. The organic extract was washed with water and
brine and dried over Na.sub.2SO.sub.4. After removal of the solvent
in vacuo, the residue was purified by silica gel column
chromatography to afford the desired m- or p-bromophenylalkene
product.
[0837] A solution of m- or p-bromophenylalkene in dry THF (0.1-0.5
M) was stirred under nitrogen in a dry ice-acetone bath, and
s-butyllithium in cyclohexane (2 eq) was added dropwise. The
mixture was stirred 10 minutes, then triisopropyl borate (3 eq) was
added dropwise. The mixture was stirred an additional 30 minutes,
then poured into excess 2M HCl and stirred 20 minutes. Then EtOAc
was added and layers were separated. The aqueous layer was
extracted with EtOAc and the organic layers combined and washed
with water and brine. The organic solution was then dried over
Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated. The
residue was recrystallized from EtOAc/hexanes, dried, and used in
boronic acid coupling reactions.
General Procedure AF: Sonogashira Coupling
[0838] To a solution of the bromo-compound (1 eq) in anhydrous DMF
(0.1-0.5 M) was added the appropriate terminal alkyne compound (2
eq) and a catalytic amount of
tetrakis(triphenylphosphine)palladium(0) (0.2 eq), followed by
copper(I) iodide (0.2 eq) and DIEA (5 eq). The reaction mixture was
stirred at 120.degree. C. under nitrogen for 6 hours. After
cooling, the reaction mixture was diluted with water and extracted
with ethyl acetate. The organic extract was washed with water and
brine, and dried over Na.sub.2SO.sub.4. After removal of the
solvent in vacuo, the residue was purified by flash column
chromatography to afford the desired compound.
General Procedure AG: Removal of Tertiary-butyl Group
[0839] A solution of N-tert-butyl compound (1.0 eq) in TFA
(0.1M-0.5M) was treated with triisopropylsilane (0.05 M). The
reaction mixture was heated at 70.degree. C. for 24 to 48 hours. At
completion, the mixture was cooled to 25.degree. C. and
concentrated in vacuo and co-evaporated with toluene. The crude
residue was purified by column chromatography to yield off white
solid.
General Procedure AH: Dealkylation
[0840] To 1 equivalent of the n-alkyl phenolic ether in DCM at
-78.degree. C. was added 10 equivalents of BBr.sub.3. The solution
was warmed to room temperature over 30 minutes, and the reaction
mixture quenched with MeOH. The reaction mixture was then diluted
with water/EtOAc and the layers separated. The aqueous layer was
further extracted with EtOAc, and the organic layers combined,
washed with water and brine, and dried over Na.sub.2SO.sub.4. The
solvent was removed in vacuo and the residue subjected to silica
gel chromatography to yield the final product.
Example 1
[0841] 4-Bromophenylacetic acid (107.5 g, 0.5 mol) was treated
according to general procedure A using 2,4-dichlorophenacyl bromide
to give
2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole.
[0842] LCMS: m/z 383 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 4.14 (s, 2H), 7.51 (d, 2H), 7.69 (d, 2H), 7.71 (m,
2H), 8.02 (m, 1H), 8.05 (s, 1H) ppm.
[0843] 2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole
(38.2 g, 0.1 mol) was treated as described in general procedure B
using 1-fluoro-4-nitrobenzene to give
2-(4-bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-
e.
[0844] LCMS: m/z 504 (M+H).sup.+.
[0845]
2-(4-Bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-im-
idazole (30.2 g, 60 mmol) was treated as described in general
procedure C to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-p-
henyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0846] LCMS: m/z 593 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.27 (d,
2H), 7.47 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89
(s, 1H), 8.19 (d, 1H) ppm.
[0847]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-tert-butylphenylboronic acid (36 mg, 0.2 mmol) to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0848] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.30 (s, 9H), 4.06 (s, 2H), 4.08 (s, 2H), 7.15 (d,
2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45 (d, 2H), 7.49 (dd, 1H), 7.52
(d, 2H), 7.54 (d, 2H), 7.64 (d, 1H), 7.90 (s, 1H), 8.20 (d, 1H)
ppm.
Example 2
[0849]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-cyclopentylphenylboronic acid (38 mg, 0.2 mmol) to give
5-{4-[2-(4'-cyclopentyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0850] LCMS: m/z 657 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.22-1.81 (m, 8H), 2.52 (m, 1H), 4.05 (s, 2H), 4.07
(s, 2H), 7.15 (d, 2H), 7.18 (d, 2H), 7.27 (d, 2H), 7.37 (d, 2H),
7.48 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89 (s,
1H), 8.19 (d, 1H) ppm.
Example 3
[0851]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
3-propoxyphenylboronic acid (36 mg, 0.2 mmol) to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(3'-propoxy-biphenyl-4-ylmethyl)-imidazol-
-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0852] LCMS: m/z 647 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.99 (t, 3H), 1.73 (m, 2H), 3.99 (t, 2H), 4.05 (s,
2H), 4.08 (s, 2H), 7.16 (d, 2H), 7.18-7.25 (m, 4H), 7.28 (d, 2H),
7.48 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.63 (d, 1H), 7.88 (s,
1H), 8.18 (d, 1H) ppm.
Example 4
[0853]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-propoxyphenylboronic acid (36 mg, 0.2 mmol) to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(4'-propoxy-biphenyl-4-ylmethyl)-imidazol-
-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0854] LCMS: m/z 647 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.01 (t, 3H), 1.74 (m, 2H), 4.00 (t, 2H), 4.05 (s,
2H), 4.08 (s, 2H), 7.15 (d, 2H), 7.18 (d, 2H), 7.20 (d, 2H), 7.27
(d, 2H), 7.48 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.63 (d, 1H),
7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 5
[0855]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
3-(cyclopentylmethoxy)phenylboronic acid (44 mg, 0.2 mmol, prepared
according to general procedure H) to give
5-{4-[2-(3'-cyclopentylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-pheny-
l)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0856] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.32-2.16 (m, 9H), 3.82 (d, 2H), 4.05 (s, 2H), 4.07
(s, 2H), 7.15 (d, 2H), 7.18-7.24 (m, 4H), 7.35 (d, 2H), 7.48 (dd,
1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19
(d, 1H) ppm.
Example 6
[0857]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
3-(3,3-dimethyl-butoxy)phenylboronic acid (45 mg, 0.2 mmol,
prepared according to general procedure H) to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[3'-(3,3-dimethyl-butoxy)-biphenyl-4-ylme-
thyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0858] LCMS: m/z 689 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.00 (s, 9H), 1.70 (t, 2H), 4.05 (s, 2H), 4.07 (t,
2H), 4.08 (s, 2H), 7.15 (d, 2H), 7.18-7.24 (m, 4H), 7.33 (d, 2H),
7.38 (d, 2H), 7.47 (dd, 1H), 7.55 (d, 2H), 7.64 (d, 1H), 7.89 (s,
1H), 8.18 (d, 1H) ppm.
Example 7
[0859]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) was
treated as described in general procedure R using
4-phenylpiperidine (162 mg, 1 mmol) to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4-(4-phenyl-piperidin-1-yl)-benzyl]-imid-
azol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0860] LCMS: m/z 672 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.62-1.79 (m, 4H), 2.56 (m, 1H), 3.21-3.34 (m, 4H),
4.05 (s, 2H), 4.08 (s, 2H), 7.15 (d, 2H), 7.18-7.34 (m, 7H), 7.38
(d, 2H), 7.47 (dd, 1H), 7.55 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H),
8.18 (d, 1H) ppm.
Example 8
[0861]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) was
treated as described in general procedure G using
3-methoxycarbonylphenylboronic acid (108 mg, 0.6 mmol) to give
4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl-
)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-3-carboxylic acid methyl
ester.
[0862] LCMS: m/z 647 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 3.79 (s, 3H), 4.06 (s, 2H), 4.09 (s, 2H), 7.15 (d,
2H), 7.18-7.24 (m, 4H), 7.33 (d, 2H), 7.38 (d, 2H), 7.47 (dd, 1H),
7.55 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 9
[0863]
4'-{4-(2,4-Dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidi-
n-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-3-carboxylic acid
methyl ester (33 mg, 0.05 mmol) was treated as described in general
procedure P to give
4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazoli-
din-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-3-carboxylic
acid.
[0864] LCMS: m/z 633 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.06 (s, 2H), 4.09 (s, 2H), 7.16 (d, 2H), 7.19-7.26
(m, 4H), 7.33 (d, 2H), 7.38 (d, 2H), 7.47 (dd, 1H), 7.55 (d, 2H),
7.64 (d, 1H), 7.90 (s, 1H), 8.19 (d, 1H) ppm.
Example 10
[0865]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (592 mg, 1 mmol) was
treated as described in general procedure G using
2-chloro-5-pyridine-boronic acid (315 mg, 2 mmol) to give
5-{4-[2-[4-(6-chloro-pyridin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)-imidaz-
ol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0866] LCMS: m/z 624 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.06 (s, 2H), 4.09 (s, 2H), 7.15 (d, 2H), 7.18-7.34
(m, 4H), 7.38 (d, 2H), 7.47 (dd, 1H), 7.55 (d, 2H), 7.64 (d, 1H),
7.89 (s, 1H), 8.18 (d, 1H), 8.37 (d, 1H) ppm.
Example 11
[0867]
5-{4-[2-[4-(6-Chloro-pyridin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (63
mg, 0.1 mmol) was treated as described in general procedure L using
cyclohexanol (20 mg, 0.2 mmol) to give
5-{4-[2-[4-(6-cyclohexyloxy-pyridin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)-
-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0868] LCMS: m/z 688 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.34-2.16 (m, 10H), 4.06 (s, 2H), 4.09 (s, 2H), 4.23
(m, 1H), 7.15 (d, 2H), 7.18-7.34 (m, 4H), 7.38 (d, 2H), 7.47 (dd,
1H), 7.55 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H), 8.28
(d, 1H) ppm.
Example 12
[0869]
5-{4-[2-[4-(6-Chloro-pyridin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (63
mg, 0.1 mmol) was treated as described in general procedure L using
piperidine (17 mg, 0.2 mmol) to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4-(3,4,5,6-tetrahydro-2H[1,2']bipyridiny-
l-5'-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-di-
oxide.
[0870] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.62-1.78 (m, 6H), 3.19-3.31 (m, 4H), 4.05 (s, 2H),
4.07 (s, 2H), 7.15 (d, 2H), 7.18-7.34 (m, 4H), 7.38 (d, 2H), 7.47
(dd, 1H), 7.55 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H),
8.25 (d, 1H) ppm.
Example 13
[0871] 2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (382
mg, 1 mmol) was treated as described in general procedure B using
5-fluoro-2-nitrotoluene (310 mg, 2 mmol) to give
2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(3-methyl-4-nitro-phenyl)-1H-
-imidazole.
[0872] LCMS: m/z 518 (M+H).sup.+.
[0873]
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(3-methyl-4-nitro-phen-
yl)-1H-imidazole (310 mg, 0.6 mmol) was treated as described in
general procedure C to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-2-methyl--
phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0874] LCMS: m/z 607 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 2.34 (s, 3H), 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d,
2H), 7.27-7.51 (m, 4H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H),
8.18 (d, 1H) ppm.
[0875]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-2-m-
ethyl-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (61 mg, 0.1
mmol) was treated as described in general procedure G using
4-cyclohexylphenylboronic acid (41 mg, 0.2 mmol) to give
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-2-methyl-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0876] LCMS: m/z 685 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.13-1.40 (m, 5H), 1.65-1.78 (m, 5H), 2.34 (s, 3H),
2.52 (m, 1H), 4.05 (s, 2H), 4.08 (s, 2H), 7.15 (d, 2H), 7.18-7.27
(m, 4H), 7.44-7.48 (m, 4H), 7.55 (d, 2H), 7.64 (d, 1H), 7.89 (s,
1H), 8.18 (d, 1H) ppm.
Example 14
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-difluoro-phenyl)-imidazol-1-yl]-phenyl}-1,-
2,5-thiadiazolidine-3-one-1,1-dioxide (prepared according to
general procedures A, B and C subsequently) (56 mg, 0.1 mmol) was
treated as described in general procedure G using
4-cyclohexylphenylboronic acid (41 mg, 0.2 mmol) to give
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-difluoro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0877] LCMS: m/z 639 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.22-1.44 (m, 5H), 1.69-1.81 (m, 5H), 2.52 (m, 1H),
4.05 (s, 2H), 4.07 (s, 2H), 7.13-7.16 (m, 5H), 7.27 (d, 2H), 7.37
(d, 2H), 7.41 (m, 1H), 7.51-7.55 (m, 5H), 8.12 (m, 1H) ppm.
[0878] By analogous methods to those used to prepare Example 14,
the following compounds were synthesized:
TABLE-US-00002 Ex. Name LC/MS (m/z) 15
5-{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-difluoro- 653 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-2-methyl-phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 16
5-{4-[4-(4-Chloro-phenyl)-2-(4'-cyclohexyl-biphenyl-4- 637 (M +
H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 17
5-{4-[4-(2-Chloro-phenyl)-2-(4'-cyclohexyl-biphenyl-4- 637 (M +
H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 18
5-{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,6-dichloro- 671 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 19
5-{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4,6-trichloro- 705
(M + H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 20
5-{4-[4-(2-Chloro-4-fluoro-phenyl)-2-(4'-cyclohexyl-biphenyl-4- 655
(M + H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide
Example 21
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,-
2,5-thiadiazolidine-3-one-1,1-dioxide (592 mg, 1 mmol) was treated
as described in general procedure G using 4-aminophenylboronic acid
(274 mg, 2 mmol) to give
5-{4-[2-(4'-amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0879] LCMS: m/z 604 (M+H).sup.+.
[0880]
5-{4-[2-(4'-Amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (61 mg,
0.1 mmol) was treated subsequently according to general procedure K
using 3-(bromomethyl)-5-methylisoxazole (27 mg, 0.15 mmol) and
general procedure U using isopropyl chloroformate (1M solution in
toluene) (0.2 mL, 0.2 mmol) to give
(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-y-
l)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-(5-methyl-isoxazol-3-ylm-
ethyl)-carbamic acid isopropyl ester.
[0881] LCMS: m/z 785 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.25 (d, 6H), 2.33 (s, 3H), 4.06 (s, 2H), 4.08 (s,
2H), 4.65 (s, 2H), 4.93 (m, 1H), 7.05-7.18 (m, 5H), 7.27 (d, 2H),
7.37 (d, 2H), 7.43-7.54 (m, 5H), 7.64 (d, 1H), 7.88 (s, 1H), 8.18
(d, 1H) ppm.
Example 22
5-{4-[2-(4'-Amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1--
yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (61 mg, 0.1
mmol) was treated subsequently according to general procedure K
using 1-bromo-2-methylpropane (21 mg, 0.15 mmol) and general
procedure U using isopropyl chloroformate (1M solution in toluene)
(0.2 mL, 0.2 mmol) to give
(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidi-
n-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-ylyisobutyl-carbamic
acid isopropyl ester.
[0882] LCMS: m/z 746 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.87 (d, 6H), 1.24 (d, 6H), 1.66 (m, 1H), 3.51 (d,
2H), 4.06 (s, 2H), 4.08 (s, 2H), 4.93 (m, 1H), 7.16 (d, 2H), 7.18
(d, 2H), 7.27 (d, 2H), 7.37 (d, 2H), 7.47 (dd, 1H), 7.51 (d, 2H),
7.53 (d, 2H), 7.64 (d, 1H), 7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 23
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenylamine
(prepared as described in general procedure M) (28.4 g, 60 mmol)
was treated as described in general procedures E to F to give
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0883] LCMS: m/z 593 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.27 (d,
2H), 7.47-7.53 (m, 5H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H)
ppm.
[0884]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (592 mg, 1 mmol) was
treated as described in general procedure G using
4-cyclohexylphenylboronic acid (408 mg, 2 mmol) to give
5-{3-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0885] LCMS: m/z 671 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.22-1.43 (m, 5H), 1.69-1.81 (m, 5H), 2.52 (m, 1H),
4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.18 (d, 2H), 7.27 (d,
2H), 7.37 (d, 2H), 7.46-7.54 (m, 5H), 7.64 (d, 1H), 7.89 (s, 1H),
8.19 (d, 1H) ppm.
[0886] The title compound can also be prepared using the following
procedure starting from 3-nitroaniline. Methyl bromoacetate (6.77
mL, 73.5 mmol) was added to a mixture of 3-nitroaniline (9.21 g,
66.7 mmol), NaHCO.sub.3 (14 g, 167 mol) and dimethylformamide (75
mL). The mixture was stirred at 70-75.degree. C. for 3 hr and then
cooled to room temperature. Water (600 mL) was added to the
reaction mixture and the product was collected by filtration and
washed 3 times with 50 mL portions of water. The yellow product,
(3-nitrophenylamino)-acetic acid methyl ester was dried under
reduced pressure to afford 12.4 g (88%).
[0887] Chlorosulfonyl isocyanate (8.68 mL, 100 mmol) was added
dropwise to a solution of t-butyl alcohol (9.61 mL, 100 mmol) in
dichloromethane (48.2 mL) at 0.degree. C. The mixture was allowed
to warm to room temperature and stirred for 30 min. 37.5 mL of this
solution was then added dropwise to a mixture of
(3-nitrophenylamino)-acetic acid methyl ester (10.5 g, 50 mmol),
diisopropylethylamine (26 mL, 150 mol) and dichloromethane (50 mL)
at 0.degree. C. After the addition the mixture was allowed to warm
to room temperature and washed with water (2.times.500 mL). The
extract was dried (MgSO.sub.4) and filtered. This extract
containing Boc-protected sulfamide was diluted to a total volume of
300 mL by the addition of dichloromethane. Trifluoroacetic acid (75
mL) was added to the solution at 0.degree. C. and the solution was
stirred for 3 hr or until no starting material remained by TLC. The
solution was washed with water (3.times.500 mL) and the product was
precipitated by the addition of hexanes and collected by
filtration. The product was washed with 5% dichloromethane in
hexanes (50 mL) and dried under reduced pressure to afford 10.5 g
of product.
[0888] A solution of NaOH (2 M, 2.0 equivalents) was added to a
suspension of the Boc deprotected material (10.5 g, 36.3 mmol) in
ethanol (75 mL) at 0.degree. C. with rapid stirring until a thick
precipitate formed (2 min). The mixture was acidified to pH of 5.0
by adding 6.0 M hydrochloric acid. The product,
1,1-dioxo-5-(3-nitrophenyl)-[1,2,5]thiadiazolidin-3-one was
collected by filtration and washed with diethyl ether (50 mL). The
product was dried under reduced pressure to afford the cyclized
product (8.5 g, 91%).
[0889] A solution of nitro compound (8.5 g) in methanol (40 mL) was
treated with 1.7 g of 10% Pd/C catalyst under hydrogen atmosphere
for 18 h. The catalyst was removed by filtration. The solution was
concentrated and
5-(3-amino-phenyl)-1,1-dioxo-[1,2,5]thiadiazolidin-3-one was
crystallized out by addition of dichloromethane, collected by
filtration and dried to provide 6.9 g of product (92% yield).
[0890] To a solution of
5-(3-amino-phenyl)-1,1-dioxo-[1,2,5]thiadiazolidin-3-one (5 g, 22
mmol) in 37.5 mL of 9:1 v/v acetonitrile-water was added
NaHCO.sub.3 (4.62 g, 55 mmol). The mixture was stirred at
25.degree. C. while 2-bromo-1-(2,4-dichloro-phenyl)-ethanone (7.1
g, 26.4 mmol) was added. The mixture was stirred for 12-16 hours at
35.degree. C. The mixture was cooled on an ice bath to further
precipitate the product, which was then collected by filtration.
The filtrate was concentrated under reduced pressure and a second
crop of crude product was collected. The combined crude product was
washed once with 25 mL water and dried, then washed once with 10 mL
methyl tert-butyl ether and dried, to provide 6.36 g (70% yield) of
5-{3-[2-(2,4-dichloro-phenyl)-2-oxo-ethylamino]-phenyl}-1,1-dio-
xo-[1,2,5]thiadiazolidin-3-one.
[0891] To a mixture of phenacyl amine (9.4 g, 23 mmol), and
NaHCO.sub.3 (5.04 g, 60 mmol) in dichloromethane (30 mL) was added
slowly a dichloromethane (10 mL) solution of
(4'-cyclohexylbiphenyl)acetyl chloride (34 mmol), which was
prepared by the reaction of oxalyl chloride with
(4'-cyclohexyl-biphenyl-4-yl)-acetic acid (10 g, 34 mmol) which in
turn was prepared from (4-cyclohexylphenyl)boronic acid and
4-bromophenylacetic acid via Suzuki coupling. The mixture was
allowed to stir at 25.degree. C. for 9 hours. The mixture was then
diluted with tetrahydrofuran, washed with dilute brine, dried over
sodium sulfate, and evaporated. The product,
2-(4'-cyclohexyl-biphenyl-4-yl)-N-[2-(2,4-dichloro-phenyl)-2-oxo-ethyl]-N-
-[3-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)-phenyl]-acetamide,
was purified by column chromatography on silica gel using 1-8%
methanol in dichloromethane.
[0892] To a solution of ammonium acetate (223 mg, 2.9 mmol) in
acetic acid (0.5 mL), was added the above tertiary amide (200 mg.
0.29 mmol) in dimethylformamide (0.5 mL) and the mixture was then
stirred at 90.degree. C. for 18 hours, after which it was diluted
with tetrahydrofuran and washed 5 times with dilute brine, dried
over sodium sulfate, and evaporated to dryness. The crude solid
material was washed extensively with methanol to provide 140 mg of
pure title product.
Example 24
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,-
2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was treated
as described in general procedure G using 4-tert-butylphenylboronic
acid (36 mg, 0.2 mmol) to give
5-{3-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0893] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.30 (s, 9H), 4.06 (s, 2H), 4.08 (s, 2H), 7.15 (d,
2H), 7.19 (d, 2H), 7.29 (d, 2H), 7.38 (d, 2H), 7.46-7.54 (m, 5H),
7.64 (d, 1H), 7.90 (s, 1H), 8.19 (d, 1H) ppm.
Example 25
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,-
2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was treated
as described in general procedure G using
3-(3,3-dimethyl-butoxy)phenylboronic acid (45 mg, 0.2 mmol,
prepared according to general procedure H) to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[3'-(3,3-dimethyl-butoxy)-biphenyl-4-ylme-
thyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0894] LCMS: m/z 689 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.97 (s, 9H), 1.67 (t, 2H), 4.05 (s, 2H), 4.07 (t,
2H), 4.08 (s, 2H), 7.05-7.12 (m, 4H), 7.29 (d, 2H), 7.38 (d, 2H),
7.46-7.54 (m, 5H), 7.64 (d, 1H), 7.90 (s, 1H), 8.19 (d, 1H)
ppm.
[0895] By analogous methods to those used to prepare Example 25,
the following compounds were synthesized:
TABLE-US-00003 Ex. Name LC/MS (m/z) 26
5-{3-[4-(2,4-Dichloro-phenyl)-2-(3'-methanesulfonyl-biphenyl- 667
(M + H).sup.+
4-ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 27
5-{3-[2-(3'-Cyclohexanesulfonyl-biphenyl-4-ylmethyl)-4-(2,4- 735 (M
+ H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 28
5-{3-[2-(4'-Cyclohexanesulfonyl-biphenyl-4-ylmethyl)-4-(2,4- 735 (M
+ H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 29
5-{3-[4-(2,4-Dichloro-phenyl)-2-(3'-propoxy-biphenyl-4- 647 (M +
H)+ ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 30
5-{3-[2-(3'-Butoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 661 (M +
H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 31
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(4,4,4-trifluoro-butoxy)- 715
(M + H)+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 32
5-{3-[4-(2,4-Dichloro-phenyl)-2-(3'-ethoxy-biphenyl-4- 633 (M +
H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 33
5-{3-[2-(3'-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4- 701 (M +
H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 34
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(3-methyl-butoxy)-biphenyl- 675
(M + H).sup.+
4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 35
5-{3-[2-(3'-Cyclopentylmethoxy-biphenyl-4-ylmethyl)-4-(2,4- 687 (M
+ H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 36
5-{3-[2-(3'-Cyclohexyloxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 687
(M + H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 37
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(2,2-dimethyl-propoxy)- 675 (M
+ H).sup.+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 38
5-{3-[2-(3'-tert-Butoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 661
(M + H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 39
5-{3-[2-[3'-(2-Cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4- 715
(M + H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 40
5-{3-[2-[3'-(2-Cyclopentyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4- 701
(M + H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 41
5-{3-[4-(2,4-Dichloro-phenyl)-2-(3'-phenethyloxy-biphenyl-4- 709 (M
+ H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 42
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(4,4-dimethyl-pentyl)- 687 (M +
H).sup.+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 43
5-{3-[2-[3'-(2-Cyclohexyl-ethyl)-biphenyl-4-ylmethyl]-4-(2,4- 699
(M + H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 44
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(3,3-dimethyl-butylsulfanyl)-
705 (M + H).sup.+
biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide
Example 45
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(3,3-dimethyl-butylsulfanyl)-biphenyl--
4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide
(14 mg, 0.02 mmol) was treated as described in general procedure S
to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[3'-(3,3-dimethyl-butane-1-sulfonyl)-
-biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1-
,1-dioxide.
[0896] LCMS: m/z 737 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.89 (s, 9H), 1.46 (m, 2H), 3.27 (m, 2H), 4.06 (s,
2H), 4.09 (s, 2H), 7.18 (d, 2H), 7.21 (d, 2H), 7.29-7.41 (m, 4H),
7.49-7.58 (m, 5H), 7.63 (d, 1H), 7.88 (s, 1H), 8.18 (d, 1H)
ppm.
Example 46
[0897]
5-(3-{4-(2,4-Dichloro-phenyl)-2-[3'-(3,3-dimethyl-butylsulfanyl)-bi-
phenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1--
dioxide (14 mg, 0.02 mmol) was treated as described in general
procedure T to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[3'-(3,3-dimethyl-butane-1-sulfin-
yl)-biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-on-
e-1,1-dioxide.
[0898] LCMS: m/z 721 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.86 (s, 9H), 1.45 (m, 2H), 2.98 (m, 2H), 4.05 (s,
2H), 4.08 (s, 2H), 7.18 (d, 2H), 7.21 (d, 2H), 7.26-7.38 (m, 4H),
7.47-7.56 (m, 5H), 7.63 (d, 1H), 7.88 (s, 1H), 8.18 (d, 1H)
ppm.
Example 47
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,-
2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) was
treated as described in general procedure G using
3-(cyclohexylmethylsulfanyl)phenylboronic acid (100 mg, 0.4 mmol,
prepared according to general procedure I) to give
5-{3-[2-(3'-cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-
-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0899] LCMS: m/z 717 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.97-1.23 (m, 6H), 1.48 (m, 1H), 1.58-1.87 (m, 4H),
2.88 (d, 2H), 4.05 (s, 2H), 4.08 (s, 2H), 7.12-7.18 (m, 4H),
7.33-7.38 (m, 4H), 7.46-7.58 (m, 5H), 7.63 (d, 1H), 7.88 (s, 1H),
8.18 (d, 1H) ppm.
Example 48
[0900]
5-{3-[2-(3'-Cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-diox-
ide (15 mg, 0.02 mmol) was treated as described in general
procedure S to give
5-{3-[2-(3'-cyclohexylmethylsulfonyl-biphenyl-4-ylmethyl)-4-(2,4-dic-
hloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxi-
de.
[0901] LCMS: m/z 749 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.00-1.24 (m, 6H), 1.53 (m, 1H), 1.59-1.89 (m, 4H),
3.20 (d, 2H), 4.05 (s, 2H), 4.08 (s, 2H), 7.18 (d, 2H), 7.21 (d,
2H), 7.29-7.41 (m, 4H), 7.46-7.58 (m, 5H), 7.63 (d, 1H), 7.88 (s,
1H), 8.18 (d, 1H) ppm.
Example 49
[0902]
5-{3-[2-(3'-Cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-diox-
ide (15 mg, 0.02 mmol) was treated as described in general
procedure T to give
5-{3-[2-(3'-cyclohexylmethylsulfinyl-biphenyl-4-ylmethyl)-4-(2,4-dic-
hloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxi-
de.
[0903] LCMS: m/z 733 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.00-1.86 (m, 11H), 3.03 (m, 2H), 4.05 (s, 2H), 4.08
(s, 2H), 7.18 (d, 2H), 7.21 (d, 2H), 7.27-7.39 (m, 4H), 7.46-7.58
(m, 5H), 7.63 (d, 1H), 7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 50
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,-
2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) was
treated as described in general procedure G using
3-(cyclohexylmethylsulfanyl)phenylboronic acid (106 mg, 0.4 mmol,
prepared according to general procedure I) to give
5-{3-[2-(3'-(2-cyclohexyl-ethylsulfanyl)-biphenyl-4-ylmethyl)-4-(2,4-dich-
loro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxid-
e.
[0904] LCMS: m/z 731 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.85-1.72 (m, 13H), 3.03 (t, 2H), 4.05 (s, 2H), 4.08
(s, 2H), 7.17-7.26 (m, 4H), 7.34-7.42 (m, 4H), 7.47-7.58 (m, 5H),
7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 51
5-{3-[2-(3'-(2-Cyclohexyl-ethylsulfanyl)-biphenyl-4-ylmethyl)-4-(2,4-dichl-
oro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
(15 mg, 0.02 mmol) was treated as described in general procedure S
to give
5-{3-[2-(3'-(2-cyclohexyl-ethanesulfonyl)-biphenyl-4-ylmethyl)-4-(2,-
4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1--
dioxide.
[0905] LCMS: m/z 763 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.85-1.72 (m, 13H), 3.33 (m, 2H), 4.05 (s, 2H), 4.08
(s, 2H), 7.22-7.29 (m, 4H), 7.37-7.47 (m, 4H), 7.51-7.59 (m, 5H),
7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 52
[0906]
5-{3-[2-(3'-(2-Cyclohexyl-ethylsulfanyl)-biphenyl-4-ylmethyl)-4-(2,-
4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1--
dioxide (15 mg, 0.02 mmol) was treated as described in general
procedure T to give
5-{3-[2-(3'-(2-cyclohexyl-ethanesulfinyl)-biphenyl-4-ylmethyl)-4--
(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1-
,1-dioxide.
[0907] LCMS: m/z 747 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 0.85-1.72 (m, 13H), 3.07 (m, 2H), 4.05 (s, 2H), 4.08
(s, 2H), 7.21-7.28 (m, 4H), 7.37-7.44 (m, 4H), 7.49-7.58 (m, 5H),
7.64 (d, 1H), 7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 53
[0908]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) was
treated as described in general procedure G using
3-(phenethylsulfanyl)phenylboronic acid (104 mg, 0.4 mmol, prepared
according to general procedure I) to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(3'-phenethylsulfanyl-biphenyl-4-ylmethyl-
)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0909] LCMS: m/z 725 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 2.89 (t, 2H), 3.30 (t, 2H), 4.07 (s, 2H), 4.09 (s,
2H), 7.18-7.22 (m, 5H), 7.25-7.32 (m, 6H), 7.37-7.49 (m, 4H), 7.53
(m, 1H), 7.57 (d, 2H), 7.64 (d, 1H), 7.90 (s, 1H), 8.20 (d, 1H)
ppm.
Example 54
[0910]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-difluoro-phenyl}-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (prepared according to
general procedures A, J and C stepwise) (112 mg, 0.2 mmol) was
treated as described in general procedure G using
3-(3,3-dimethyl-butylsulfanyl)phenylboronic acid (96 mg, 0.4 mmol,
prepared according to general procedure I) to give
5-(3-{4-(2,4-difluoro-phenyl)-2-[3'-(3,3-dimethyl-butylsulfanyl)-biphenyl-
-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxid-
e.
[0911] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.91 (s, 9H), 1.49 (m, 2H), 2.96 (m, 2H), 4.05 (s,
2H), 4.07 (s, 2H), 7.12-7.18 (m, 4H), 7.27-7.36 (m, 5H), 7.53-7.59
(m, 5H), 7.95-8.11 (m, 2H) ppm.
Example 55
[0912]
5-(3-{4-(2,4-Difluoro-phenyl)-2-[3'-(3,3-dimethyl-butylsulfanyl)-bi-
phenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1--
dioxide (14 mg, 0.02 mmol) was treated as described in general
procedure S to give
5-(3-{4-(2,4-difluoro-phenyl)-2-[3'-(3,3-dimethyl-butane-1-sulfon-
yl)-biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-on-
e-1,1-dioxide.
[0913] LCMS: m/z 705 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 0.90 (s, 9H), 1.48 (m, 2H), 3.25 (m, 2H), 4.05 (s,
2H), 4.07 (s, 2H), 7.14-7.21 (m, 4H), 7.28-7.39 (m, 5H), 7.53-7.59
(m, 5H), 7.95-8.11 (m, 2H) ppm.
Example 56
[0914]
5-(3-{4-(2,4-Difluoro-phenyl)-2-[3'-(3,3-dimethyl-butylsulfanyl)-bi-
phenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1--
dioxide (14 mg, 0.02 mmol) was treated as described in general
procedure T to give
5-(3-{4-(2,4-difluoro-phenyl)-2-[3'-(3,3-dimethyl-butane-1-sulfin-
yl)-biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-on-
e-1,1-dioxide.
[0915] LCMS: m/z 689 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.91 (s, 9H), 1.48 (m, 2H), 2.98 (m, 2H), 4.05 (s,
2H), 4.08 (s, 2H), 7.13-7.21 (m, 4H), 7.27-7.39 (m, 5H), 7.53-7.59
(m, 5H), 7.95-8.11 (m, 2H) ppm.
Example 57
[0916]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-difluoro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (prepared according to
general procedures A, R and C stepwise) (56 mg, 0.1 mmol) was
treated as described in general procedure G using
4-cyclohexylphenylboronic acid (41 mg, 0.2 mmol) to give
5-{3-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-difluoro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0917] LCMS: m/z 639 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.22-1.44 (m, 5H), 1.69-1.81 (m, 5H), 2.52 (m, 1H),
4.05 (s, 2H), 4.07 (s, 2H), 7.13-7.16 (m, 5H), 7.27 (d, 2H), 7.37
(d, 2H), 7.41 (m, 1H), 7.51-7.55 (m, 5H), 8.12 (m, 1H) ppm.
[0918] By analogous methods to those used to prepare Example 57,
the following compounds were synthesized:
TABLE-US-00004 Ex. Name LC/MS (m/z) 58
5-{5-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-difluoro- 653 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-2-methyl-phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 59
5-{5-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 685 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-2-methyl-phenyl}-1,2,5-thiadiazolidine-
3-one-1,1-dioxide 60
5-{5-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 701 (M
+ H).sup.+ phenyl)-imidazol-1-yl]-2-methoxy-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 61
5-{3-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,6-dichloro- 671 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 62
5-{3-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4,6-trichloro- 705
(M + H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 63
5-(3-{4-(2,6-Dichloro-phenyl)-2-[3'-(3,3-dimethyl-butoxy)- 689 (M +
H).sup.+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 64
5-{3-[2-(3'-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,6- 701 (M +
H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 65
5-(3-{4-(2,4-Difluoro-phenyl)-2-[3'-(3,3-dimethyl-butoxy)- 657 (M +
H)+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide
Example 66
[0919] 4-Iodophenylacetic acid (26.2 g, 0.1 mol) was treated
according to general procedure A using 2,4-dichlorophenacyl bromide
to give 4-(2,4-dichloro-phenyl)-2-(4-iodo-benzyl)-1H-imidazole.
[0920] LCMS: m/z 429 (M+H).sup.+.
[0921] 4-(2,4-Dichloro-phenyl)-2-(4-iodo-benzyl)-1H-imidazole (12.9
g, 30 mmol) was treated as described in general procedures B and C
stepwise to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(4-iodo-benzyl)-imidazol-1-yl]-pheny-
l}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0922] LCMS: m/z 639 (M+H).sup.+.
[0923]
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4-iodo-benzyl)-imidazol-1-yl]-phen-
yl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (3.2 g, 5 mmol) was
treated as described in general procedure G using
4-bromophenylboronic acid (2.0 g, 10 mmol) to give
5-{4-[2-(4'-bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0924] LCMS: m/z 669 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.19 (d,
2H), 7.36 (d, 2H), 7.45 (d, 2H), 7.49 (dd, 1H), 7.52 (d, 2H), 7.54
(d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
[0925]
5-{4-[2-(4'-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (268 mg,
0.4 mmol) was treated as described in general procedure R using
excess piperazine (346 mg, 4 mmol) to give the desired compound
5-{4-[4-(2,4-dichloro-phenyl)-2-(4'-piperazin-1-yl-biphenyl-4-ylmethyl)-i-
midazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0926] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 3.01 (m, 4H), 3.31 (m, 4H), 4.05 (s, 2H), 4.08 (s,
2H), 6.94 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45-7.52 (m, 5H),
7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 67
[0927]
5-{4-[2-(4'-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (67 mg,
0.1 mmol) was treated as described in general procedure R using
excess 1-methylpiperazine (100 mg, 1 mmol) to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4'-(4-methyl-piperazin-1-yl)-biphenyl-4--
ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0928] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 2.43 (s, 3H), 3.12 (m, 4H), 3.34 (m, 4H), 4.05 (s,
2H), 4.08 (s, 2H), 6.94 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H),
7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18
(d, 1H) ppm.
Example 68
[0929]
5-{4-[2-(4'-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (134 mg,
0.2 mmol) was treated as described in general procedure R using
excess piperazin-2-one (200 mg, 2 mmol) to give
4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)piperazin-2-one.
[0930] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 3.22-3.34 (m, 4H), 4.01 (s, 2H), 4.05 (s, 2H), 4.08
(s, 2H), 6.94 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45-7.52 (m,
5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H)
ppm.
Example 69
[0931]
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4'-piperazin-1-yl-biphenyl-4-ylmet-
hyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
(20 mg, 0.03 mmol) was treated as described in general procedure U
using neopentyl chloroformate (9 mg, 0.06 mmol) to give
4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)piperazine-1-carboxylic
acid 2,2-dimethyl-propyl ester.
[0932] LCMS: m/z 787 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.06 (s, 9H), 3.17-3.36 (m, 8H), 4.02 (s, 2H), 4.06
(s, 2H), 4.08 (s, 2H), 6.94 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H),
7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.20
(d, 1H) ppm.
Example 70
[0933]
5-{4-[2-(4'-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (268 mg,
0.4 mmol) was treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (142 .mu.L, 0.8 mmol) to
give
5-{4-[2-(4'-bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]-phenyl}-2-(2-trimethylsilanyl-ethoxymethyl)-1,2,5-thiadiazolidine-3-o-
ne-1,1-dioxide.
[0934] LCMS: m/z 799 (M+H).sup.+.
[0935]
5-{4-[2-(4'-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-2-(2-trimethylsilanyl-ethoxymethyl)-1,2,5-thiadiazolidi-
ne-3-one-1,1-dioxide (240 mg, 0.3 mmol) was treated as described in
general procedure R using excess piperazin-2-one (301 mg, 3 mmol)
to give
4-[4'-(4-(2,4-dichloro-phenyl)-1-{4-[1,1,4-trioxo-5-(2-trimethylsilanyl-e-
thoxymethyl)-[1,2,5]thiadiazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-b-
iphenyl-4-yl]-piperazin-2-one.
[0936] LCMS: m/z 817 (M+H).sup.+.
[0937]
4-[4'-(4-(2,4-Dichloro-phenyl)-1-{4-[1,1,4-trioxo-5-(2-trimethylsil-
anyl-ethoxy
methyl)-[1,2,5]thiadiazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-biphe-
nyl-4-yl]-piperazin-2-one (17 mg, 0.02 mmol) was treated as
described in general procedure L (using iodomethane) and general
procedure W stepwise to give the desired compound
4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-1-methyl-piperazin-2-o-
ne.
[0938] LCMS: m/z 701 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 2.94 (s, 3H), 3.28-3.36 (m, 4H), 4.01 (s, 2H), 4.08
(s, 2H), 4.16 (s, 2H), 6.94 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H),
7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18
(d, 1H) ppm.
Example 71
[0939]
4-[4'-(4-(2,4-Dichloro-phenyl)-1-{4-[1,1,4-trioxo-5-(2-trimethylsil-
anyl-ethoxy
methyl)-[1,2,5]thiadiazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-biphe-
nyl-4-yl]-piperazin-2-one (17 mg, 0.02 mmol) was treated as
described in general procedure L (using iodoethane) and general
procedure W stepwise to give
4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiaz-
olidin-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-1-ethyl-pipera-
zin-2-one.
[0940] LCMS: m/z 715 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.09 (t, 3H), 3.28-3.36 (m, 4H), 3.57 (q, 2H), 4.01
(s, 2H), 4.08 (s, 2H), 4.16 (s, 2H), 6.94 (d, 2H), 7.19 (d, 2H),
7.36 (d, 2H), 7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89
(s, 1H), 8.18 (d, 1H) ppm.
Example 72
[0941]
4-[4'-(4-(2,4-Dichloro-phenyl)-1-{4-[1,1,4-trioxo-5-(2-trimethylsil-
anyl-ethoxy
methyl)-[1,2,5]thiadiazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-biphe-
nyl-4-yl]-piperazin-2-one (17 mg, 0.02 mmol) was treated as
described in general procedure L (using 2-iodopropane) and general
procedure W stepwise to give
4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-1-isopropyl-piperazin--
2-one.
[0942] LCMS: m/z 729 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.06 (d, 6H), 3.28-3.36 (m, 4H), 3.71 (m, 1H), 4.01
(s, 2H), 4.08 (s, 2H), 4.15 (s, 2H), 6.94 (d, 2H), 7.19 (d, 2H),
7.36 (d, 2H), 7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89
(s, 1H), 8.18 (d, 1H) ppm.
Example 73
[0943]
4-[4'-(4-(2,4-Dichloro-phenyl)-1-{4-[1,1,4-trioxo-5-(2-trimethylsil-
anyl-ethoxy
methyl)-[1,2,5]thiadiazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-biphe-
nyl-4-yl]-piperazin-2-one (17 mg, 0.02 mmol) was treated as
described in general procedure L [using iodocyclohexane (13 mg,
0.06 mmol)] and general procedure W stepwise to give
1-cyclohexyl-4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thi-
adiazolidin-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-piperazin-
-2-one.
[0944] LCMS: m/z 769 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.42-1.71 (m, 10H), 3.28-3.36 (m, 4H), 4.01 (s, 2H),
4.07 (s, 2H), 4.09 (m, 1H), 4.17 (s, 2H), 6.94 (d, 2H), 7.19 (d,
2H), 7.36 (d, 2H), 7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H),
7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 74
[0945]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (592 mg, 1 mmol) was
treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (354 .mu.L, 2 mmol) to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[0946] LCMS: m/z 723 (M+H).sup.+.
[0947]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-
-one (361 mg, 0.5 mmol) was treated as described in general
procedure G using 4-aminophenylboronic acid (137 mg, 1 mmol) to
give
5-{4-[2-(4'-amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiaz-
olidin-3-one.
[0948] LCMS: m/z 734 (M+H).sup.+.
[0949]
5-{4-[2-(4'-Amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]th-
iadiazolidin-3-one (74 mg, 0.1 mmol) was treated as described in
general procedure U using 5-bromovaleryl chloride (40 mg, 0.2 mmol)
to give the intermediate 5-bromo-pentanoic acid
[4'-(4-(2,4-dichloro-phenyl)-1-{-[1,1,4-trioxo-5-(2-trimethylsilanyl-etho-
xymethyl)-[1,2,5]thia-diazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-bip-
henyl-4-yl]-amide, which was treated with
1,8-diazabicyclo[5,4,0]undec-7-ene (46 mg, 0.3 mmol) at 0.degree.
C. in 1 mL anhydrous DMF (stirring at room temperature under
nitrogen over night), followed by regular ethyl acetate/water
workup and silica gel column chromatography to give
1-[4'-(4-(2,4-dichloro-phenyl)-1-{-[1,1,4-trioxo-5-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thia-diazolidin-2-yl]-phenyl}-1H-imidazol-2-ylmethyl)-b-
iphenyl-4-yl]-piperidin-2-one, which was finally treated as
described in general procedure W to give the desired compound
1-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-piperidin-2-one.
[0950] LCMS: m/z 686 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.84 (m, 4H), 2.43 (m, 2H), 3.39 (m, 2H), 4.08 (s,
2H), 4.16 (s, 2H), 7.21 (d, 2H), 7.29 (d, 2H), 7.36 (d, 2H),
7.45-7.52 (m, 5H), 7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18
(d, 1H) ppm.
Example 75
[0951]
2-(4-Bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-im-
idazole (5.0 g, 10 mmol) was treated as described in general
procedure G using 3-chloro-4-pyridine-boronic acid (3.2 g, 20 mmol)
to give
2-chloro-4-{4-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-2-y-
lmethyl]-phenyl}-pyridine.
[0952] LCMS: m/z 535 (M+H).sup.+.
[0953]
2-Chloro-4-{4-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidaz-
ol-2-ylmethyl]-phenyl}-pyridine (1.6 g, 3 mmol) was refluxed with
6M NaOH in 1/1 water/ethanol (10 mL, 60 mmol) for 2 to 4 hours,
followed by regular ethyl acetate/water workup and silica gel
column chromatography to give the intermediate
4-{4-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-2-ylmethyl]--
phenyl}-1H-pyridin-2-one, which was then treated as described in
general procedure L [using iodocyclohexane (0.78 mL, 6 mmol)] to
give
1-cyclohexyl-4-{4-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-
-2-ylmethyl]-phenyl}-1H-pyridin-2-one.
[0954] LCMS: m/z 599 (M+H).sup.+.
[0955]
1-Cyclohexyl-4-{4-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-im-
idazol-2-ylmethyl]-phenyl}-1H-pyridin-2-one (300 mg, 0.5 mmol) was
treated as described in general procedure C to give the desired
compound
1-cyclohexyl-4-(4-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thia-
diazolidin-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-phenyl)-1H-pyridin-2-one.
[0956] LCMS: m/z 688 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.66-1.84 (m, 6H), 2.33-2.46 (m, 4H), 4.05 (s, 2H),
4.08 (s, 2H), 4.23 (m, 1H), 7.11-7.36 (m, 5H), 7.45-7.52 (m, 4H),
7.56 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H), 8.28 (d,
1H) ppm.
Example 76
[0957]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-(3-ethyl-cyclobutyl)phenylboronic acid (41 mg, 0.2 mmol, prepared
according to general procedure Y using
3-(4-bromophenyl)cyclobutan-1-one in stead of bromobenzaldehyde) to
give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4'-(3-ethyl-cyclobutyl)-biphenyl-4-ylmet-
hyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0958] LCMS: m/z 671 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.94 (t, 3H), 1.32-1.81 (m, 7H), 2.52 (m, 1H), 4.05
(s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.18 (d, 2H), 7.27 (d, 2H),
7.37 (d, 2H), 7.48 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64 (d,
1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 77
[0959]
2-(4-Bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-im-
idazole (503 mg, 1 mmol) was treated as described in general
procedures E and F using methyl 2-bromopropionate (335 .mu.L, 3
mmol) to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-4-
-methyl-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0960] LCMS: m/z 607 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.09 (d, 3H), 4.05 (s, 2H), 4.10 (m, 1H), 7.15 (d,
2H), 7.27 (d, 2H), 7.47 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64
(d, 1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
[0961]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-4-methyl-1,2,5-thiadiazolidine-3-one-1,1-dioxide (61 mg, 0.1
mmol) was treated as described in general procedure G using
4-tert-butylphenylboronic acid (36 mg, 0.2 mmol) to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-phenyl}-4-methyl-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0962] LCMS: m/z 659 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.09 (d, 3H), 1.30 (s, 9H), 4.06 (s, 2H), 4.10 (m,
1H), 7.15 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45 (d, 2H), 7.49
(dd, 1H), 7.52 (d, 2H), 7.54 (d, 2H), 7.64 (d, 1H), 7.90 (s, 1H),
8.20 (d, 1H) ppm.
[0963] By analogous methods to those used to prepare Example 77,
the following compounds were synthesized:
TABLE-US-00005 Ex. Name LC/MS (m/z) 78
5-{4-[2-(4'-tert-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 673 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-4-ethyl-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 79
5-{4-[2-(4'-tert-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 673 (M
+ H).sup.+ phenyl)-imidazol-1-yl]-phenyl}-4,4-dimethyl-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 80
1-{4-[2-(4'-tert-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 713 (M
+ H).sup.+ phenyl)-imidazol-1-yl]-phenyl}-2,2-dioxo-thia-1,3-diaza-
spiro[4.5]decan-4-one
Example 81
[0964]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-difluoro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (prepared according to
general procedures A, B and C subsequently) (56 mg, 0.1 mmol) was
treated as described in general procedure G using
4-tert-butylphenylboronic acid (36 mg, 0.2 mmol) to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-difluoro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0965] LCMS: m/z 613 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.31 (s, 9H), 4.05 (s, 2H), 4.07 (s, 2H), 7.13-7.16
(m, 5H), 7.27 (d, 2H), 7.37 (d, 2H), 7.41 (m, 1H), 7.51-7.55 (m,
5H), 8.12 (m, 1H) ppm.
Example 82
[0966] 2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (3.8
g, 10 mmol) was treated as described in general procedure G using
4-tert-butylphenylboronic acid (3.6 g, 20 mmol) to give
2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-
e, which was treated as described in general procedure R using
1,4-diiodobenzene (13.2 g, 40 mmol) to give
2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1-(4-iodo-p-
henyl)-1H-imidazole.
[0967] LCMS: m/z 637 (M+H).sup.+.
[0968]
2-(4'-tert-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1-(4--
iodo-phenyl)-1H-imidazole (191 mg, 0.3 mmol) was treated as
described in general procedure R using D-2-aminobutyric acid (310
mg, 3 mmol) to give
(R)-2-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-i-
midazol-1-yl]-phenylamino}-butyric acid, which was then treated as
described in general procedure F to give
(4R)-5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenyl}-4-ethyl-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0969] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.03 (t, 3H), 1.30 (s, 9H), 1.45 (m, 2H), 4.06 (s,
2H), 4.10 (t, 1H), 7.15 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45
(d, 2H), 7.49 (dd, 1H), 7.52 (d, 2H), 7.54 (d, 2H), 7.64 (d, 1H),
7.88 (s, 1H), 8.19 (d, 1H) ppm.
Example 83
[0970]
2-(4'-tert-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1-(4--
iodo-phenyl)-1H-imidazole (191 mg, 0.3 mmol) was treated as
described in general procedure R using L-2-aminobutyric acid (310
mg, 3 mmol) to give
(S)-2-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-i-
midazol-1-yl]-phenylamino}-butyric acid, which was then treated as
described in general procedure F to give
(4S)-5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenyl}-4-ethyl-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0971] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.04 (t, 3H), 1.31 (s, 9H), 1.45 (m, 2H), 4.06 (s,
2H), 4.10 (t, 1H), 7.15 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45
(d, 2H), 7.49 (dd, 1H), 7.52 (d, 2H), 7.54 (d, 2H), 7.64 (d, 1H),
7.89 (s, 1H), 8.20 (d, 1H) ppm.
Example 84
[0972]
2-(4'-tert-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1-(4--
iodo-phenyl)-1H-imidazole (191 mg, 0.3 mmol) was treated as
described in general procedure R using L-norvaline (352 mg, 3 mmol)
to give
(S)-2-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-i-
midazol-1-yl]-phenylamino}-pentanoic acid, which was then treated
as described in general procedure F to give
(4S)-5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenyl}-4-propyl-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0973] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.99 (t, 3H), 1.31 (s, 9H), 1.39-1.46 (m, 4H), 4.06
(s, 2H), 4.10 (t, 1H), 7.15 (d, 2H), 7.19 (d, 2H), 7.36 (d, 2H),
7.45 (d, 2H), 7.49 (dd, 1H), 7.52 (d, 2H), 7.54 (d, 2H), 7.64 (d,
1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 85
[0974] 4-Iodophenylacetic acid (26.2 g, 0.1 mol) was treated
according to general procedure A using 2,4-dichlorophenacyl bromide
to give 4-(2,4-dichloro-phenyl)-2-(4-iodo-benzyl)-1H-imidazole.
[0975] LCMS: m/z 429 (M+H).sup.+.
[0976] 4-(2,4-Dichloro-phenyl)-2-(4-iodo-benzyl)-1H-imidazole (12.9
g, 30 mmol) was treated as described in general procedures R and C
stepwise to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4-iodo-benzyl)-imidazol-1-yl]-pheny-
l}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0977] LCMS: m/z 639 (M+H).sup.+.
[0978]
5-{3-[4-(2,4-Dichloro-phenyl)-2-(4-iodo-benzyl)-imidazol-1-yl]-phen-
yl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (3.2 g, 5 mmol) was
treated as described in general procedure G using
4-bromophenylboronic acid (2.0 g, 10 mmol) to give
5-{3-[2-(4'-bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0979] LCMS: m/z 669 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.19 (d,
2H), 7.36-7.49 (m, 5H), 7.52 (d, 2H), 7.54 (d, 2H), 7.64 (d, 1H),
7.89 (s, 1H), 8.19 (d, 1H) ppm.
[0980]
5-{3-[2-(4'-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (134 mg,
0.2 mmol) was treated as described in general procedure R using
excess (S)-3-phenyl-pyrrolidine (147 mg, 1 mmol) to give the
desired compound
5-(3-{4-(2,4-dichloro-phenyl)-2-{4'-(3S)-3-phenyl-pyrrolidin-1-yl]-biphen-
yl-4-ylmethy}-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxi-
de.
[0981] LCMS: m/z 734 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.87-2.35 (m, 2H), 3.00-3.60 (m, 5H), 4.07 (s, 2H),
4.10 (s, 2H), 6.94 (d, 2H), 7.19 (d, 2H), 7.27 (m, 1H), 7.32-7.46
(m, 9H), 7.55-7.76 (m, 5H), 7.89 (s, 1H), 8.18 (d, 1H) ppm.
[0982] By analogous methods to those used to prepare Example 85,
the following compounds were synthesized:
TABLE-US-00006 Ex. Name LC/MS (m/z) 86
5-(3-{4-(2,4-Dichloro-phenyl)-2-{4'-[(3R)-3-phenyl-pyrrolidin-1-
734 (M + H).sup.+
yl]-biphenyl-4-ylmethyl}-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 87
5-{3-[2-{4'-[(3S)-3-Cyclohexyl-pyrrolidin-1-yl]-biphenyl-4- 740 (M
+ H).sup.+
ylmethyl}-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 88
5-{3-[2-{4'-[(3R)-3-Cyclohexyl-pyrrolidin-1-yl]-biphenyl-4- 740 (M
+ H).sup.+
ylmethyl}-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 89
5-{3-[2-{3'-[(3S)-3-Cyclohexyl-pyrrolidin-1-yl]-biphenyl-4- 740 (M
+ H).sup.+
ylmethyl}-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1-dioxide
Example 90
[0983]
2-(4-Bromo-phenyl)-4-(2,4-dichloro-phenyl)-5-(4-nitro-phenyl)-1H-im-
idazole (prepared according to general procedure A) (979 mg, 2
mmol) was treated as described in general procedure G using
4-tert-butylphenylboronic acid (712 mg, 4 mmol) to give
2-(4'-tert-butyl-biphenyl-4-yl)-4-(2,4-dichloro-phenyl)-5-(4-nitro-phenyl-
)-1H-imidazole, which was treated as described in general procedure
L using 2-(trimethylsilyl)ethoxymethyl chloride (0.7 mL, 4 mmol) to
give
2-(4'-tert-butyl-biphenyl-4-yl)-4-(2,4-dichloro-phenyl)-5-(4-nitro-phenyl-
)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole.
[0984] LCMS: m/z 672 (M+H).sup.+.
[0985]
2-(4'-tert-Butyl-biphenyl-4-yl)-4-(2,4-dichloro-phenyl)-5-(4-nitro--
phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole (336 mg,
0.5 mmol) was treated as described in general procedure C [using
methyl bromoacetate (95 .mu.L, 1 mmol)] to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-yl)-5-(2,4-dichloro-phenyl)-3-(2-trimet-
hylsilanyl-ethoxymethyl)-3H-imidazol-4-yl]-phenyl}-1,2,5-thiadiazolidine-3-
-one-1,1-dioxide, which was then treated according to general
procedure W to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-yl)-5-(2,4-dichloro-phenyl)-3H--
imidazol-4-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0986] LCMS: m/z 631 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.30 (s, 9H), 4.09 (s, 2H), 7.15 (d, 2H), 7.19 (d,
2H), 7.36 (d, 2H), 7.45 (d, 2H), 7.49 (dd, 1H), 7.52-7.64 (m, 4H),
7.90 (s, 1H), 8.20 (d, 1H) ppm.
Example 91
[0987]
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-5-(4-nitro-phenyl)-1H-im-
idazole (prepared according to general procedure A) (1.0 g, 2 mmol)
was treated as described in general procedure G using
4-tert-butylphenylboronic acid (712 mg, 4 mmol) to give
2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-5-(4-nitro--
phenyl)-1H-imidazole, which was treated as described in general
procedure L using 2-(trimethylsilyl)ethoxymethyl chloride (0.7 mL,
4 mmol) to give
2-(4'-tert-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-5-(4-nitro--
phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole.
[0988] LCMS: m/z 686 (M+H).sup.+.
[0989]
2-(4'-tert-Butyl-biphenyl-4-yl)-4-(2,4-dichloro-phenyl)-5-(4-nitro--
phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole (343 mg,
0.5 mmol) was treated as described in general procedure C [using
methyl bromoacetate (95 .mu.L, 1 mmol)] to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-5-(2,4-dichloro-phenyl)-3-(2--
trimethylsilanyl-ethoxymethyl)-3H-imidazol-4-yl]-phenyl}-1,2,5-thiadiazoli-
dine-3-one-1,1-dioxide, which was then treated according to general
procedure W to give
5-{4-[2-(4'-tert-butyl-biphenyl-4-ylmethyl)-5-(2,4-dichloro-phenyl)-3H-im-
idazol-4-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0990] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.29 (s, 9H), 4.06 (s, 2H), 4.09 (s, 2H), 7.15 (d,
2H), 7.19 (d, 2H), 7.36 (d, 2H), 7.45 (d, 2H), 7.49 (dd, 1H),
7.52-7.64 (m, 4H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 92
[0991] 2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (382
mg, 1 mmol) was treated as described in general procedure K using
4-nitrobenzyl bromide (432 mg, 2 mmol) to give
2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(4-nitro-benzyl)-1H-imidazol-
e.
[0992] LCMS: m/z 518 (M+H).sup.+.
[0993]
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(4-nitro-benzyl)-1H-im-
idazole (310 mg, 0.6 mmol) was treated as described in general
procedure C to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-ylmet-
hyl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0994] LCMS: m/z 607 (M+H).sup.+.
[0995]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-ylmethy-
l]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (61 mg, 0.1
mmol) was treated as described in general procedure G using
4-cyclohexylphenylboronic acid (41 mg, 0.2 mmol) to give
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-ylmethyl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[0996] LCMS: m/z 685 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.13-1.40 (m, 5H), 1.65-1.78 (m, 5H), 2.52 (m, 1H),
4.05 (s, 2H), 4.08 (s, 2H), 5.35 (s, 2H), 7.15 (d, 2H), 7.20 (d,
2H), 7.32 (d, 2H), 7.41 (d, 2H), 7.47 (d, 2H), 7.51-7.58 (m, 3H),
7.64 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 93
[0997] 4-Nitro-benzoic acid (1.7 g, 10 mmol) was treated as
described in general procedure A to give
4-(2,4-dichloro-phenyl)-2-(4-nitro-phenyl)-1H-imidazole, which was
the treated as described in general procedure K using 4-bromobenzyl
bromide (3.8 g, 15 mmol) to give
1-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-2-(4-nitro-phenyl)-1H-imidazol-
e.
[0998] LCMS: m/z 504 (M+H).sup.+.
[0999]
1-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-2-(4-nitro-phenyl)-1H-im-
idazole (503 mg, 1 mmol) was treated as described in general
procedure C to give
5-{4-[1-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl-
]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1000] LCMS: m/z 593 (M+H).sup.+.
[1001]
5-{4-[1-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]--
phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol)
was treated as described in general procedure G using
4-cyclohexylphenylboronic acid (41 mg, 0.2 mmol) to give
5-{4-[1-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1H-im-
idazol-2-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1002] LCMS: m/z 671 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.13-1.40 (m, 5H), 1.65-1.78 (m, 5H), 2.52 (m, 1H),
4.08 (s, 2H), 5.35 (s, 2H), 7.15 (d, 2H), 7.20 (d, 2H), 7.32 (d,
2H), 7.41 (d, 2H), 7.47 (d, 2H), 7.51-7.58 (m, 3H), 7.64 (d, 1H),
7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 94
[1003]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
3-hydroxyphenylboronic acid (28 mg, 0.2 mmol) to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(3'-hydroxy-biphenyl-4-ylmethyl)-imidazol-
-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1004] LCMS: m/z 605 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.08 (s, 2H), 6.93-7.22 (m, 5H), 7.32
(d, 2H), 7.38 (d, 2H), 7.46 (d, 2H), 7.51 (d, 2H), 7.64 (d, 1H),
7.90 (s, 1H), 8.20 (d, 1H) ppm.
Example 95
[1005]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (592 mg, 1 mmol) was
treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (354 .mu.L, 2 mmol) to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one,
which was then treated according to general procedure AD to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborol-
an-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1006] LCMS: m/z 769 (M+H).sup.+.
[1007]
5-(4-{4-(2,4-Dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]diox-
aborolan-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsila-
nyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one (154 mg, 0.2 mmol)
was treated as described in general procedure G using
2,5-dibromopyridine (95 mg, 0.4 mmol) to give
5-{4-[2-[4-(5-bromo-pyridin-2-yl)-benzyl]-4-(2,4-dichloro-phenyl)-imidazo-
l-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiad-
iazolidin-3-one, which was again treated as described in general
procedure G using cyclohexen-1-ylboronic acid (51 mg, 0.4 mmol) to
give
5-{4-[2-[4-(5-cyclohex-1-enyl-pyridin-2-yl)-benzyl]-4-(2,4-dichloro-pheny-
l)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1-
,2,5]thiadiazolidin-3-one.
[1008] LCMS: m/z 800 (M+H).sup.+.
[1009]
5-{4-[2-[4-(5-Cyclohex-1-enyl-pyridin-2-yl)-benzyl]-4-(2,4-dichloro-
-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymeth-
yl)-[1,2,5]thiadiazolidin-3-one (40 mg, 0.05 mmol) was dissolved in
1 mL dry acetic acid, iron powder (-325 mesh, 56 mg, 1 mmol) was
added and the mixture was then heated at 100.degree. C. under
nitrogen for 2 days. At completion, the reaction mixture was then
diluted with water/EtOAc and the leftover iron powder was filtered
and washed with EtOAc. The combined organic layer was washed with
water, saturated NaHCO.sub.3 and brine. The organic layer was then
dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated and purified by silica gel chromatography to afford
5-{4-[2-[4-(5-cyclohexyl-pyridin-2-yl)-benzyl]-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)--
[1,2,5]thiadiazolidin-3-one.
[1010] LCMS: m/z 802 (M+H).sup.+.
[1011]
5-{4-[2-[4-(5-Cyclohexyl-pyridin-2-yl)-benzyl]-4-(2,4-dichloro-phen-
yl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[-
1,2,5]thiadiazolidin-3-one (16 mg, 0.02 mmol) was treated as
described in general procedure W using tetrabutylammonium fluoride
(26 mg, 0.1 mmol) to give
5-{4-[2-[4-(5-cyclohexyl-pyridin-2-yl)-benzyl]-4-(2,4-dichloro-ph-
enyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1012] LCMS: m/z 672 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.22-1.43 (m, 5H), 1.69-1.81 (m, 5H), 2.52 (m, 1H),
4.08 (s, 2H), 4.10 (s, 2H), 7.15-7.27 (m, 5H), 7.37 (d, 2H),
7.46-7.54 (m, 5H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H)
ppm.
Example 96
[1013]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (1.19 g, 2 mmol) was
treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (708 .mu.L, 4 mmol) to give
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one,
which was then treated according to general procedure AD to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborol-
an-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1014] LCMS: m/z 769 (M+H).sup.+.
[1015]
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]diox-
aborolan-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsila-
nyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one (385 mg, 0.5 mmol)
was treated as described in general procedure G using
3,6-dichloropyridazine (149 mg, 1 mmol) to give
5-{3-[2-[4-(6-chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]th-
iadiazolidin-3-one.
[1016] LCMS: m/z 756 (M+H).sup.+.
[1017]
5-{3-[2-[4-(6-Chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,-
2,5]thiadiazolidin-3-one (38 mg, 0.05 mmol) was treated as
described in general procedure L using 2-cyclohexyl ethanol (35
.mu.L, 0.25 mmol) to give
5-{3-[2-{4-[6-(2-cyclohexyl-ethoxy)-pyridazin-3-yl]-benzyl}-4-(2,4-d-
ichloro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-eth-
oxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1018] LCMS: m/z 847 (M+H).sup.+.
[1019]
5-{3-[2-{4-[6-(2-Cyclohexyl-ethoxy)-pyridazin-3-yl]-benzyl}-4-(2,4--
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one (17 mg, 0.02 mmol) was
treated as described in general procedure W using
tetrabutylammonium fluoride (26 mg, 0.1 mmol) to give
5-{3-[2-{4-[6-(2-cyclohexyl-ethoxy)-pyridazin-3-yl]-benzyl}-4-(2,4-dichlo-
ro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1020] LCMS: m/z 717 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 0.97-1.43 (m, 5H), 1.65 (m, 2H), 1.69-1.81 (m, 6H),
4.05 (t, 2H), 4.08 (s, 2H), 4.10 (s, 2H), 7.15-7.27 (m, 5H), 7.37
(d, 2H), 7.46-7.54 (m, 4H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d,
1H) ppm.
Example 97
[1021]
5-{3-[2-[4-(6-Chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,-
2,5]thiadiazolidin-3-one (76 mg, 0.1 mmol) was dissolved in 1 mL
dry ethanol. Thiourea (76 mg, 1 mmol) was added and the mixture was
refluxed under nitrogen over night. At completion, the reaction
mixture was then diluted with water/EtOAc. The combined organic
layer was washed with water, and brine, dried over
Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated to
give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(6-mercapto-pyridazin-3-yl)-benzyl]-im-
idazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]-
thiadiazolidin-3-one, which was then treated as described in
general procedure K using 1-bromo-2-cyclohexylethane (79 4, 0.5
mmol) to give
5-{3-[2-{4-[6-(2-cyclohexyl-ethylsulfanyl)-pyridazin-3-yl]-benzyl}-4-(2,4-
-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-e-
thoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1022] LCMS: m/z 863 (M+H).sup.+.
[1023]
5-{3-[2-{4-[6-(2-Cyclohexyl-ethylsulfanyl)-pyridazin-3-yl]-benzyl}--
4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsil-
anyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one (17 mg, 0.02 mmol)
was treated as described in general procedure W using
tetrabutylammonium fluoride (26 mg, 0.1 mmol) to give
5-{3-[2-{4-[6-(2-cyclohexyl-ethylsulfanyl)-pyridazin-3-yl]-benzyl}-4-(2,4-
-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-d-
ioxide.
[1024] LCMS: m/z 733 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 0.97-1.41 (m, 5H), 1.48 (m, 2H), 1.69-1.81 (m, 6H),
3.03 (t, 2H), 4.08 (s, 2H), 4.10 (s, 2H), 7.15-7.27 (m, 5H), 7.37
(d, 2H), 7.46-7.54 (m, 4H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d,
1H) ppm.
Example 98
[1025] 4-Bromophenylacetic acid (10.7 g, 50 mmol) was treated
according to general procedure A using 2,4-dichlorophenacyl bromide
to give 2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole.
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (3.8 g, 10
m mol) was reacted with 4-nitro benzylbromide (2.5 g, 12 mmol) as
described in general procedure B to give
2-(4-bromobenzyl)-4-(2,4-dichloro-phenyl)-1-(4-nitro-benzyl)-1H-imidazole-
.
[1026]
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(4-nitro-benzyl)-1H-im-
idazole (2.6 g, 5 mmol) was reduced to amine and was reacted with
methyl bromoacetate following general procedures D & E to give
{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-ylmethyl]-pheny-
lamino}-acetic acid methyl ester.
[1027]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-ylmethyl]-
-phenylamino}-acetic acid methyl ester (1.4 g, 2.5 mmol) was
coupled with 4-sec-butyl phenyl-boronic acid (600 mg, 3.3 mmol)
following general procedure G to give
{4-[2-(4'-sec-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-
-1-ylmethyl]-phenylamino}-acetic acid methyl ester.
[1028]
5-{4-[2-(4'-sec-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)--
imidazol-1-ylmethyl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
was prepared from
{4-[2-(4'-sec-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-
-1-ylmethyl]-phenylamino}-acetic acid methyl ester (275 mg, 0.4
mmol) following general procedure F. LCMS: m/z 659 (M+H).sup.+.
Example 99
[1029] 4-Bromophenylacetic acid (107.5 g, 0.5 mol) was treated
according to general procedure A using 2,4-dichlorophenacyl bromide
to give 2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole.
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (38.2 g,
0.1 mol) was treated as described in general procedure B using
1-fluoro-4-nitrobenzene to give
2-(4-bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-
e.
[1030]
4-(2,4-Dichloro-phenyl)-1-(4-nitro-phenyl)-2-(4-bromo-benzyl)-1H-im-
idazole (5.0 g, 10 mmol) was reduced to amine and was reacted with
methyl bromoacetate following general procedures D & E to give
{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenylamino-
}-acetic acid methyl ester.
[1031]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (1.8 g, 3.3 mmol) was coupled with
4-sec butyl-phenyl boronic acid (750 mg, 4.0 mmol) according to
general procedure G to give
{4-[2-(4'-sec-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-
-1-yl]-phenylamino}-acetic acid methyl ester.
[1032]
{4-[2-(4'-sec-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-im-
idazol-1-yl]-phenylamino}-acetic acid methyl ester (300 mg, 0.5
mmol) was treated following general procedure F to give
5-{4-[2-(4'-sec-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidaz-
ol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1033] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): 0.89 (t, 3H), 1.18-1.20 (m, 2H), 1.22 (m, 1H), 3.99 (t, 2H),
4.04 (s, 2H), 4.07 (s, 2H), 7.14 (d, 2H), 7.16 (d, 2H), 7.24 (d,
2H), 7.35 (d, 2H), 7.46 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.63
(d, 1H), 7.79 (s, 1H), 7.89 (d, 1H), 8.20 (d, 1H) ppm.
Example 100
[1034]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (1.5 g, 2.7 mmol) was coupled with
4-cyclohexyl phenyl-boronic acid (700 m g, 3.4 mmol) according to
general procedure G to give
{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazo-
l-1-yl]-phenylamino}acetic acid methyl ester.
[1035]
{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-i-
midazol-1-yl]-phenylamino}-acetic acid methyl ester (312 mg, 0.5
mmol) was treated following general procedure F to give
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1036] LCMS: m/z 671 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.35-43 (m, 5H), 1.78-1.84 (m, 5H), 4.04 (s, 2H),
4.07 (d, 2H), 7.14 (d, 2H), 7.18 (d, 2H), 7.28 (d, 2H), 7.37 (d,
2H), 7.46 (d, 2H), 7.48 (d, 2H), 7.50-7.53 (m, 2H), 7.63 (d, 1H),
7.89 (s, 1H), 8.19 (d, 1H) ppm.
[1037] By analogous methods to those used to prepare Example 100,
the following compounds were synthesized:
TABLE-US-00007 Ex. Name LC/MS (m/z) 101
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4'-isobutyl-biphenyl-4- 645 (M +
H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 102
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4'-morpholin-4-yl-biphenyl-4- 674
(M + H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 103
5-{4-[2-(4'-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)- 645
(M + H).sup.+
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide 104
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4'-piperidin-1-yl-biphenyl-4- 672
(M + H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 105
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4'-isopropyl-biphenyl-4- 631 (M +
H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 106
5-{4-[2-(3'-Nitro-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4- 690 (M +
H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide
Example 107
[1038]
5-{4-[2-(3'-Nitro-4'-Iso-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-
-phenyl)-imidazol-1-yl]-phenyl}-[1,2,5]thiadiazolidin-3-one-1,1-dioxide
(70 mg, 0.10 mmol) was reduced to
5-{4-[2-(3'-amino-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
according to general procedure D.
[1039] LCMS: m/z 660 (M+H).sup.+.
Example 108
[1040]
5-{4-[2-(3'-Amino-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro--
phenyl)-imidazol-1-yl]-phenyl}-[1,2,5]
thiadiazolidin-3-one-1,1-dioxide (22 mg, 0.03 mmol) was reacted
with acetaldehyde (1.7 mg, 0.03 mmol) according to general
procedure X to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(3'-diethylamino-4'-isobutyl-biphenyl-4-y-
lmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1041] LCMS: m/z 716 (M+H).sup.+.
Example 109
[1042] 4-Bromophenylacetic acid (10.7 g, 50 mmol) was treated
according to general procedure A using 4-(2-Bromo-acetyl)-benzoic
acid methyl ester to give
4-[2-(4-bromo-benzyl)-1H-imidazol-4-yl]-benzoic acid methyl
ester.
[1043] 4-[2-(4-Bromo-benzyl)-1H-imidazol-4-yl]-benzoic acid methyl
ester (12.3 g, 33 mmol) was treated as described in general
procedure B using 1-fluoro-4-nitrobenzene to give
4-[2-(4-bromo-benzyl)-1-(4-Nitro-phenyl)-1H-imidazol-4-yl]-benzoicacid
methyl ester.
[1044]
4-[2-(4-Bromo-benzyl)-1-(4-Nitro-phenyl)-1H-imidazol-4-yl]-benzoica-
cid methyl ester (9.8 g, 20 mmol) was reduced to amine and was
reacted with methyl bromoacetate following general procedures D
& E to give
4-{2-(4-Bromo-benzyl)-1-[4-(methoxy-carbonylmethyl-amino)-phenyl]-1H-imid-
azol-4-yl}-benzoic acid methyl ester.
4-{2-(4-Bromo-benzyl)-1-[4-(methoxycarbonylmethyl-amino)-phenyl]-1H-imida-
zol-4-yl}-benzoic acid methyl ester (2.7 g, 5 mmol) was coupled
with 4-cyclohexyl-phenylboronic acid (1.25 g, 6.0 mmol) according
to general procedure G to give
4-{2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-1-[4-(methoxycarbonylmethyl-amin-
o)-phenyl]-1H-imidazol-4-yl}-benzoic acid methyl ester.
[1045]
4-{2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-1-[4-(methoxycarbonylmethy-
l-amino)-phenyl]-1H-imidazol-4-yl}-benzoic acid methyl ester (1.0
g, 1.6 mmol) was treated following general procedure F to give
4-{2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-1-[4-(1,1,4-trioxo-1-[1,2,5]
thiadiazolidin-2-yl)-phenyl]-1H-imidazol-4-yl}-benzoic acid methyl
ester.
[1046] LCMS: m/z 660 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.19-1.38 (m, 5H), 1.66-1.89 (m, 5H), 2.39 (m, 1H),
3.59 (s, 3H), 4.04 (s, 2H), 4.09 (s, 2H), 7.17 (d, 2H), 7.19 (d,
2H), 7.28 (d, 2H), 7.36-7.42 (m, 4H), 7.44-7.57 (m, 4H), 7.66 (d,
1H), 7.87 (s, 1H), 8.18 (d, 1H) ppm.
Example 110
[1047]
4-{2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-1-[4-(1,1,4-trioxo-1-[1,2,-
5]thiadiazolidin-2-yl)-phenyl]-1H-imidazol-4-yl}-benzoic acid
methyl ester (220 mg, 0.33 mmol) was hydrolyzed following general
procedure P to give
4-{2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-1-[4-(1,1,4-trioxo-1-[1,2,5]thia-
diazolidin-2-yl)-phenyl]-1H-imidazol-4-yl}-benzoic acid.
[1048] LCMS: m/z 646 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.22-1.43 (m, 5H), 1.69-1.81 (m, 5H), 2.52 (m, 1H),
4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.18 (d, 2H), 7.26 (d,
2H), 7.34-7.42 (m, 4H), 7.46-7.54 (m, 5H), 7.64 (d, 1H), 7.89 (s,
1H), 8.19 (d, 1H) ppm.
Example 111
[1049]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (1.8 g, 3.3 mmol) was coupled with
4-propionyl-phenyl boronic acid (712 m g, 4.0 mmol) according to
general procedure G to give
{4-[4-(2,4-dichloro-phenyl)-2-(4'-propionyl-biphenyl-4-ylmethyl)-imidazol-
-1-yl]-phenylamino}-acetic acid methyl ester.
[1050]
{4-[4-(2,4-Dichloro-phenyl)-2-(4'-propionyl-biphenyl-4-ylmethyl)-im-
idazol-1-yl]-phenylamino}-aceticacid methyl ester (299 mg, 0.5
mmol) was treated following general procedure F to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(4'-propionyl-biphenyl-4-ylmethyl)-imidaz-
ol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1051] LCMS: m/z 645 (M+H).sup.+.
Example 112
[1052]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (1.8 g, 3.3 mmol) was coupled with
4-n-pentylbenzene boronic acid (769 m g, 4.0 mmol) according to
general procedure G to give
{4-[4-(2,4-dichloro-phenyl)-2-(4'-pentyl-biphenyl-4-ylmethyl)-imidazol-1--
yl]-phenylamino}-acetic acid methyl ester.
[1053]
{4-[4-(2,4-Dichloro-phenyl)-2-(4'-pentyl-biphenyl-4-ylmethyl)-imida-
zol-1-yl]-phenylamino}-acetic acid methyl ester (310 mg, 0.5 mmol)
was treated following general procedure F to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(4'-pentyl-biphenyl-4-ylmethyl)-imidazol--
1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1054] LCMS: m/z 659 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.98 (t, 3H), 1.29 (m, 2H), 1.41 (m, 2H), 1.83 (m,
2H), 4.02 (t, 2H), 4.05 (s, 2H), 4.08 (s, 2H), 7.05-7.12 (m, 4H),
7.29 (d, 2H), 7.38 (d, 2H), 7.46-7.54 (m, 5H), 7.64 (d, 1H), 7.89
(s, 1H), 8.19 (d, 1H) ppm.
Example 113
[1055] 4-Bromophenylacetic acid (10.7 g, 50 mmol) was treated
according to general procedure A using 4-trifluoromethylphenacyl
bromide to give
2-(4-bromo-benzyl)-4-(4-trifluoromethyl-phenyl)-1H-imidazole.
[1056] 2-(4-Bromo-benzyl)-4-(4-trifluoromethyl-phenyl)-1H-imidazole
(9.6 g, 25 mmol) was treated as described in general procedure B
using 1-fluoro-4-nitrobenzene to give
2-(4-bromo-benzyl)-1-(4-Nitro-phenyl)-4-(4-trifluoromethyl-phenyl)-1H-imi-
dazole.
[1057]
2-(4-Bromo-benzyl)-1-(4-Nitro-phenyl)-4-(4-trifluoromethyl-phenyl)--
1H-imidazole (2.5 g, 5 mmol) was reduced to amine and was reacted
with methyl bromoacetate following general procedures D & E to
give
{4-[2-(4-bromo-benzyl)-4-(4-trifluoromethyl-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester.
[1058]
{4-[2-(4-Bromo-benzyl)-4-(4-trifluoromethyl-phenyl)-imidazol-1-yl]--
phenylamino}-acetic acid methyl ester (1.3 g, 2.4 m mol) was
coupled with 4-cyclohexyl-phenylboronic acid (615 mg, 3.0 mmol)
according to general procedure G to give
{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(4-trifluoromethyl-phenyl)-im-
idazol-1-yl]phenylamino}-acetic acid methyl ester.
[1059]
{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(4-trifluoromethyl-phen-
yl)-imidazol-1-yl]phenylamino}-acetic acid methyl ester (312 mg,
0.5 mmol) was treated following general procedure F to give
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(4-trifluoromethyl-phenyl)--
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1060] LCMS: m/z 670 (M+H).sup.+.
Example 114
[1061]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (1.8 g, 3.3 mmol) was coupled with
4-n-propyl-phenyl boronic acid (659 m g, 4.0 mmol) according to
general procedure G to give
{4-[4-(2,4-dichloro-phenyl)-2-(4'-propyl-biphenyl-4-ylmethyl)-imidazol-1--
yl]-phenylamino}-acetic acid methyl ester.
[1062]
{4-[4-(2,4-Dichloro-phenyl)-2-(4'-propyl-biphenyl-4-ylmethyl)-imida-
zol-1-yl]-phenylamino}-acetic acid methyl ester (295 mg, 0.5 mmol)
was treated following general procedure F to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(4'-propyl-biphenyl-4-ylmethyl)-imidazol--
1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1063] LCMS: m/z 631 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.99 (t, 3H), 1.41 (m, 2H), 4.02 (t, 2H), 4.04 (s,
2H), 4.07 (s, 2H), 7.02-7.15 (m, 4H), 7.27 (d, 2H), 7.39 (d, 2H),
7.42-7.54 (m, 5H), 7.66 (d, 1H), 7.87 (s, 1H), 8.19 (d, 1H)
ppm.
Example 115
[1064] 4-Bromophenylacetic acid (10.7 g, 50 mmol) was treated
according to general procedure A using
2-bromo-1-(4-methylsulfonyl-phenyl)-1-ethanone to give
2-(4-bromo-benzyl)-4-(4-methanesulfonyl-phenyl)-1H-imidazole.
[1065] 2-(4-Bromo-benzyl)-4-(4-methanesulfonyl-phenyl)-1H-imidazole
(9.8 g, 25 mmol) was treated as described in general procedure B
using 1-fluoro-4-nitrobenzene to give
2-(4-Bromo-benzyl)-1-(4-nitro-phenyl)-4-(4-methanesulfonyl-phenyl)-1H-imi-
dazole.
[1066]
2-(4-Bromo-benzyl)-1-(4-nitro-phenyl)-4-(4-methanesulfonyl-phenyl)--
1H-imidazole (2.6 g, 5 mmol) was reduced to amine and was reacted
with methyl bromoacetate following general procedures D & E to
give
{4-[2-(4-bromo-benzyl)-4-(4-methanesulfonyl-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester.
[1067]
{4-[2-(4-Bromo-benzyl)-4-(4-methanesulfonyl-phenyl)-imidazol-1-yl]--
phenyl-amino}-acetic acid methyl ester (1.4 g, 2.5 mmol) was
coupled with 4-cyclohexyl-phenyl boronic acid (615 mg, 3.0 mmol)
according to general procedure G to give
{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(4-methanesulfonyl-phenyl)-im-
idazol-1-yl]-phenylamino}-acetic acid methyl ester.
[1068]
{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(4-methanesulfonyl-phen-
yl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester (317 mg,
0.5 mmol) was treated following general procedure F to give
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(4-methanesulfonyl-phenyl)--
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1069] LCMS: m/z 680 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.17-1.42 (m, 5H), 1.68-1.80 (m, 5H), 2.39 (m, 1H),
3.21 (s, 3H), 4.10 (s, 2H), 4.49 (s, 2H), 7.11 (d, 2H), 7.13 (d,
2H), 7.26 (d, 2H), 7.46 (d, 2H), 7.48-7.7.52 (m, 5H), 7.74 (d, 2H),
7.89 (s, 1H), 8.09 (d, 1H) ppm.
Example 116
[1070]
5-{4-[4-(2,4-Dichloro-phenyl)-2-(4'-propionyl-biphenyl-4-ylmethyl)--
imidazol-1-yl]-phenyl}-[1,2,5] thiadiazolidin-3-one-1,1-dioxide (66
mg, 0.1 mmol) was reacted with ethyl magnesium bromide (40 mg, 0.3
mmol) following general procedure Z and resulted tertiary alcohol
was reduced according to general procedure AA to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4'-(1-ethyl-propyl)-biphenyl-4-ylmethyl]-
-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1071] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.98-1.11 (m, 3H), 1.13-1.21 (m, 3H), 1.28 (t, 1H),
3.87 (m, 2H), 3.99 (m, 2H), 4.04 (s, 2H), 4.09 (s, 2H), 7.11-7.21
(m, 4H), 7.27 (d, 2H), 7.35 (d, 2H), 7.38 (d, 2H), 7.46-7.54 (m,
3H), 7.63 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 117
[1072]
5-{4-[2-(3'-Amino-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro--
phenyl)-imidazol-1-yl]-phenyl}-[1,2,5]
thiadiazolidin-3-one-1,1-dioxide (22 mg, 0.03 mmol) was reacted
with isopropyl chloroformate (5 mg, 0.04 mmol) according to general
procedure U to give
(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-1-[1,2,5]
thiadiazolidin-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-4-isobutyl-biphenyl--
3-yl)-carbamic acid isopropyl ester.
[1073] LCMS: m/z 746 (M+H).sup.+.
Example 118
[1074]
5-{4-[2-(3'-Amino-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro--
phenyl)-imidazol-1-yl]-phenyl}-[1,2,5]
thiadiazolidin-3-one-1,1-dioxide (22 mg, 0.03 mmol) was reacted
with butyraldehyde (2.2 mg, 0.03 mmol) according to general
procedure X to give
5-{4-[2-(3'-butylamino-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1075] LCMS: m/z 716 (M+H).sup.+.
Example 119
[1076] 2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (3.9
g, 10 mmol) was treated as described in general procedure B using
1-iodo-3-nitrobenzene to give
2-(4-bromo-benzyl)-1-(3-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-
e.
[1077]
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(3-nitrophenyl-phenyl)-
-1H-imidazole (1.3 g, 2.5 mmol) was reduced to amine and was
reacted with methyl bromo acetate following general procedures D
& E to give
{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenylamino-
}-acetic acid methyl ester.
[1078]
{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (55 mg, 0.1 mmol) was coupled with
4-n-butyl-phenylboronic acid (36 mg, 0.2 mmol) according to general
procedure G to give
{3-[2-(4'-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-y-
l]-phenylamino}-acetic acid methyl ester.
[1079]
{3-[2-(4'-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidaz-
ol-1-yl]-phenylamino}-acetic acid methyl ester (30 mg, 0.05 mmol)
was treated following general procedure F to give
5-{3-[2-(4'-butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1080] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.98 (t, 3H), 1.19 (m, 2H), 1.34 (m, 2H), 2.67 (t,
2H), 4.04 (s, 2H), 4.09 (s, 2H), 7.11-7.18 (m, 4H), 7.26 (d, 2H),
7.37 (d, 2H), 7.45-7.53 (m, 5H), 7.61 (d, 1H), 7.88 (s, 1H), 8.19
(d, 1H) ppm.
Example 120
[1081]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
aminoyacetic acid methyl ester (55 mg, 0.1 mmol) was coupled with
4-iso-butyl-phenylboronic acid (36 m g, 0.2 mmol) according to
general procedure G to give
{3-[2-(4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol--
1-yl]-phenylamino}-acetic acid methyl ester.
[1082]
{3-[2-(4'-Iso-Butyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-im-
idazol-1-yl]-phenylamino}-acetic acid methyl ester (20 mg, 0.033
mmol) was treated following general procedure F to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4'-isobutyl-biphenyl-4-ylmethyl)-imidazo-
l-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1083] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): 1.11-1.23 (m, 6H), 2.95 (t, 1H), 3.29 (m, 2H), 4.04 (s, 2H),
4.09 (s, 2H), 7.09-7.17 (m, 3H), 7.27 (d, 2H), 7.36 (d, 2H), 7.47
(d, 2H), 7.42-7.54 (m, 4H), 7.65 (d, 1H), 7.87 (s, 1H), 8.19 (d,
1H) ppm.
[1084] By analogous methods to those used to prepare Example 120,
the following compounds were synthesized:
TABLE-US-00008 Ex. Name LC/MS (m/z) 121
5-{3-[4-(2,4-Dichloro-phenyl)-2-(4'-piperidin-1-yl-biphenyl-4- 672
(M + H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 122
5-{3-[2-(3'-Nitro-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4- 690 (M +
H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide
Example 123
[1085]
5-{3-[2-(3'-amino-4'-isobutyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro--
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
was prepared according to general procedure D from the compound of
Example 122.
[1086] LCMS: m/z 660 (M+H).sup.+.
Example 124
[1087] (4'-{4-(2,4-Dichloro-phenyl)-1-[3-(1,1,4-trioxo-[1,2,5]
thiadiazolidin-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-4-isobutyl-biphenyl--
3-yl)-carbamic acid methyl ester was prepared according to general
procedure U from the compound of Example 123.
[1088] By analogous methods to those used to prepare Example 120,
the following compounds were synthesized:
TABLE-US-00009 Ex. Name LC/MS (m/z) 125
5-{3-[4-(2,4-Dichloro-phenyl)-2-(2'-fluoro-5'-propoxy-biphenyl- 665
(M + H).sup.+
4-ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 126
5-{3-[2-(2'-Butoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 661 (M +
H).sup.+
phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 127
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4'-(3,3-dimethyl-butoxy)- 689 (M +
H).sup.+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 128
5-{3-[4-(2,4-Dichloro-phenyl)-2-(4'-isobutoxy-biphenyl-4- 689 (M +
H).sup.+
ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-
1,1-dioxide 129
5-{3-[2-(4'-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4- 701 (M +
H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 130
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4'-(3,3-dimethyl-butylsulfanyl)-
705 (M + H).sup.+
biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide
Example 131
[1089]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was treated as
described in general procedure G using
4-(cyclohexylmethylsulfanyl)-phenylboronic acid (50 mg, 0.2 mmol,
prepared according to general procedure I) to give
{3-[2-(4'-cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenylamino}-aceticacid methyl ester.
[1090]
{3-[2-(4'-Cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-dich-
loro-phenyl)-imidazol-1-yl]-phenylamino}-aceticacid methyl ester
(23 mg, 0.033 mmol) was treated following general procedure F to
give
5-{3-[2-(4'-cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-
-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1091] LCMS: m/z 717 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.99-1.21 (m, 6H), 1.47 (m, 1H), 1.57-1.88 (m, 4H),
2.87 (d, 2H), 4.04 (s, 2H), 4.09 (s, 2H), 7.11-7.17 (m, 4H),
7.31-7.38 (m, 4H), 7.42-7.58 (m, 5H), 7.63 (d, 1H), 7.87 (s, 1H),
8.19 (d, 1H) ppm.
Example 132
[1092]
5-{3-[2-(4'-Cyclohexylmethylsulfanyl-biphenyl-4-ylmethyl)-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-diox-
ide (7.2 mg, 0.01 mmol) was treated as described in general
procedure S to give
5-{3-[2-(4'-cyclohexylmethanesulfonyl-biphenyl-4-ylmethyl)-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-diox-
ide.
[1093] LCMS: m/z 749 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.00-1.25 (m, 6H), 1.52 (m, 1H), 1.58-1.87 (m, 4H),
3.21 (d, 2H), 4.04 (s, 2H), 4.09 (s, 2H), 7.17 (d, 2H), 7.21 (d,
2H), 7.27-7.41 (m, 4H), 7.44-7.58 (m, 5H), 7.64 (d, 1H), 7.87 (s,
1H), 8.19 (d, 1H) ppm.
Example 133
[1094]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was treated as
described in general procedure G
using-3-(2-cyclohexyl-ethoxy)-phenylboronic acid (50 mg, 0.2 mmol,
prepared according to general procedure H) to give
{3-[2-[4'-(2-cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-phen-
yl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester.
[1095]
{3-[2-[4'-(2-Cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4-dichlor-
o-phenyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester (22
mg, 0.03 mmol) was treated following general procedure F to give
5-{3-[4-[4'-(2-cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-ph-
enyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1096] LCMS: m/z 715 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.86-0.88 (m, 2H), 1.14-1.21 (m, 4H), 1.45 (m, 1H),
1.49-1.71 (m, 6H), 4.01 (m, 4H), 4.12 (s, 2H), 6.87 (dd, 1H),
7.13-7.19 (m, 5H), 7.31 (d, 2H), 7.37 (d, 2H), 7.46-7.57 (m, 3H),
7.65 (d, 1H), 7.87 (s, 1H), 8.19 (d, 1H) ppm.
Example 134
[1097]
5-{3-[2-(4'-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-ph-
enyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-(cyclohexylmethylamino)-phenylboronic acid (47 mg, 0.2 mmol,
prepared according to general procedure J) to give
5-{3-[2-[4'-(cyclohexylmethyl-amino)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-
-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1098] LCMS: m/z 700 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.90-0.93 (m, 2H), 1.18-1.25 (m, 5H), 1.67-1.80 (m,
4H), 2.84 (d, 2H), 4.01 (s, 2H), 4.07 (s, 2H), 6.57 (d, 2H), 6.91
(dd, 1H), 6.93-7.09 (m, 2H), 7.23 (d, 2H), 7.25 (d, 2H), 7.32-7.49
(m, 3H), 7.64 (d, 2H), 7.92 (s, 1H), 8.18 (d, 1H) ppm.
Example 135
[1099]
5-{3-[2-(4'-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-ph-
enyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-amino-phenylboronic acid (28 mg, 0.2 mmol) to give
5-{3-[2-(4'-amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-
-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1100] LCMS: m/z 604 (M+H).sup.+.
Example 136
[1101]
5-{3-[2-(4'-Amino-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-[1,2,5] thiadiazolidin-3-one-1,1-dioxide (7 mg,
0.01 mmol) was reacted with 1-bromo-3-3-dimethyl butane (3.3 mg,
0.02 mmol) following general procedure E to
give-5-{3-[2-{4'-[bis-(3,3-dimethyl-butyl)-amino]-biphenyl-4-ylmethyl}-4--
(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1-
,1-dioxide.
[1102] LCMS: m/z 772 (M+H).sup.+.
Example 137
[1103]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was coupled with
4-morpholino-phenyl boronic acid (40 m g, 0.2 mmol) according to
general procedure G to give
{3-[4-(2,4-dichloro-phenyl)-2-(4'-morpholin-4-yl-biphenyl-4-ylmethyl)-imi-
dazol-1-yl]-phenylamino}-acetic acid methylester.
[1104]
{3-[4-(2,4-Dichloro-phenyl)-2-(4'-morpholin-4-yl-biphenyl-4-ylmethy-
l)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester (20 mg,
0.03 mmol) was treated following general procedure F to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4'-morpholin-4-yl-biphenyl-4-ylmethyl)-i-
midazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1105] LCMS: m/z 674 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.83-1.05 (m, 2H), 1.10-1.20 (m, 2H), 3.12-3.14 (m,
2H), 3.72-3.74 (m, 2H), 4.01 (s, 2H), 4.10 (s, 2H), 6.98 (d, 2H),
7.01 (d, 2H), 7.12 (d, 2H), 7.20 (d, 2H), 7.42-7.50 (m, 3H), 7.64
(d, 1H), 7.86 (s, 1H), 7.92 (d, 2H), 8.18 (d, 1H) ppm.
Example 138
[1106]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was treated as
described in general procedure G using
4-(2-cyclohexylethylsulfanyl)-phenylboronic acid (52 mg, 0.2 mmol,
prepared according to general procedure I) to give
{3-[2-[4'-(2-cyclohexyl-ethylsulfanyl)-biphenyl-4-ylmethyl]-4-(2,4-dichlo-
ro-phenyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl
ester.
[1107]
{3-[2-[4'-(2-Cyclohexyl-ethylsulfanyl)-biphenyl-4-ylmethyl]-4-(2,4--
dichloro-phenyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl
ester (23 mg, 0.033 mmol) was treated following general procedure F
to give
5-{3-[2-[4'-(2-cyclohexyl-ethylsulfanyl)-biphenyl-4-ylmethyl]-4-(2,4-dich-
loro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxid-
e.
[1108] LCMS: m/z 731 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.86-0.89 (m, 2H), 1.14-1.21 (m, 6H), 1.45 (m, 1H),
1.47-1.80 (m, 4H), 2.97 (m, 2H), 4.01 (s, 2H), 4.12 (s, 2H), 7.02
(d, 2H), 7.04 (d, 2H), 7.16 (d, 2H), 7.33 (d, 2H), 7.42-7.57 (m,
5H), 7.64 (d, 1H), 7.78 (s, 1H), 8.17 (d, 1H) ppm.
Example 139
[1109]
5-{3-[2-[4'-(Cyclohexylmethyl-amino)-biphenyl-4-ylmethyl]-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-[1,2,5]
thiadiazolidin-3-one-1,1-dioxide (7 mg, 0.01 mmol) was reacted with
acetaldehyde (2 mg, 0.04 mmol) following general procedure X to
give
5-{3-[2-[4'-(cyclohexylmethyl-ethyl-amino)-biphenyl-4-ylmethyl]-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-diox-
ide.
[1110] LCMS: m/z 728 (M+H).sup.+.
Example 140
[1111] 2-tert-Butyl-5-chloro-isothiazolin-3-one-1,1-dioxide [(2.3
g, 10 mmol)-prepared following general procedure AB) was coupled
with 3-boc-amino-phenylboronic acid (3.0 g, 12 mmol) according to
general procedure AC to give
[3-(2-tert-butyl-1,1,3-trioxo-2,3-dihydro-1H-isothiazol-5-yl)-phenyl]-car-
bamic acid tert-butylester.
[1112]
[3-(2-tert-Butyl-1,1,3-trioxo-2,3-dihydro-1H-isothiazol-5-yl)-pheny-
l]-carbamic acid tert-butylester (77 mg, 0.20 mmol) was treated
with 1,4-dioxane-HCl following general procedure V to give
5-(3-Amino-phenyl)-2-tert-butyl-isothiazol-3-one-1,1-dioxide.
[1113] LCMS: m/z 280 (M+H).sup.+; .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 1.68 (s, 9H), 6.66 (s, 1H), 7.32 (d, 2H), 7.34 (d,
2H), 7.39 (dd, 1H), 7.79 (s, 1H) ppm.
[1114] 5-(3-Amino-phenyl)-2-tert-butyl-isothiazol-3-one-1,1-dioxide
(70 mg, 0.25 mmol) was treated with
2-bromo-2,4-dichloro-acetophenone (70 g, 0.26 mmol) following
general procedure N to give
2-tert-butyl-5-{3-[2-(2,4-dichloro-phenyl)-2-oxo-ethylamino]-phenyl}-isot-
hiazol-3-one-1,1-dioxide.
[1115] LCMS: m/z 467 (M+H).sup.+; .sup.1H NMR (CDCl3, 400 MHz):
.delta. 1.69 (s, 9H), 4.57 (s, 2H), 6.62 (s, 1H), 6.78 (d, 1H),
6.87 (s, 1H), 7.03 (d, 1H), 7.33 (dd, 1H), 7.37 (d, 1H), 7.52 (s,
1H), 7.64 (d, 1H) ppm.
[1116]
2-tert-Butyl-5-{3-[2-(2,4-dichloro-phenyl)-2-oxo-ethylamino]-phenyl-
}-isothiazol-3-one-1,1-dioxide (47 mg, 0.10 mmol) was reacted with
4-bromo-phenacetyl chloride (25 mg, 0.10 mmol) according to general
procedure N to give
2-(4-bromo-phenyl)-N-[3-(2-tert-butyl-1,1,3-trioxo-2,3-dihydro-1H-isothia-
zol-5-yl)-phenyl]-N-[2-(2,4-dichloro-phenyl)-2-oxo-ethyl]-acetamide.
[1117] LCMS: m/z 664 (M+H).sup.+; .sup.1H NMR (CDCl3, 400 MHz):
.delta. 1.68 (s, 9H), 3.62 (s, 2H), 3.70 (s, 2H), 6.66 (s, 1H),
7.16 (d, 2H), 7.22 (d, 2H), 7.40 (d, 2H), 7.41-7.48 (m, 2H), 7.53
(d, 2H), 7.98 (s, 1H) ppm.
[1118]
2-(4-Bromo-phenyl)-N-[3-(2-tert-butyl-1,1,3-trioxo-2,3-dihydro-isot-
hiazol-5-yl)-phenyl]-N-[2-(2,4-dichloro-phenyl)-2-oxo-ethyl]-acetamide-1,1-
-dioxide (23 mg, 0.03 mmol) was treated as described in general
procedure 0 to give
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-
-phenyl}-2-tert-butyl-isothiazol-3-one-1,1-dioxide.
[1119] LCMS: m/z 645 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.59 (s, 9H), 3.66 (s, 2H), 7.14 (s, 1H), 7.28 (d,
2H), 7.47-7.53 (m, 5H), 7.73 (d, 2H), 8.06 (s, 1H), 10.4 (s, 1H)
ppm.
[1120]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-2-tert-butyl-isothiazol-3-one-1,1-dioxide (7 mg, 0.01 mmol)
was treated as described in general procedure G using
4-(cyclohexylmethoxy)-phenylboronic acid (5 mg, 0.02 mmol, prepared
according to general procedure H) to give
2-tert-Butyl-5-{3-[2-(4'-cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-isothiazol-3-one-1,1-dioxide.
[1121] LCMS: m/z 754 (M+H).sup.+; .sup.1H NMR (CDCl3, 400 MHz):
.delta. 0.89-1.07 (m, 2H), 1.25-1.32 (m, 5H), 1.64 (s, 9H),
1.69-1.90 (m, 6H), 3.77 (s, 2H), 3.79 (s, 2H), 6.59 (s, 1H), 6.70
(s, 1H), 6.93 (d, 2H), 7.08 (d, 1H), 7.10 (d, 2H), 7.36-7.47 (m,
5H), 7.70 (d, 2H), 7.78 (d, 1H) ppm.
Example 141
[1122] 2-(4-Bromo-benzyl)-4-(2,4-dichlorophenyl)-1H-imidazole (3.27
g, 8.6 mmol) was treated as described in general procedure B using
4-fluoronitrobenzene to provide
2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-
e, which was treated with 4-hydroxyphenyl boronic acid according to
general procedure G to provide
4'-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-2-ylmethyl]-bi-
phenyl-4-ol (996 mg, 22% for two steps). To a solution of the
phenol in THF (0.5 M) was added N-boc-4-hydroxypiperidine (2 eq)
and triphenylphosphine (2 eq) under nitrogen, then while sonicating
this mixture diisopropyl azodicarboxylate (2 eq) was added. After
sonicating 1 hour the reaction mixture was evaporated in vacuo and
the reside was purified by silica gel column chromatography to
afford
4-{4'-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-2-ylmethyl]-
biphenyl-4-yloxy}-piperidine-1-carboxylic acid tert-butyl
ester.
[1123] The boc-protected alkyl aryl ether product (911 mg, 1.3
mmol) was deprotected according to general procedure V and the
neopentyl carbamate group was introduced according to general
procedure U to provide
4-{4'-[4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-1H-imidazol-2-ylmethyl]-
biphenyl-4-yloxy}-piperidine-1-carboxylic acid 2,2-dimethyl-propyl
ester. The resulting nitro compound was reduced, alkylated and
cyclized according to general procedure C to provide
4-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yloxy)-piperidine-1-carbox-
ylic acid 2,2-dimethyl-propyl ester.
[1124] LCMS: m/z 802 (M+H).sup.+; .sup.1H NMR (acetone-d.sub.6, 400
MHz): .delta. 0.95 (s, 9H), 1.28 (m, 2H), 1.66 (m, 2H), 1.97 (m,
2H), 3.37 (m, 2H), 3.78 (m, 4H), 4.02 (s, 1H), 4.32 (s, 1H), 4.60
(m, 1H), 6.97-7.04 (m, 2H), 7.14 (m, 2H), 7.21, (m, 2H), 7.28 (m,
2H), 7.38-7.45 (m, 3H), 7.47-7.54 (m, 3H), 7.83 (s, 1H), 8.35 (d,
1H) ppm.
Example 142
[1125]
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (100 mg, 0.17 mmol)
was treated as described in general procedure G using
3-isopropylphenyl boronic acid to provide
5-{4-[4-(2,4-dichloro-phenyl)-2-(3'-isopropyl-biphenyl-4-ylmethyl)-imidaz-
ol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1126] LCMS: m/z 631 (M+H).sup.+.
Example 143
[1127]
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (100 mg, 0.17 mmol)
was treated as described in general procedure G using
4-trifluoromethylphenylboronic acid to provide
5-{4-[4-(2,4-dichloro-phenyl)-2-(4'-trifluoromethyl-biphenyl-4-ylmethyl)--
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1128] LCMS: m/z 657 (M+H).sup.+.
Example 144
[1129]
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (143 mg, 0.24 mmol)
was stirred in DMF (0.1-0.5 M) with 1.1 eq of N-chlorosuccinimide
under nitrogen at room temperature for 12 hours. The mixture was
poured into water and extracted with ethyl acetate. The organic
extract was washed with water, saturated aqueous NaHCO.sub.3 and
brine and dried over Na.sub.2SO.sub.4. After removal of the solvent
in vacuo, the residue was dried and used directly in the next
step.
[1130] The crude chlorinated compound was treated as described in
general procedure G using 4-cyclohexylphenyl boronic acid to
provide
5-{2-chloro-4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phen-
yl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1131] LCMS: m/z 705 (M+H).sup.+.
Example 145
[1132]
2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1H-im-
idazole (250 mg, 0.54 mmol) was treated according to general
procedure B using 2-fluoro-5-nitrotoluene to provide
2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-1-(2-methyl-
-4-nitro-phenyl)-1H-imidazole, which was collected without
purification. Treatment of the nitro compound as described in
general procedure C provided
5-{4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phen-
yl)-imidazol-1-yl]-3-methyl-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxid-
e.
[1133] LCMS: m/z 685 (M+H).sup.+.
[1134] By analogous methods to those used to prepare Example 145,
the following compounds were synthesized:
TABLE-US-00010 Ex. Name LC/MS (m/z) 146
5-{3-Chloro-4-[2-(4'-cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4- 705 (M
+ H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 147
5-{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 739 (M
+ H).sup.+ phenyl)-imidazol-1-yl]-3-trifluoromethyl-phenyl}-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 148
5-{4-[2-(4'-Cyclohexyl-biphenyl-4-ylmethyl)-4-(2,4-dichloro- 689 (M
+ H).sup.+
phenyl)-imidazol-1-yl]-3-fluoro-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide
Example 149
[1135]
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (200 mg, 0.34 mmol)
was treated as described in general procedure G using
4-(2-ethoxycarbonyl-vinyl)phenyl boronic acid to provide
3-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-acrylic acid
ethyl ester.
[1136] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.27 (t, 3H), 4.05 (s, 2H), 4.10 (s, 2H), 4.19 (q,
2H), 6.67 (d, 1H), 7.15-7.22 (m, 4H), 7.37 (m, 2H), 7.45-7.53 (m,
2H), 7.59-7.72 (m, 5H), 7.79 (m, 2H), 7.90 (s, 1H), 8.19 (d, 1H)
ppm.
Example 150
[1137]
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (300 mg, 0.51 mmol)
was treated as described in general procedure G using
4-(2-ethoxycarbonyl-ethyl)phenyl boronic acid to provide
3-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-propionic acid
ethyl ester.
[1138] LCMS: m/z 689 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.16 (t, 3H), 2.63 (t, 2H), 2.87 (t, 2H), 4.01-4.12
(m, 6H), 7.13-7.21 (m, 4H), 7.29 (m, 2H), 7.37 (m, 2H), 7.48 (m,
1H), 7.51-7.57 (m, 4H), 7.65 (m, 1H), 7.90 (s, 1H), 8.19 (d, 1H)
ppm.
Example 151
[1139]
(4'-{4-(2,4-Dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolid-
in-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-acrylic
acid ethyl ester (36 mg, 52 .mu.mol) was treated as described in
general procedure P to provide
3-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-acrylic
acid.
[1140] LCMS: m/z 659 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.10 (s, 2H), 6.57 (d, 1H), 7.14-7.22
(m, 4H), 7.38 (m, 2H), 7.48 (m, 1H), 7.58-7.66 (m, 4H), 7.70 (m,
2H), 7.76 (m, 2H), 7.90 (s, 1H), 8.19 (d, 1H) ppm.
Example 152
[1141]
3-(4'-{4-(2,4-Dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazol-
idin-2-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-propionic
acid ethyl ester (54 mg, 78 .mu.mol) was treated as described in
general procedure P to provide
3-(4'-{4-(2,4-dichloro-phenyl)-1-[4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-
-yl)-phenyl]-1H-imidazol-2-ylmethyl}-biphenyl-4-yl)-propionic
acid.
[1142] LCMS: m/z 661 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 2.56 (t, 2H), 2.84 (t, 2H), 4.07 (s, 2H), 4.12 (s,
2H), 7.14-7.22 (m, 4H), 7.29 (m, 2H), 7.40 (m, 2H), 7.49-7.57 (m,
5H), 7.69 (m, 1H), 7.96 (s, 1H), 8.13 (d, 1H) ppm.
Example 153
[1143]
4'-[4-(2,4-Dichloro-phenyl)-1H-imidazol-2-ylmethyl]-biphenyl-4-carb-
oxylic acid ethyl ester (500 mg, 1.1 mmol) was treated as described
in general procedure Z using 2 equivalents of propylmagnesium
chloride. The crude Grignard product was subjected directly to
reduction according to general procedure AA, after which the
reduction product was alkylated with 4-fluoronitrobenzene according
to general procedure B. The crude nitro compound was treated as
described in general procedure C to provide
5-(4-{4-(2,4-dichloro-phenyl)-2-[4'-(1-propyl-butyl)-biphenyl-4-ylmethyl]-
-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1144] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.82 (t, 6H), 1.05-1.20 (m, 4H), 1.48-1.61 (m, 4H),
2.55 (m, 1H), 3.91 (s, 2H), 4.05 (s, 2H), 7.12-7.20 (m, 4H), 7.23
(m, 2H), 7.36 (m, 2H), 7.47 (dd, 1H), 7.55 (m, 4H), 7.64 (d, 1H),
7.90 (s, 1H), 8.20 (d, 1H) ppm.
Example 154
[1145] 2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1H-imidazole (1
g, 2.6 mmol) was treated with (3-iodo-phenyl)-carbamic acid
tert-butyl ester following general procedure R to provide
{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-car-
bamic acid tert-butyl ester. The bromophenyl product (370 mg, 0.64
mmol) was treated as described in general procedure G using
4-ethoxycarbonylphenyl boronic acid to provide
4'-[1-(3-tert-butoxycarbonylamino-phenyl)-4-(2,4-dichloro-phenyl)-1H-imid-
azol-2-ylmethyl]-biphenyl-4-carboxylic acid ethyl ester.
[1146] The benzoate ester obtained above (153 mg, 0.24 mmol) was
treated to general procedure Z using 2 eq of
3,3-dimethylbutylmagnesium chloride, followed by reduction of the
Grignard product according to general procedure AA to provide
[3-(4-(2,4-dichloro-phenyl)-2-{4'-[1-(3,3-dimethyl-butyl)-4,4-dimethyl-pe-
ntyl]-biphenyl-4-ylmethyl}-imidazol-1-yl)-phenyl]-carbamic acid
tert-butyl ester. After removal of the Boc group according to
general procedure V, the resulting aniline compound was treated
according to general procedures E and F successively to provide
5-[3-(4-(2,4-dichloro-phenyl)-2-{4'-[1-(3,3-dimethyl-butyl)-4,4-dimethyl--
pentyl]-biphenyl-4-ylmethyl]-imidazol-1-yl)-phenyl}-1,2,5-thiadiazolidine--
3-one-1,1-dioxide.
[1147] LCMS: m/z 771 (M+H).sup.+.
Example 155
[1148] 4-Bromobenzaldehyde (1 g, 5.4 mmol) was converted to
4-(4,4-dimethyl-pentyl)phenyl boronic acid according to general
procedure Y using 3,3-dimethylbutylmagnesium chloride (1 eq).
[1149]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amine was prepared from 3-aminoacetanilide according to general
procedure M, then alkylated with methyl bromoacetate according to
general procedure E to produce crude
{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenylamino-
}-acetic acid methyl ester. The bromo compound (44 mg, 80 .mu.mol)
was coupled with 4-(4,4-dimethyl-pentyl)phenyl boronic acid as
described in general procedure G to provide
(3-{4-(2,4-dichloro-phenyl)-2-[4'-(4,4-dimethyl-pentyl)-biphenyl-4-ylmeth-
yl]-imidazol-1-yl}-phenylamino)-acetic acid methyl ester. The
product was then treated according to general procedure F to
provide
5-(3-{4-(2,4-dichloro-phenyl)-2-[4'-(4,4-dimethyl-pentyl)-biphenyl-4-ylme-
thyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1150] LCMS: m/z 687 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.76 (s, 9H), 1.10-1.20 (m, 2H), 1.48 (m, 2H), 2.47
(t, 2H), 4.03 (s, 2H), 4.22 (s, 2H), 6.71 (m, 1H), 7.04-7.16 (m,
5H), 7.20 (m, 2H), 7.29 (dd, 1H), 7.31-7.40 (m, 5H), 7.79 (s, 1H),
8.23 (d, 1H) ppm.
[1151] By analogous methods to those used to prepare Example 155,
the following compounds were synthesized:
TABLE-US-00011 Ex. Name LC/MS (m/z) 156
5-{3-[2-[4'-(2-Cyclohexyl-ethyl)-biphenyl-4-ylmethyl]-4-(2,4- 699
(M + H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 157
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4'-(3,3-dimethyl-butyl)- 673 (M +
H).sup.+ biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-
thiadiazolidine-3-one-1,1-dioxide 158
5-{3-[2-(4'-Cyclohexylmethyl-biphenyl-4-ylmethyl)-4-(2,4- 685 (M +
H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide 159
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4'-(4-methyl-pentyl)-biphenyl- 673
(M + H).sup.+
4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-
1,1-dioxide
Example 160
[1152] 4-Bromobenzaldehyde (6.5 g, 35 mmol) was converted to
4-(2-cyclohexylvinyl)phenyl boronic acid according to general
procedure AE using cyclohexylmethylmagnesium bromide.
[1153]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amine was prepared from 3-aminoacetanilide according to general
procedure M, then alkylated with methyl bromoacetate according to
general procedure E to produce crude
{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenylamino-
}-acetic acid methyl ester. The bromo compound (500 mg, 0.91 mmol)
was coupled with 4-(2-cyclohexylvinyl)phenyl boronic acid as
described in general procedure G to provide
{3-[2-[4'-(2-cyclohexyl-vinyl)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-pheny-
l)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester. The
product was then treated according to general procedure F to
provide
5-{3-[2-[4'-(2-cyclohexyl-vinyl)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1154] LCMS: m/z 697 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.12-1.36 (m, 5H), 1.65 (m, 2H), 1.75 (m, 3H), 2.14
(m, 1H), 4.00 (s, 2H), 4.13 (s, 2H), 6.29 (dd, 1H), 6.39 (d, 1H),
6.94 (m, 1H), 7.05 (m, 1H), 7.18 (m, 2H), 7.26 (m, 1H), 7.41-7.46
(m, 3H), 7.49 (dd, 1H), 7.51-7.58 (m, 4H), 7.65 (d, 1H), 7.94 (s,
1H), 8.19 (d, 1H) ppm.
Example 161
[1155] 4-Bromophenylacetic acid (2.2 g, 10 mmol) was treated
according to general procedures A and B to give
2-(4-bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-imidazol-
e, which was then treated as described in general procedure C to
give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-2-
,5-thiadiazolidine-3-one-1,1-dioxide.
[1156] LCMS: m/z 593 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.27 (d,
2H), 7.47 (dd, 1H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89
(s, 1H), 8.19 (d, 1H) ppm.
Example 162
[1157] 4-Bromophenylacetic acid (2.2 g, 10 mmol) was treated
according to general procedures A and B to give
2-(4-bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,6-dichloro-phenyl)-1H-imidazol-
e, which was then treated as described in general procedure C to
give
5-{4-[2-(4-bromo-benzyl)-4-(2,6-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1158] LCMS: m/z 593 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.27 (d,
2H), 7.44-7.52 (m, 5H), 7.63 (d, 1H), 7.88 (s, 1H), 8.18 (d, 1H)
ppm.
Example 163
[1159]
2-(4-Bromo-benzyl)-1-(3-nitro-phenyl)-4-(2,4-dichloro-phenyl)-1H-im-
idazole (prepared from 4-bromophenylacetic acid according to
general procedures A and R) (503 mg, 1 mmol) was treated as
described in general procedure C to give
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1160] LCMS: m/z 593 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.15 (d, 2H), 7.29-7.50
(m, 5H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H)
ppm.
Example 164
[1161]
2-(4-Bromo-benzyl)-1-(4-nitro-phenyl)-4-(2,4-difluoro-phenyl)-1H-im-
idazole (prepared from 4-bromophenylacetic acid according to
general procedures A and B) (470 mg, 1 mmol) was treated as
described in general procedure C to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-difluoro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1162] LCMS: m/z 560 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.07 (s, 2H), 7.12-7.19 (m, 5H), 7.47
(m, 1H), 7.51-7.56 (m, 5H), 8.12 (m, 1H) ppm.
Example 165
[1163]
2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-1-(4-methyl-3-nitro-phen-
yl)-1H-imidazole (prepared from 4-bromophenylacetic acid according
to general procedures A and R) (517 mg, 1 mmol) was treated as
described in general procedure C to give
5-{5-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-2-methyl--
phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1164] LCMS: m/z 607 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 2.30 (s, 3H), 4.05 (s, 2H), 4.07 (s, 2H), 7.27-7.43
(m, 4H), 7.51 (d, 2H), 7.53 (d, 2H), 7.64 (d, 1H), 7.89 (s, 1H),
8.19 (d, 1H) ppm.
Example 166
[1165]
2-(4-Bromo-benzyl)-4-(2,4-difluoro-phenyl)-1-(4-methyl-3-nitro-phen-
yl)-1H-imidazole (prepared from 4-bromophenylacetic acid according
to general procedures A and R) (484 mg, 1 mmol) was treated as
described in general procedure C to give
5-{5-[2-(4-bromo-benzyl)-4-(2,4-difluoro-phenyl)-imidazol-1-yl]-2-methyl--
phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1166] LCMS: m/z 574 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 2.29 (s, 3H), 4.05 (s, 2H), 4.07 (s, 2H), 7.12-7.19
(m, 4H), 7.47 (m, 1H), 7.51-7.56 (m, 5H), 8.12 (m, 1H) ppm.
Example 167
[1167]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-phenoxyphenylboronic acid (43 mg, 0.2 mmol) to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4'-phenoxy-biphenyl-4-ylmethyl)-imidazol-
-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1168] LCMS: m/z 681 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 4.05 (s, 2H), 4.08 (s, 2H), 7.05 (d, 2H), 7.07 (d,
2H), 7.14-7.19 (m, 5H), 7.36-7.43 (m, 4H), 7.47 (m, 1H), 7.53 (d,
2H), 7.64-7.66 (m, 3H), 7.90 (s, 1H), 8.20 (d, 1H) ppm.
[1169] By analogous methods to those used to prepare Example 167,
the following compounds were synthesized:
TABLE-US-00012 Ex. Name LC/MS (m/z) 168
5-{3-[4-(2,4-Dichloro-phenyl)-2-(4-hex-1-enyl-benzyl)-imidazol- 595
(M + H).sup.+ 1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
169 5-(3-{4-(2,4-Dichloro-phenyl)-2-[4-(3,3-dimethyl-but-1-enyl)-
595 (M + H).sup.+
benzyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-
dioxide 170
5-{3-[2-[4-(2-Cyclohexyl-vinyl)-benzyl]-4-(2,4-dichloro-phenyl)-
595 (M + H).sup.+
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide 171
5-{4-[2-[3'-(2-Cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4- 715
(M + H).sup.+
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-
one-1,1-dioxide
Example 172
[1170]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (1.19 g, 2 mmol) was
treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (708 .mu.L, 4 mmol) to give
5-{4-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one,
which was then treated according to general procedure AD to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborol-
an-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1171] LCMS: m/z 769 (M+H).sup.+.
[1172]
5-(4-{4-(2,4-Dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]diox-
aborolan-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsila-
nyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one (385 mg, 0.5 mmol)
was treated as described in general procedure G using
3,6-dichloropyridazine (149 mg, 1 mmol) to give
5-{4-[2-[4-(6-chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]th-
iadiazolidin-3-one.
[1173] LCMS: m/z 756 (M+H).sup.+.
[1174]
5-{4-[2-[4-(6-Chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,-
2,5]thiadiazolidin-3-one (38 mg, 0.05 mmol) was treated as
described in general procedure L using 2-cyclohexyl ethanol (35
.mu.L, 0.25 mmol) to give
5-{4-[2-{4-[6-(2-cyclohexyl-ethoxy)-pyridazin-3-yl]benzyl}-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-etho-
xymethyl)-[1,2,5]thiadiazolidin-3-one.
[1175] LCMS: m/z 847 (M+H).sup.+.
[1176]
5-{4-[2-{4-[6-(2-Cyclohexyl-ethoxy)-pyridazin-3-yl]-benzyl}-4-(2,4--
dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one (17 mg, 0.02 mmol) was
treated as described in general procedure W using
tetrabutylammonium fluoride (26 mg, 0.1 mmol) to give
5-{4-[2-{4-[6-(2-cyclohexyl-ethoxy)-pyridazin-3-yl]-benzyl}-4-(2,4-dichlo-
ro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1177] LCMS: m/z 717 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 0.97-1.43 (m, 5H), 1.65 (m, 2H), 1.69-1.81 (m, 6H),
4.05 (t, 2H), 4.08 (s, 2H), 4.10 (s, 2H), 7.17 (d, 2H), 7.21 (d,
2H), 7.37 (d, 2H), 7.46-7.54 (m, 5H), 7.64 (d, 1H), 7.89 (s, 1H),
8.19 (d, 1H) ppm.
Example 173
[1178]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl}-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (1.19 g, 2 mmol) was
treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (708 .mu.L, 4 mmol) to give
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one,
which was then treated according to general procedure AD to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborol-
an-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1179] LCMS: m/z 769 (M+H).sup.+.
[1180]
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]diox-
aborolan-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsila-
nyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one (385 mg, 0.5 mmol)
was treated as described in general procedure G using
3,6-dichloropyridazine (149 mg, 1 mmol) to give
5-{3-[2-[4-(6-chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]th-
iadiazolidin-3-one.
[1181] LCMS: m/z 756 (M+H).sup.+.
[1182]
5-{3-[2-[4-(6-Chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,-
2,5]thiadiazolidin-3-one (38 mg, 0.05 mmol) was treated as
described in general procedure G using 1-cyclohexen-1-yl-boronic
acid (13 mg, 0.1 mmol) to give
5-{3-[2-[4-(6-cyclohex-1-enyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)--
[1,2,5]thiadiazolidin-3-one.
[1183] LCMS: m/z 801 (M+H).sup.+.
[1184]
5-{3-[2-[4-(6-Cyclohex-1-enyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichlo-
ro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxyme-
thyl)-[1,2,5]thiadiazolidin-3-one (16 mg, 0.02 mmol) was treated as
described in general procedure W using tetrabutylammonium fluoride
(26 mg, 0.1 mmol) to give
5-{3-[2-[4-(6-cyclohex-1-enyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1185] LCMS: m/z 671 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.56 (m, 4H), 2.15 (m, 4H), 4.06 (s, 2H), 4.09 (s,
2H), 6.41 (m, 1H), 7.15-7.27 (m, 5H), 7.37 (d, 2H), 7.46-7.54 (m,
4H), 7.64 (d, 1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 174
[1186]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
trans-1-octen-1-ylboronic acid (47 mg, 0.3 mmol) to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4-oct-1-enyl-benzyl)-imidazol-1-yl]-phen-
yl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1187] LCMS: m/z 623 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.86 (t, 3H), 1.27 (m, 6H), 1.41 (m, 2H), 2.16 (m,
2H), 4.02 (s, 2H), 4.05 (s, 2H), 6.22 (m, 1H), 6.32 (d, 1H), 7.01
(d, 2H), 7.17 (m, 2H), 7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d,
1H), 7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 175
[1188]
5-{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) was
treated as described in general procedure AF using 1-hexyne (46
.mu.L, 0.4 mmol) to give
5-{4-[4-(2,4-dichloro-phenyl)-2-(4-hex-1-ynyl-benzyl)-imidazol-1-yl]-phen-
yl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1189] LCMS: m/z 593 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.90 (t, 3H), 1.41 (m, 2H), 1.50 (m, 2H), 2.39 (t,
2H), 4.02 (s, 2H), 4.04 (s, 2H), 7.04 (d, 2H), 7.16 (d, 2H), 7.24
(d, 2H), 7.32 (d, 2H), 7.47 (dd, 1H), 7.64 (d, 1H), 7.89 (s, 1H),
8.18 (d, 1H) ppm.
Example 176
[1190]
2-tert-Butyl-5-{3-[2-(4'-cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(-
2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-isothiazol-3-one-1,1-dioxide
(4 mg, 0.005 mmol) was treated with TFA following general procedure
to give
5-{3-[2-(4'-cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]phenyl}-isothiazol-3-one-1,1-dioxide.
[1191] LCMS: m/z 698 (M+H).sup.+; .sup.1H NMR (CDCl3, 400 MHz):
.delta. 0.89-1.07 (m, 2H), 1.25-1.32 (m, 5H), 1.69-1.90 (m, 6H),
3.77 (s, 2H), 3.79 (s, 2H), 6.59 (s, 1H), 6.70 (s, 1H), 6.93 (d,
2H), 7.08 (d, 1H), 7.10 (d, 2H), 7.36-7.47 (m, 5H), 7.70 (d, 2H),
7.78 (d, 1H) ppm.
Example 177
[1192]
4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was treated as
described in general procedure G using
4-(cyclohexylmethoxy)phenylboronic acid (47 mg, 0.2 mmol, prepared
according to general procedure H) to give
{4-[2-(4'-cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenylamino}-acetic acid methyl ester.
[1193]
{4-[2-(4'-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-ph-
enyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester (22 mg,
0.033 mmol) was treated following general procedure F to give
5-{4-[2-(4'-cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1194] LCMS: m/z 701 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.01-1.27 (m, 5H), 1.69-1.82 (m, 6H), 3.79 (d, 2H),
4.07 (s, 2H), 4.10 (s, 2H), 6.96 (d, 2H), 7.12 (d, 2H), 7.18 (d,
2H), 7.38 (d, 2H), 7.49-7.55 (m, 5H), 7.69 (d, 1H), 7.96 (s, 1H),
8.11 (d, 1H) ppm.
Example 178
[1195]
4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was treated as
described in general procedure G using
4-(3,3-dimethyl-butoxy)phenylboronic acid (45 mg, 0.2 mmol,
prepared according to general procedure H) to give
(4-{4-(2,4-dichloro-phenyl)-2-[4'-(3,3-dimethyl-butoxy)-biphenyl-4-ylmeth-
yl]-imidazol-1-yl}phenylamino)-acetic acid methyl ester.
[1196]
(4-{4-(2,4-Dichloro-phenyl)-2-[4'-(3,3-dimethyl-butoxy)-biphenyl-4--
ylmethyl]-imidazol-1-yl}phenylamino)-acetic acid methyl ester (22
mg, 0.033 mmol) was treated following general procedure F to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4'-(3,3-dimethyl-butoxy)-biphenyl-4-ylme-
thyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1197] LCMS: m/z 689 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.96 (s, 9H), 1.64 (t, 2H), 4.02 (t, 2H), 4.04 (s,
2H), 4.06 (s, 2H), 6.97 (d, 2H), 7.12-7.18 (m, 4H), 7.35 (d, 2H),
7.48-7.55 (m, 5H), 7.63 (d, 1H), 7.89 (s, 1H), 8.18 (d, 1H)
ppm.
Example 179
[1198]
4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amino}-acetic acid methyl ester (55 mg, 0.1 mmol) was treated as
described in general procedure G using
3-(2-cyclohexyl-ethoxy)-phenylboronic acid (50 mg, 0.2 mmol,
prepared according to general procedure H) to give
{4-[2-[4'-(2-cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-phen-
yl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester.
[1199]
{4-[2-[4'-(2-Cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4-dichlor-
o-phenyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester (22
mg, 0.03 mmol) was treated following general procedure F to give
5-{4-[2-[4'-(2-cyclohexyl-ethoxy)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-ph-
enyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1200] LCMS: m/z 715 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.93-0.96 (m, 2H), 1.14-1.23 (m, 5H), 1.59-1.75 (m,
6H), 4.00 (m, 2H), 4.02 (s, 2H), 4.06 (s, 2H), 6.96 (d, 2H),
7.12-7.18 (m, 4H), 7.35 (d, 2H), 7.46-7.55 (m, 5H), 7.63 (d, 1H),
7.89 (s, 1H), 8.20 (d, 1H) ppm.
Example 180
[1201] 6-methoxy-2-naphthylacetic acid (1.0 g, 4 mmol) was treated
according to general procedure A using 2,4-dichlorophenacyl bromide
to give
4-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-ylmethyl)-1H-imida-
zole.
[1202] LCMS: m/z 383 (M+H).sup.+, .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 3.67 (s, 3H), 4.10 (s, 2H), 7.21 (d, 2H), 7.37 (d,
2H), 7.42-7.51 (m, 2H), 7.57-7.69 (m, 3H), 8.05 (s, 1H) ppm
[1203]
4-(2,4-Dichloro-phenyl)-2-(6-methoxy-naphthalen-2-ylmethyl)-1H-imid-
azole (383 mg, 1 mmol) was treated as described in general
procedure B using 1-fluoro-4-nitrobenzene to give
4-(2,4-dichloro-phenyl)-1-(4-nitro-phenyl)-2-(6-methoxy-naphthalen-2-ylme-
thyl)-1H-imidazole.
[1204]
4-(2,4-Dichloro-phenyl)-1-(4-nitro-phenyl)-2-(6-methoxy-naphthalen--
2-ylmethyl)-1H-imidazole (252 mg, 0.5 mmol) was reduced to amine
and was reacted with methyl bromoacetate following general
procedures D & E to give
{4-[4-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-ylmethyl)-imid-
azol-1-yl]-phenylamino}-acetic acid methyl ester.
[1205]
{4-[4-(2,4-Dichloro-phenyl)-2-(6-methoxy-naphthalen-2-ylmethyl)-imi-
dazol-1-yl]-phenylamino}-acetic acid methyl ester (137 mg, 0.25
mmol) was de-alkylated with BBr.sub.3 following general procedure
AH and resulted phenol was alkylated with bromomethyl-cyclohexane
following general procedure H to give
{4-[2-(6-cyclohexylmethoxy-naphthalen-2-ylmethyl)-4-(2,4-dichloro-phenyl)-
-imidazol-1-yl]-phenylamino}-acetic acid methyl ester.
[1206]
{4-[2-(6-Cyclohexylmethoxy-naphthalen-2-ylmethyl)-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl ester (60 mg,
0.09 mmol) was treated as described in general procedure F to give
5-{4-[2-(6-cyclohexylmethoxy-naphthalen-2-ylmethyl)-4-(2,4-dichloro-pheny-
l)-imidazol-1-yl]-phenyl}1,2,5]-thiadiazolidin-3-one-1,1-dioxide.
[1207] LCMS: m/z 675 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.0-1.25 (m, 5H), 1.70-1.88 (m, 6H), 3.77 (d, 2H),
4.03 (s, 2H), 4.10 (s, 2H), 6.91 (dd, 1H), 6.97 (d, 2H), 7.04 (s,
1H), 7.15 (d, 2H), 7.27 (d, 2H), 7.41-7.51 (m, 3H), 7.55 (d, 1H),
7.67 (s, 1H), 8.19 (d, 1H) ppm.
Example 181
[1208]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (137 mg, 0.25 mmol) was coupled
with 2-cyclohexylvinylboronic acid (59 m g, 0.38 mmol) according to
general procedure G to give
{4-[2-[4-(2-cyclohexyl-vinyl)-benzyl]-4-(2,4-dichloro-phenyl)-imidazol-1--
yl]-phenylamino}-acetic acid methyl ester.
[1209]
{4-[2-[4-(2-Cyclohexyl-vinyl)-benzyl]-4-(2,4-dichloro-phenyl)-imida-
zol-1-yl]-phenylamino}-acetic acid methyl ester (60 mg, 1 mmol) was
treated following general procedure F to give
5-{4-[2-[4-(2-cyclohexyl-vinyl)-benzyl]-4-(2,4-dichloro-phenyl)-imidazol--
1-yl]-phenyl}-1,2,5]-thiadiazolidin-3-one-1,1-dioxide.
[1210] LCMS: m/z 621 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.84-0.86 (m, 2H), 1.11-1.29 (m, 5H), 1.69-1.89 (m,
5H), 4.01 (s, 2H), 4.04 (s, 2H), 6.19 (dd, 1H), 6.26 (d, 1H), 6.98
(d, 2H), 7.14 (d, 2H), 7.24 (d, 2H), 7.31 (d, 2H), 7.45 (d, 1H),
7.48 (d, 2H), 7.63 (s, 1H), 8.17 (d, 1H) ppm.
Example 182
[1211]
4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzaldehyde (3.48
g, 15 mmol) was converted to
2-cyclopentyl-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
-ethanol according to general procedure Z using
cyclopentylmethylmagnesium bromide.
[1212]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amine was prepared from 3-aminoacetanilide according to general
procedure M, then the aniline was converted to
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidin-3-one-1,1-dioxide as described in general
procedures E and F. The bromo-thiadiazolidinone (100 mg, 0.17 mmol)
was coupled with
2-cyclopentyl-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
-ethanol according to general procedure G to provide
5-{3-[2-[4'-(2-cyclopentyl-1-hydroxy-ethyl)-biphenyl-4-ylmethyl]-4-(2,4-d-
ichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidin-3-one-1,1-diox-
ide.
[1213] LCMS: m/z 701 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 1.06-1.16 (m, 2H), 1.40-1.50 (m, 2H), 1.51-1.60 (m,
3H), 1.65-1.84 (m, 4H), 4.00 (s, 2H), 4.13 (s, 2H), 4.53 (m, 1H),
5.10 (d, 1H), 6.94 (m, 1H), 7.05 (m, 1H), 7.18 (m, 2H), 7.26 (m,
1H), 7.36 (m, 2H), 7.47 (t, 1H), 7.49 (dd, 1H), 7.52 (m, 2H), 7.56
(m, 2H), 7.65 (d, 1H), 7.94 (s, 1H), 8.19 (d, 1H) ppm.
Example 183
[1214]
5-{3-[2-[4'-(2-Cyclopentyl-1-hydroxy-ethyl)-biphenyl-4-ylmethyl]-4--
(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidin-3-one-1,-
1-dioxide (45 mg, 64 .mu.mol) was reduced according to general
procedure AA to provide
5-{3-[2-[4'-(2-cyclopentyl-ethyl)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-ph-
enyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidin-3-one-1,1-dioxide.
[1215] LCMS: m/z 685 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.08-1.20 (m, 2H), 1.47-1.57 (m, 2H), 1.58-1.68 (m,
4H), 1.75-1.86 (m, 3H), 2.64 (t, 2H), 4.17 (s, 2H), 4.21 (s, 2H),
6.83 (m, 1H), 7.07 (m, 2H), 7.15 (m, 1H), 7.21 (m, 2H), 7.28 (m,
1H), 7.34-7.48 (m, 7H), 7.73 (s, 1H), 8.01 (d, 1H) ppm.
Example 184
[1216] 4-Bromobenzaldehyde (4.26 g, 23 mmol) was converted to
4'-(4,4-dimethyl-pent-1-enyl)phenyl boronic acid according to
general procedure AE using 3,3-dimethylbutylmagnesium chloride.
[1217]
3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl-
amine was prepared from 3-aminoacetanilide according to general
procedure M, then the aniline was converted to
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-1,2,5-thiadiazolidin-3-one-1,1-dioxide as described in
general procedures E and F. The bromo-thiadiazolidinone (50 mg, 84
.mu.mol) was coupled with 4'-(4,4-dimethyl-pent-1-enyl)phenyl
boronic acid according to general procedure G to provide
5-(3-{4-(2,4-dichloro-phenyl)-2-[4'-(4,4-dimethyl-pent-1-enyl)-biphenyl-4-
-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidin-3-one-1,1-dioxide.
[1218] LCMS: m/z 685 (M+H).sup.+.
Example 185
[1219] 4-Bromobenzaldehyde was converted to
4-(4-methylpentyl)phenyl boronic acid according to general
procedure Y using 3-methylbutylmagnesium bromide (1 eq). The crude
boronic acid was used below without purification.
[1220]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (500 mg, 0.91 mmol) was coupled
with 4-(4-methylpentyl)phenyl boronic acid according to general
procedure G to give
(4-{4-(2,4-dichloro-phenyl)-2-[4'-(4-methyl-pentyl)-biphenyl-4-ylmet-
hyl]-imidazol-1-yl}-phenylamino)-acetic acid methyl ester.
[1221]
(4-{4-(2,4-Dichloro-phenyl)-2-[4'-(4-methyl-pentyl)-biphenyl-4-ylme-
thyl]-imidazol-1-yl}-phenylamino)-acetic acid methyl ester (356 mg,
0.57 mmol) was treated following general procedure F to give
5-(4-{4-(2,4-dichloro-phenyl)-2-[4'-(4-methyl-pentyl)-biphenyl-4-ylmethyl-
]-imidazol-1-yl}phenyl)-1,2,5-thiadiazolidin-3-one-1,1-dioxide.
[1222] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.86 (d, 6H), 1.20 (m, 2H), 1.50-1.63 (m, 3H), 2.58
(t, 2H), 4.07 (s, 2H), 4.09 (s, 2H), 7.14-7.21 (m, 4H), 7.25 (m,
2H), 7.37 (m, 2H), 7.48 (dd, 1H), 7.51-7.56 (m, 4H), 7.64 (d, 1H),
7.90 (s, 1H), 8.20 (d, 1H) ppm.
Example 186
[1223]
4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzaldehyde (3.48
g, 15 mmol) was converted to
2-cyclopentyl-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
-ethanol according to general procedure Z using
cyclopentylmethylmagnesium bromide.
[1224]
{4-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-pheny-
lamino}-acetic acid methyl ester (433 mg, 0.79 mmol) was coupled
with
2-cyclopentyl-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
-ethanol according to general procedure G to give
{-4-[2-[4'-(2-cyclopentyl-1-hydroxy-ethyl)-biphenyl-4-ylmethyl]-4-(2,4-di-
chloro-phenyl)-imidazol-1-yl]-phenylamino}-acetic acid methyl
ester. The product benzyl alcohol was reduced according to general
procedure AA and the reduced product was treated following general
procedure F to give
5-{-4-[2-[4'-(2-cyclopentyl-ethyl)-biphenyl-4-ylmethyl]-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidin-3-one-1,1-dioxide.
[1225] LCMS: m/z 685 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.10-1.22 (m, 2H), 1.45-1.69 (m, 6H), 1.75-1.87 (m,
3H), 2.65 (t, 2H), 4.11 (s, 2H), 4.30 (s, 2H), 7.09 (m, 2H),
7.19-7.27 (m, 6H), 7.37 (dd, 1H), 7.44-7.49 (m, 5H), 7.69 (s, 1H),
8.02 (d, 1H) ppm.
Example 187
[1226] L
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-p-
henyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol)
was treated as described in general procedure G using
trans-1-heptenylboronic acid (43 mg, 0.3 mmol) to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4-hept-1-enyl-benzyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1227] LCMS: m/z 609 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.86 (t, 3H), 1.29 (m, 4H), 1.42 (m, 2H), 2.14 (m,
2H), 4.02 (s, 2H), 4.05 (s, 2H), 6.23 (m, 1H), 6.32 (d, 1H), 7.01
(d, 2H), 7.17 (m, 2H), 7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d,
1H), 7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 188
[1228]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
trans-1-penten-1-ylboronic acid (34 mg, 0.3 mmol) to give
5-{3-[4-(2,4-dichloro-phenyl)-2-(4-pent-1-enyl-benzyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1229] LCMS: m/z 581 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.90 (t, 3H), 1.43 (m, 2H), 2.13 (m, 2H), 4.02 (s,
2H), 4.05 (s, 2H), 6.22 (m, 1H), 6.32 (d, 1H), 7.01 (d, 2H), 7.17
(m, 2H), 7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d, 1H), 7.88 (s,
1H), 8.18 (d, 1H) ppm.
Example 189
[1230]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
trans-3-phenyl-1-propen-1-ylboronic acid (49 mg, 0.3 mmol) to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(3-phenyl-propenyl)-benzyl]-imidazol-1-
-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1231] LCMS: m/z 629 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 3.49 (d, 2H), 4.02 (s, 2H), 4.04 (s, 2H), 6.37 (m,
1H), 6.42 (d, 1H), 7.01 (d, 2H), 7.17 (m, 2H), 7.20-7.36 (m, 9H),
7.47 (dd, 1H), 7.63 (d, 1H), 7.87 (s, 1H), 8.18 (d, 1H) ppm.
Example 190
[1232]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (1.19 g, 2 mmol) was
treated as described in general procedure L using
2-(trimethylsilyl)ethoxymethyl chloride (708 .mu.L, 4 mmol) to give
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one,
which was then treated according to general procedure AD to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborol-
an-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsilanyl-et-
hoxymethyl)-[1,2,5]thiadiazolidin-3-one.
[1233] LCMS: m/z 769 (M+H).sup.+.
[1234]
5-(3-{4-(2,4-Dichloro-phenyl)-2-[4-(4,4,5,5-tetramethyl-[1,3,2]diox-
aborolan-2-yl)-benzyl]-imidazol-1-yl}-phenyl)-1,1-dioxo-2-(2-trimethylsila-
nyl-ethoxymethyl)-[1,2,5]thiadiazolidin-3-one (385 mg, 0.5 mmol)
was treated as described in general procedure G using
3,6-dichloropyridazine (149 mg, 1 mmol) to give
5-{3-[2-[4-(6-chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)-imid-
azol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,2,5]th-
iadiazolidin-3-one.
[1235] LCMS: m/z 756 (M+H).sup.+.
[1236]
5-{3-[2-[4-(6-Chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,-
2,5]thiadiazolidin-3-one (38 mg, 0.05 mmol) was treated as
described in general procedure L using cyclohexanemethanol (31 4,
0.25 mmol) to give
5-{3-[2-[4-(6-cyclohexylmethoxy-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl-
)-[1,2,5]thiadiazolidin-3-one.
[1237] LCMS: m/z 833 (M+H).sup.+.
[1238]
5-{3-[2-[4-(6-Cyclohexylmethoxy-pyridazin-3-yl)-benzyl]-4-(2,4-dich-
loro-phenyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxy-
methyl)-[1,2,5]thiadiazolidin-3-one (17 mg, 0.02 mmol) was treated
as described in general procedure W using tetrabutylammonium
fluoride (26 mg, 0.1 mmol) to give
5-{3-[2-[4-(6-cyclohexylmethoxy-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1239] LCMS: m/z 703 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 0.97-1.93 (m, 11H), 3.91 (d, 2H), 4.08 (s, 2H), 4.10
(s, 2H), 7.15-7.27 (m, 5H), 7.37 (d, 2H), 7.46-7.54 (m, 4H), 7.64
(d, 1H), 7.89 (s, 1H), 8.19 (d, 1H) ppm.
Example 191
[1240]
5-{3-[2-[4-(6-Chloro-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl-
)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-[1,-
2,5]thiadiazolidin-3-one (76 mg, 0.1 mmol) was treated as described
in general procedure G using 1-cyclohexen-1-yl-boronic acid (51 mg,
0.4 mmol) to give
5-{3-[2-[4-(6-cyclohex-1-enyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phe-
nyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)--
[1,2,5]thiadiazolidin-3-one, which was then dissolved in 1 mL dry
acetic acid, iron powder (-325 mesh, 112 mg, 2 mmol) was added and
the mixture was then heated at 100.degree. C. under nitrogen for 2
days. At completion, the reaction mixture was then diluted with
water/EtOAc and the leftover iron powder was filtered and washed
with EtOAc. The combined organic layer was washed with water,
saturated NaHCO.sub.3 and brine. The organic layer was then dried
over Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated
and purified by silica gel chromatography to afford
5-{3-[2-[4-(6-cyclohexyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-p-
henyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl-
)-[1,2,5]thiadiazolidin-3-one.
[1241] LCMS: m/z 803 (M+H).sup.+.
[1242]
5-{3-[2-[4-(6-Cyclohexyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-ph-
enyl)-imidazol-1-yl]-phenyl}-1,1-dioxo-2-(2-trimethylsilanyl-ethoxymethyl)-
-[1,2,5]thiadiazolidin-3-one (16 mg, 0.02 mmol) was treated as
described in general procedure W using tetrabutylammonium fluoride
(26 mg, 0.1 mmol) to give
5-{3-[2-[4-(6-cyclohexyl-pyridazin-3-yl)-benzyl]-4-(2,4-dichloro-phenyl)--
imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1243] LCMS: m/z 673 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 1.14-1.77 (m, 10H), 2.53 (m, 1H), 4.06 (s, 2H), 4.09
(s, 2H), 7.15-7.27 (m, 5H), 7.37 (d, 2H), 7.46-7.54 (m, 4H), 7.64
(d, 1H), 7.89 (s, 1H), 8.18 (d, 1H) ppm.
Example 192
[1244]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
4-methyl-1-pentenylboronic acid (39 mg, 0.3 mmol) to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(4-methyl-pent-1-enyl)-benzyl]-imidazo-
l-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1245] LCMS: m/z 595 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.89 (d, 6H), 1.68 (m, 1H), 2.03 (q, 2H), 4.02 (s,
2H), 4.05 (s, 2H), 6.22 (m, 1H), 6.32 (d, 1H), 7.01 (d, 2H), 7.17
(m, 2H), 7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d, 1H), 7.88 (s,
1H), 8.18 (d, 1H) ppm.
Example 193
[1246] To a solution of 2-heptyne (129 .mu.L, 1 mmol) in 2 mL dry
THF at 0.degree. C. was added 2 mL 0.5 M 9-BBN solution in THF. The
resulting solution was stirred at room temperature under nitrogen
for 4 hr. Then it was condensed under vacuum and used as boronic
acid derivative according to general procedure G, reacting with
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(1-methyl-hex-1-enyl)-benzyl]-imidazol-
-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1247] LCMS: m/z 609 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.90 (t, 3H), 1.29-1.40 (m, 4H), 1.93 (d, 3H), 2.13
(m, 2H), 4.02 (s, 2H), 4.05 (s, 2H), 5.77 (m, 1H), 7.01 (d, 2H),
7.17 (m, 2H), 7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d, 1H), 7.88
(s, 1H), 8.18 (d, 1H) ppm.
Example 194
[1248]
5-{3-[2-(4-Bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phe-
nyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (59 mg, 0.1 mmol) was
treated as described in general procedure G using
5-methyl-1-hexenylboronic acid (43 mg, 0.3 mmol) to give
5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(5-methyl-hex-1-enyl)-benzyl]-imidazol-
-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1249] LCMS: m/z 609 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.89 (d, 6H), 1.31 (m, 2H), 1.53 (m, 1H), 2.16 (m,
2H), 4.02 (s, 2H), 4.05 (s, 2H), 6.22 (m, 1H), 6.33 (d, 1H), 7.01
(d, 2H), 7.17 (m, 2H), 7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d,
1H), 7.88 (s, 1H), 8.18 (d, 1H) ppm.
Example 195
[1250] To a solution of 3-cyclohexyl-1-propyne (145 .mu.L, 1 mmol)
in 2 mL dry THF at 0.degree. C. was added 2 mL 0.5 M 9-BBN solution
in THF. The resulting solution was stirred at room temperature
under nitrogen for 4 hr. Then it was condensed under vacuum and
used as boronic acid derivative according to general procedure G,
reacting with
5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1-
,2,5-thiadiazolidine-3-one-1,1-dioxide (119 mg, 0.2 mmol) to give
5-{3-[2-[4-(3-cyclohexyl-propenyl)-benzyl]-4-(2,4-dichloro-phenyl)-imidaz-
ol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
[1251] LCMS: m/z 635 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 0.87-1.71 (m, 11H), 2.05 (m, 2H), 4.02 (s, 2H), 4.05
(s, 2H), 6.21 (m, 1H), 6.30 (d, 1H), 7.01 (d, 2H), 7.17 (m, 2H),
7.25 (d, 2H), 7.36-7.48 (m, 3H), 7.64 (d, 1H), 7.88 (s, 1H), 8.18
(d, 1H) ppm.
BIOLOGICAL ASSAY
[1252] The following assay methods are utilized to identify
compounds of formula I which are effective in inhibiting the
activity of certain phosphatases, an example of which, as used
herein, is PTP1B.
PTP1B Assay
[1253] The assay for PTP1B inhibition is based on the detection of
the complex between Malachite Green dye and free phosphate,
liberated from the phosphopeptide substrate by PTPase action. To
each well of a flat-bottom assay plate is added 45 .mu.L assay
buffer [-50 mM Imidazole, pH 7.2, 100 mM NaCl, 5 mM DTT, and 1 mM
EDTA] and 10 .mu.L of peptide substrate (Tyrosine Phosphopeptide-1,
END(.sub.pY)INASL (SEQ ID NO: 1), 80 .mu.M FAC, Promega Cat #
V256A) to a total volume of 55 .mu.L. Test compound (10 .mu.L in up
to 50% DMSO) is then added. The mixture is incubated for 5 min, at
25.degree. C., and 10 .mu.L of PTP-1B (Protein Tyrosine Phosphatase
1B (PTP-1B); FAC 0.8 nM; BIOMOL-SE332) is then added. The mixture
is incubated for 30 min at 25.degree. C. Subsequently, 25 .mu.L of
Malachite Green reagent (10% (w/v) Ammonium Molybdate in water,
Sigma Cat #A-7302, 0.2% (w/v) Malachite Green in 4 N HCl, Aldrich
Cat #21, 302-0) is then added. After incubation for 15 min at
27.degree. C., the reaction endpoint is measured at 640 nM.
[1254] The Malachite Green reagent is prepared by mixing one volume
of 10% Ammonium Molybdate with 3 volumes of 0.2% Malachite Green
solution, stirring at room temperature for 30 min and then
filtering and collecting the filtrate. The Malachite Green reagent
is treated with 10 .mu.L of 5% Tween 20 per 990 .mu.L of dye
solution before use.
[1255] Test compounds are typically examined at eight
concentrations in the above assay. For this assay, the IC50 (.mu.M)
of the enzyme inhibition assay represents the concentration of
compound at which 50% signal has been inhibited. The compounds of
Formula I in Table I inhibit PTP-IB with an IC50 of less than 10
.mu.M.
[1256] While the invention has been described and illustrated with
reference to certain embodiments thereof, those skilled in the art
will appreciate that various changes, modifications and
substitutions can be made therein without departing from the spirit
and scope of the invention. For example, effective dosages other
than the dosages as set forth herein may be applicable as a
consequence of variations in the responsiveness of the subject
being treated for PTPase-mediated disease(s). Likewise, the
specific pharmacological responses observed may vary according to
and depending on the particular active compound selected or whether
there are present pharmaceutical carriers, as well as the type of
formulation and mode of administration employed, and such expected
variations or differences in the results are contemplated in
accordance with the objects and practices of the present
invention.
* * * * *